0001564590-21-005551.txt : 20210211 0001564590-21-005551.hdr.sgml : 20210211 20210211161713 ACCESSION NUMBER: 0001564590-21-005551 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210211 DATE AS OF CHANGE: 20210211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OTONOMY, INC. CENTRAL INDEX KEY: 0001493566 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262590070 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36591 FILM NUMBER: 21619896 BUSINESS ADDRESS: STREET 1: 4796 EXECUTIVE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (619) 323-2200 MAIL ADDRESS: STREET 1: 4796 EXECUTIVE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Otonomy, Inc. DATE OF NAME CHANGE: 20100607 10-K 1 otic-10k_20201231.htm 10-K otic-10k_20201231.htm
false 2020 FY 0001493566 --12-31 P2Y 2016-12 P94M The Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees true true P94M P1Y 2020 0 0 0 0 0 us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:OtherNoncurrentLiabilitiesMember P7Y1M6D P7Y1M6D P5Y8M12D P6Y1M6D P6Y1M6D P5Y4M24D P1Y3M18D P1Y3M18D P1Y3M18D 0001493566 2020-01-01 2020-12-31 xbrli:shares 0001493566 2021-02-05 iso4217:USD 0001493566 2020-06-30 0001493566 2020-12-31 0001493566 2019-12-31 iso4217:USD xbrli:shares 0001493566 2019-01-01 2019-12-31 0001493566 2018-01-01 2018-12-31 0001493566 us-gaap:CommonStockMember 2017-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001493566 us-gaap:RetainedEarningsMember 2017-12-31 0001493566 2017-12-31 0001493566 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001493566 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001493566 us-gaap:CommonStockMember 2018-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001493566 us-gaap:RetainedEarningsMember 2018-12-31 0001493566 2018-12-31 0001493566 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001493566 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001493566 us-gaap:CommonStockMember 2019-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001493566 us-gaap:RetainedEarningsMember 2019-12-31 0001493566 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001493566 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001493566 us-gaap:CommonStockMember 2020-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001493566 us-gaap:RetainedEarningsMember 2020-12-31 0001493566 us-gaap:IPOMember 2020-07-01 2020-07-31 0001493566 2020-07-01 2020-07-31 0001493566 2020-07-31 otic:Segment 0001493566 srt:MinimumMember 2020-01-01 2020-12-31 0001493566 srt:MaximumMember 2020-01-01 2020-12-31 xbrli:pure 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerOneMember 2020-01-01 2020-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerOneMember 2019-01-01 2019-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerOneMember 2018-01-01 2018-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerTwoMember 2020-01-01 2020-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerTwoMember 2019-01-01 2019-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerTwoMember 2018-01-01 2018-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerThreeMember 2020-01-01 2020-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerThreeMember 2019-01-01 2019-12-31 0001493566 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember otic:CustomerThreeMember 2018-01-01 2018-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001493566 us-gaap:AvailableforsaleSecuritiesMember otic:MoneyMarketFundsAndCertificateOfDepositMember 2020-12-31 0001493566 us-gaap:AvailableforsaleSecuritiesMember otic:MoneyMarketFundsAndCertificateOfDepositMember 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember 2020-01-01 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2019-01-01 2019-12-31 otic:Security 0001493566 otic:LaboratoryEquipmentMember 2020-12-31 0001493566 otic:LaboratoryEquipmentMember 2019-12-31 0001493566 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001493566 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001493566 otic:ComputersAndSoftwareMember 2020-12-31 0001493566 otic:ComputersAndSoftwareMember 2019-12-31 0001493566 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001493566 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001493566 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001493566 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001493566 us-gaap:BuildingMember 2016-12-01 2016-12-31 0001493566 2016-12-31 0001493566 2016-12-01 2016-12-31 0001493566 otic:RestrictedCashMember 2015-05-31 0001493566 otic:DevelopmentMember 2020-12-31 0001493566 otic:RegulatoryMember 2020-12-31 0001493566 otic:CommercializationMember 2020-12-31 otic:Milestone 0001493566 otic:RegulatoryMember us-gaap:IntellectualPropertyMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember otic:DevelopmentMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember otic:RegulatoryMember 2020-12-31 0001493566 otic:UpfrontPaymentMember otic:LicenseAgreementMember 2020-07-01 2020-07-31 0001493566 otic:LicenseAgreementMember 2020-07-01 2020-07-31 0001493566 us-gaap:RoyaltyAgreementsMember 2020-01-01 2020-12-31 0001493566 us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0001493566 us-gaap:LicensingAgreementsMember 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember otic:ThereafterSecondAnniversaryOfClosingDateMember 2020-01-01 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember 2020-01-01 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember srt:MinimumMember 2020-01-01 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember otic:OccurrenceAndDuringContinuanceOfEventOfDefaultMember 2020-01-01 2020-12-31 0001493566 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2020-12-31 0001493566 otic:CARESActOf2020Member otic:JPMorganChaseBankNAMember otic:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2020-04-10 0001493566 otic:CARESActOf2020Member otic:JPMorganChaseBankNAMember otic:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001493566 srt:MinimumMember 2020-12-31 0001493566 srt:MaximumMember 2020-12-31 0001493566 us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001493566 us-gaap:ComputerEquipmentMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001493566 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2020-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2019-12-31 0001493566 otic:PrefundedWarrantsMember 2020-12-31 0001493566 otic:PrefundedWarrantsMember 2019-12-31 0001493566 otic:AvailableFutureGrantYearMember us-gaap:EmployeeStockOptionMember 2020-12-31 0001493566 otic:AvailableFutureGrantYearMember us-gaap:EmployeeStockOptionMember 2019-12-31 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-12-31 0001493566 otic:PrefundedWarrantsMember 2020-07-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember 2020-01-01 2020-12-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember srt:MinimumMember 2020-01-01 2020-12-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember srt:MaximumMember 2020-01-01 2020-12-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember us-gaap:SubsequentEventMember 2021-01-01 2021-01-01 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember us-gaap:SubsequentEventMember 2021-01-01 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember 2020-12-31 0001493566 us-gaap:CommonStockMember us-gaap:PerformanceSharesMember 2018-02-01 2018-02-28 0001493566 us-gaap:EmployeeStockOptionMember srt:MinimumMember us-gaap:ExchangeTradedMember 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:ExchangeTradedMember 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember us-gaap:ExchangeTradedMember otic:EquityIncentivePlanTwoThousandFourteenMember 2017-12-19 2017-12-20 0001493566 srt:MinimumMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 srt:MaximumMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001493566 srt:MaximumMember otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001493566 srt:MinimumMember us-gaap:SubsequentEventMember otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2021-01-01 2021-01-01 0001493566 us-gaap:SubsequentEventMember otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2021-01-01 0001493566 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001493566 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001493566 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001493566 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001493566 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001493566 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001493566 otic:AGTCCollaborationMember 2020-01-01 2020-12-31 0001493566 otic:GlenmarkCoPromotionAgreementMember 2019-09-30 0001493566 srt:MinimumMember otic:MissionCoPromotionAgreementMember 2020-01-01 2020-12-31 0001493566 otic:MissionCoPromotionAgreementMember 2020-01-01 2020-12-31 0001493566 otic:MissionCoPromotionAgreementMember 2019-01-01 2019-12-31 0001493566 us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0001493566 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001493566 2018-01-01 0001493566 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001493566 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001493566 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-12-31 0001493566 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-01-01 2020-12-31

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2020

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission file number 001-36591

 

Otonomy, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

26-2590070

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

4796 Executive Drive

San Diego, California 92121

(Address of principal executive offices and Zip Code)

(619) 323-2200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

OTIC

The NASDAQ Stock Market LLC

(The NASDAQ Global Select Market)

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☐

 

Accelerated filer

 

☐

Non-accelerated filer

 

☒   

 

Smaller reporting company

 

☒

Emerging growth company

 

☐

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒

The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2020 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately $103.3 million based on the closing price of the registrant’s common stock, as reported by the NASDAQ Global Select Market on June 30, 2020 of $3.62 per share. Shares of the registrant’s common stock held by executive officers, directors and their affiliates have been excluded from this calculation. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of February 5, 2021, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 48,318,970.

DOCUMENTS INCORPORATED BY REFERENCE

As noted herein, the information called for by Part III is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2021 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2020.

 

 

 

 

 

 

 

OTONOMY, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE YEAR ENDED DECEMBER 31, 2020

TABLE OF CONTENTS

 

 

 

 

 

Page

 

 

PART I

 

 

 

 

 

 

 

Item 1.

 

Business

 

5

Item 1A.

 

Risk Factors

 

27

Item 1B.

 

Unresolved Staff Comments

 

68

Item 2.

 

Properties

 

69

Item 3.

 

Legal Proceedings

 

69

Item 4.

 

Mine Safety Disclosures

 

69

 

 

 

 

 

 

 

PART II

 

 

 

 

 

 

 

Item 5.

 

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

70

Item 6.

 

Reserved

 

 

Item 7.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

71

Item 7A.

 

Quantitative and Qualitative Disclosures About Market Risk

 

81

Item 8.

 

Financial Statements

 

82

Item 9.

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

108

Item 9A.

 

Controls and Procedures

 

108

Item 9B.

 

Other Information

 

108

 

 

 

 

 

 

 

PART III

 

 

 

 

 

 

 

Item 10.

 

Directors, Executive Officers and Corporate Governance

 

109

Item 11.

 

Executive Compensation

 

109

Item 12.

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

109

Item 13.

 

Certain Relationships and Related Transactions, and Director Independence

 

109

Item 14.

 

Principal Accounting Fees and Services

 

109

 

 

 

 

 

 

 

PART IV

 

 

 

 

 

 

 

Item 15.

 

Exhibits, Financial Statement Schedules

 

110

Item 16.

 

Form 10-K Summary

 

113

 

 

 

 

 

 

 

Signatures

 

114

 

1

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:

 

•

our expectations regarding our clinical development of OTIVIDEX, including expectations regarding trial conduct and availability of top-line results from the ongoing Phase 3 clinical trial, acceptance and adequacy of the statistical analysis plan for such trial, expectations regarding submission of a New Drug Application, and expectations that one additional successful pivotal trial is sufficient to support the United States registration of OTIVIDEX in Ménière’s disease;

 

•

the size of the market opportunity and the number of patients who suffer from the diseases and disorders we are targeting;

 

•

our expectations regarding the clinical development of OTO-313, including future development activities;

 

•

our expectations regarding the clinical development of OTO-413, including future development activities;

 

•

our expectations regarding the potential impacts on our business, preclinical programs and clinical trials due to the COVID-19 pandemic;

 

•

the timing or likelihood of regulatory filings and approvals;

 

•

our expectations regarding the future development of other product candidates, including but not limited to our development plans for our OTO-510 and OTO-6XX programs;

 

•

our expectations regarding our strategic collaboration with Applied Genetic Technologies Corporation (AGTC) to develop and commercialize a gene therapy for congenital hearing loss (OTO-825);

 

•

our expectations regarding OTIPRIO co-promotion partnerships;

 

•

the potential for commercialization of our product candidates, if approved;

 

•

our expectations and statements regarding the benefits, pricing, market size, opportunity and growth potential for OTIVIDEX, OTO-313, OTO-413 and our other product candidates, if approved for commercial use;

 

•

our expectations and statements regarding the adoption and use of OTIPRIO and OTIVIDEX, OTO-313 and OTO-413, if approved;

 

•

our expectations regarding potential coverage and reimbursement relating to OTIPRIO, and OTIVIDEX, OTO-313 and OTO-413, if approved, or any other approved product candidates;

 

•

our plans regarding the use of contract manufacturers for the production of our product candidates for clinical trials and, if approved, commercial use;

 

•

our plans and ability to effectively establish and manage our own sales and marketing capabilities, or seek and establish collaborative partners, to commercialize our products;

 

•

our ability to advance product candidates into, and successfully complete, clinical trials;

 

•

the implementation of our business model, strategic plans for our business, product candidates and technology;

 

•

the initiation, timing, progress and results of future nonclinical studies and clinical trials;

 

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

2

 

 

•

estimates of our expenses, future revenue, capital requirements and our needs for additional financing;

 

•

our expectations regarding the benefits of the loan provided by Oxford Finance LLC;

 

•

our financial performance;

 

•

accounting principles, policies and estimates; and

 

•

developments and projections relating to our competitors and our industry.

These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including but not limited to: delays and disruption resulting from the COVID-19 pandemic and governmental responses to the pandemic, including current and future impacts to our operations, the manufacturing of our product candidates, the progression of our current clinical trials, and patient conduct and compliance; our limited operating history and our expectation that we will incur significant losses for the foreseeable future; our ability to obtain additional financing; our dependence on the clinical, regulatory and commercial success of OTIVIDEX and advancement of additional product candidates, such as OTO-313 and OTO-413, through clinical development to regulatory approval and commercialization; the uncertainties inherent in the clinical drug development process, including, without limitation, our ability to adequately demonstrate the safety and efficacy of our product candidates, the nonclinical and clinical results for our product candidates, which may not support further development, and challenges related to patient enrollment, conduct and compliance in clinical trials; the integrity of patient-reported outcomes in our current and future clinical trials; our ability to obtain regulatory approval for our product candidates and to successfully commercialize our product candidates, if approved; side effects or adverse events associated with our product candidates; competition in the biopharmaceutical industry and general economic and market conditions; our dependence on third parties to conduct nonclinical studies and clinical trials, to supply raw materials, and for the manufacture of OTIPRIO and our product candidates; the timing and outcome of hospital pharmacy and therapeutics reviews and other facility reviews; the impact of coverage and reimbursement decisions by third-party payors on the pricing and market acceptance of OTIPRIO; our ability to protect our intellectual property related to OTIPRIO and our product candidates in the United States and throughout the world; our ability to ensure compliance by contractors and partners with various laws and regulations in countries in which we conduct clinical trials; expectations regarding potential therapy benefits, market size, opportunity and growth; our ability to manage operating expenses; implementation of our business model and strategic plans for our business, product candidates and technology; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of promotional or collaboration agreements; the risks of the occurrence of any event, change or other circumstances that could give rise to the termination of our collaboration agreement with AGTC, our co-promotion agreement with ALK-Abelló, Inc. (ALK), or our license agreements with third parties, or that could impact our ability to repay or comply with the terms of the loan provided by Oxford Finance LLC; and other risks. These forward-looking statements reflect our beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report on Form 10-K and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section titled “Risk Factors” included in Part I, Item 1A and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We qualify all the forward-looking statements in this Annual Report on Form 10-K by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.

Otonomy, the Otonomy logo, OTIPRIO, OTIVIDEX and other trademarks or service marks of Otonomy appearing in this report are the property of Otonomy. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We have generally omitted the ®, ™ and other designations, as applicable, in this report.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and

3

 

completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations, except as required by law.

You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the Securities and Exchange Commission (SEC) as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.

4

 

PART I

Item 1. BUSINESS

Overview

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. We pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and has been utilized to develop a pipeline of product candidates including three clinical-stage programs (OTIVIDEX for Ménière’s disease, OTO-313 for tinnitus, and OTO-413 for hearing loss) as well as several preclinical development programs including a gene therapy collaboration targeting the most common form of congenital hearing loss. We estimate, based on an external market report commissioned by us, that approximately 39 million patients in the United States suffer from the hearing and balance disorders that we are targeting in our clinical and preclinical programs, including moderate or severe vertigo (approximately 11 million), tinnitus (approximately 8 million) or hearing loss (approximately over 20 million). We also developed, registered and commercialized in the United States an otic antibiotic called OTIPRIO that is being marketed by a co-promotion partner, ALK.

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease. Two Phase 3 trials in Ménière’s disease patients were completed in the second half of 2017. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029), while the AVERTS-1 trial, conducted in the United States, did not (p value = 0.62). Based on a Type C meeting with the United States Food and Drug Administration (FDA), we believe that one additional successful pivotal trial is sufficient to support the United States registration of OTIVIDEX in Ménière’s disease.  We have completed enrollment in such additional Phase 3 trial with top-line results expected by the end of February 2021.

OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. In July 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity. We plan to initiate a Phase 2 clinical trial for OTO-313 in the first quarter of 2021, with top-line results expected in mid-2022.

OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. In December 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-413, demonstrating that a single intratympanic injection of OTO-413 was well-tolerated and showed therapeutic activity across multiple speech-in-noise hearing tests. We plan to initiate an expansion of the Phase 1/2 trial in the second quarter of 2021 to evaluate a refined study protocol in additional hearing loss patients, with top-line results expected in mid-2022.

We also have multiple preclinical stage programs addressing additional hearing loss pathologies including a gene therapy for treatment of congenital hearing loss (OTO-825), an otoprotectant for prevention of cisplatin-induced hearing loss (OTO-510), and a hair cell repair and regeneration program for treatment of severe hearing loss (OTO-6XX). In October 2019, we entered into a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy to restore hearing in patients with congenital hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. In July 2020, we entered into an exclusive license agreement with Kyorin Pharmaceutical Co., Ltd. (Kyorin) that provides us with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for our OTO-6XX program.

In addition, we developed, received FDA approval for and commercially launched OTIPRIO (ciprofloxacin otic suspension) for use during tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis externa (AOE). In June 2020, we entered into a co-promotion agreement with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

5

 

Given the unprecedented and evolving nature of the COVID-19 pandemic, there continues to be significant uncertainty about the progression and ultimate impact of the pandemic on our business operations. We have taken steps to mitigate the impact of the COVID-19 pandemic on our clinical trials, including developing processes to ensure the integrity of data collection from enrolled patients and supporting sites able to enroll patients, among other activity. Nonetheless, we do not know the full extent of potential future delays or impacts on our business operations, our preclinical programs and clinical trials, healthcare systems, our financial condition, or the global economy as a whole resulting from the COVID-19 pandemic.

In addition, as a result of the COVID-19 pandemic, we have taken steps to protect the health and safety of our employees and community by generally adopting a work from home policy in line with directives from the State of California and the applicable local governments, and guidance from the U.S. Centers for Disease Control and Prevention (CDC). On-site activities have been restricted to certain essential facility and laboratory support functions and various safety protocols have been implemented.

Our Product Pipeline

The following table summarizes the status of our product candidates currently in development and the indications for our approved product, and is followed by a brief description of each program:

 

Program (Compound)

Target Population

Status or Upcoming Milestone

OTIVIDEX (dexamethasone)

Ménière’s Disease

Phase 3 clinical trial results by end of February 2021

OTO-313 (gacyclidine)

Tinnitus

Initiate Phase 2 clinical trial in 1Q21 with top-line results in mid-2022

OTO-413 (BDNF)

Hearing Loss

Initiate expansion of Phase 1/2 clinical trial in 2Q21 with top-line results in mid-2022

OTO-825 (GJB2 gene therapy)

Congenital Hearing Loss

Preclinical development

OTO-510 (otoprotectant)

Cisplatin-Induced Hearing Loss

Preclinical development

OTO-6XX (hair cell repair and regeneration)

Severe Hearing Loss

Preclinical development

OTIPRIO (ciprofloxacin)

TTP Surgery

Acute Otitis Externa

Co-promotion partnership for TTP surgery and AOE

 

OTIVIDEX: Sustained-Exposure Steroid for Ménière’s Disease

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease. Ménière’s disease is a chronic condition characterized by acute vertigo attacks, tinnitus, fluctuating hearing loss and a feeling of aural fullness. The underlying cause of Ménière’s disease is not well understood and there is no known cure. There are more than 850,000 patients diagnosed with Ménière’s disease in the United States and there are currently no FDA-approved drug treatments. Typical first line treatment in the United States is observance of a low-salt diet and off-label use of diuretics. Oral and intratympanic (IT) steroids are used in a subset of Ménière’s patients who have persistent or severe symptoms. Patients who are unresponsive to steroid treatment may resort to surgical or chemical ablation, which can cause irreversible hearing loss.

In November 2017, we announced positive results from the AVERTS-2 Phase 3 clinical trial for OTIVIDEX conducted in Europe. The clinical trial achieved its primary endpoint of count of definitive vertigo days (DVD) by Poisson Regression analysis in Month 3 for OTIVIDEX vs. placebo (p value = 0.029) based on analysis of all 174 Ménière’s disease patients enrolled in the trial. The OTIVIDEX group demonstrated a 6.2-day reduction in the mean reported number of DVD from baseline to Month 3 with a 2.5-day mean difference between OTIVIDEX and placebo in Month 3. For subjects who completed daily diaries through Month 3 (n=105), there was a 68% reduction in vertigo frequency from baseline to Month 3 in the OTIVIDEX group vs. 40% for placebo. In January 2018, we reported that a number of additional efficacy endpoints were also statistically significant for the 111 patients who were enrolled in the AVERTS-2 trial through Month 3 at the time of study termination, including count of DVD by Poisson Regression analysis (p value = 0.014).

6

 

In August 2017, we announced negative results from the AVERTS-1 Phase 3 clinical trial conducted in the United States that enrolled a total of 165 patients with Ménière’s disease. The clinical trial missed its primary endpoint, count of DVD by Poisson Regression analysis in Month 3 (p value = 0.62), and also failed to achieve statistical significance (p value < 0.05) for any of the key secondary vertigo endpoints at Month 3. Patients in both the OTIVIDEX and placebo groups showed similar reductions in the number and severity of vertigo episodes during the three-month observation period. OTIVIDEX patients reported a 58% reduction from baseline in vertigo frequency in Month 3 vs. 55% for placebo patients.

The clinically significant treatment benefit demonstrated by OTIVIDEX versus placebo in AVERTS-2 was consistent with our expectations from the Phase 2b trial. We believe that the AVERTS-1 trial failed due to a significantly higher placebo response and was not attributable to a difference in patient demographics or baseline characteristics compared to AVERTS-2. A review of the AVERTS trials including consultation with outside experts suggests that the higher placebo response was primarily due to increased patient expectation bias in the U.S. trial. We completed a Type C meeting with the FDA in March 2018 that included a review of the AVERTS and other clinical trial results. Based on FDA feedback, we believe that one additional successful pivotal trial is sufficient to support the U.S. registration of OTIVIDEX in Ménière’s disease.

In July 2020, Otonomy submitted a revised statistical analysis plan for the ongoing Phase 3 trial to the FDA that proposed use of the Negative Binomial model for primary analysis of the daily vertigo count data reported by patients. We believe that this statistical test provides the best fit of the OTIVIDEX clinical data based on the Phase 2b trial, the AVERTS-2 Phase 3 trial, and the integrated dataset from both trials. In November 2020, Otonomy announced that FDA’s review of the statistical analysis plan confirms use of the Negative Binomial model for analysis of the primary endpoint in the ongoing Phase 3 trial. We have completed enrollment in this trial, with a total of 149 Ménière’s disease patients enrolled, and expect to announce top-line results by the end of February 2021. Assuming positive results, submission of a New Drug Application to the FDA is planned for the third quarter of 2021.

OTO-313: Sustained-Exposure NMDA Receptor Antagonist for Tinnitus

OTO-313 is a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine in development for the treatment of tinnitus. Tinnitus is often described as a ringing in the ear but can also sound like roaring, clicking, hissing or buzzing. There are approximately 8 million people in the United States with moderate or severe tinnitus who may have trouble hearing, working and sleeping. At this time, there is no cure for tinnitus and there are no FDA-approved drugs for the treatment of this debilitating condition. Historic and emerging clinical data provide support for the use of NMDA receptor antagonists, including gacyclidine, for the treatment of tinnitus. Mechanistically, agents from this therapeutic class may act to reduce dysfunctional activity resulting from injury to the hearing organ, or cochlea, and be perceived by the patient as tinnitus.

In July 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity. This trial demonstrated a positive clinical response for a single intratympanic injection of OTO-313 using the Tinnitus Functional Index (TFI) that was correlated with tinnitus loudness, tinnitus annoyance and patient global impression of change measures. Based on continued analysis of this data, input from key opinion leaders, and feedback from the FDA in a Type C meeting, we intend to evaluate the same dose for OTO-313 in a Phase 2 trial that will enroll an enriched unilateral tinnitus patient population. To enrich the study population, we intend to exclude patients with severe hearing loss and increase the minimum TFI score required for entry. We will also expand the unilateral patient population eligible for enrollment by increasing the time from tinnitus onset from six months to one year, and will extend the observation period to assess durability of the treatment effect. We plan to initiate this Phase 2 trial in the first quarter of 2021, with top-line results expected in mid-2022.

Development Programs for the Treatment of Sensorineural Hearing Loss

Hearing loss is a large and growing unmet need with estimates by the World Health Organization that more than 360 million people worldwide have disabling levels of loss. This leads to social isolation, lower quality of life and higher rates of dementia and depression. Common causes include aging, noise, exposure to ototoxic drugs and genetics, with increased noise exposure from use of recreational music devices accelerating the onset of hearing

7

 

loss. The pathologies of hearing loss typically involve damage to hair cells and/or spiral ganglion neurons in the inner ear. As briefly described below, we are advancing four distinct hearing loss programs targeting different pathologies: repair of cochlear synaptopathy for treatment of speech-in-noise hearing difficulty (OTO-413), a gene therapy for the most common cause of congenital hearing loss (OTO-825), protection of hair cells from ototoxic drugs including cisplatin chemotherapy (OTO-510), and hair cell repair and regeneration for treatment of severe hearing loss (OTO-6XX).

OTO-413: Neurotrophic Growth Factor for Cochlear Synaptopathy

Cochlear synaptopathy is a hearing pathology caused by damage to ribbon synapses that has become an active focus of otology research in the last decade. Ribbon synapses are critical to hearing because they connect sound transducers in the cochlea called hair cells to auditory nerve fibers, which carry the electrical sound impulse to the brain for interpretation. Damage to ribbon synapses can be caused by exposure to loud noise and/or aging, and results in hearing problems in the presence of background noise referred to as speech-in-noise hearing difficulty. This condition is estimated to affect a significant proportion of the approximately 20 million people in the U.S. with moderate or severe hearing loss. Hearing aids provide limited benefit for speech-in-noise hearing problems and there is no FDA-approved drug treatment for this condition.

OTO-413 is a proprietary, sustained-exposure formulation of BDNF which is a naturally occurring protein involved in neuron growth and repair. Nonclinical studies by us and other research groups have demonstrated that local administration of BDNF repairs ribbon synapses damaged due to noise trauma or exposure to ototoxic chemicals and restores hearing function. In December 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-413 in subjects with hearing loss. The randomized, double-blind, placebo-controlled, ascending dose trial demonstrated that a single intratympanic injection of OTO-413 was well-tolerated across all dose cohorts. Furthermore, there was demonstration of therapeutic activity of OTO-413 versus placebo across multiple clinically-validated speech-in-noise hearing tests at consecutive time points (Days 57 and 85). We plan to initiate an expansion of the Phase 1/2 trial in the second quarter of 2021 to evaluate a refined study protocol in additional hearing loss patients, with top-line results expected in mid-2022.

OTO-825: GJB2 Gene Therapy Program for Congenital Hearing Loss

Congenital hearing loss is a significant unmet medical need with about 1 out of 500 children born with or developing hearing loss early in life. Genetic mutations are the most common cause of congenital hearing loss and a defect in the gap junction beta-2 (GJB2) gene is the most common of these mutations, accounting for approximately 30% of cases. Patients with GJB2 mutation can have severe-to-profound deafness in both ears that is identified in screening tests routinely performed in newborns.

In October 2019, Otonomy and AGTC announced a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the GJB2 gene. Under the collaboration agreement, Otonomy and AGTC will equally share the program costs and any revenue or other proceeds related to the program. The agreement provides for technology sharing and establishment of joint intellectual property as appropriate. The parties may consider including additional genetic hearing loss targets in the future.

During 2020, Otonomy and AGTC presented preclinical results at several research conferences demonstrating that a gene of interest can be expressed in support cells of the cochlea, which are the relevant target cells for treating GJB2 deficiency, using novel and proprietary AAV capsids. In addition, studies conducted in non-human primates demonstrated that consistent gene expression could be observed for at least 12 weeks following a single local administration. Based on these results, Otonomy and AGTC have selected a GJB2 product candidate (OTO-825) for further development.

8

 

OTO-510: Otoprotectant for Cisplatin-Induced Hearing Loss

Cisplatin and other platinum-based chemotherapeutic agents are routinely used in treating numerous tumor types with approximately 500,000 patients including 5,000 children treated each year in the United States according to market estimates. While use of platinum agents has contributed to improved patient survival, ototoxicity and associated permanent hearing loss is well documented in the clinical literature. In particular, hearing loss has been reported in up to 90% of children and young adults treated with platinum-based agents. This adversely affects speech and language development and has been associated with academic and social difficulties which can have a significant impact on patients and their families. At this time, there is no FDA-approved drug treatment to protect against platinum-based ototoxicity.

We established feasibility of conducting clinical trials in patients undergoing cisplatin chemotherapy through a small Phase 2 trial with OTIVIDEX in pediatric patients, and have identified a therapeutic target that offers a potentially higher level of otoprotection than steroids based on nonclinical studies. This program, called OTO-510, is focused on the development of a sustained-exposure otoprotectant for local delivery to preserve hearing without protecting the tumor.

OTO-6XX: Hair Cell Repair and Regeneration for Severe Hearing Loss

Auditory hair cells are specialized sensory cells in the cochlea that convert sound vibrations into a signal that can be transmitted to the brain for interpretation as hearing. Unlike non-mammalian species such as birds that are able to naturally regenerate hair cells, a human is born with approximately 15,000 auditory hair cells per cochlea that do not regenerate. As a result, the loss of hair cells due to damage from excessive noise, physical trauma, exposure to ototoxic chemicals, or through the natural aging process is irreversible and results in permanent hearing loss. The treatment of hearing loss is a significant unmet need with approximately 360 million people worldwide having a disabling level of loss including approximately 6.6 million people in the U.S. with severe hearing loss. Hearing aids provide limited benefit and there are no FDA-approved drugs to treat hearing loss.

Considerable interest and attention has been focused by otology researchers over the past several decades for ways to regenerate auditory hair cells as an approach to treating severe hearing loss. This effort has included extensive research with non-mammalian species that do regenerate hair cells to identify pathways for therapeutic intervention. Targeting one of these pathways, we have demonstrated regeneration of hair cells in a nonclinical proof-of-concept model using a class of small molecules formulated for sustained-exposure local delivery. In July 2020, we entered into an exclusive license agreement with Kyorin that provides us with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for our OTO-6XX program.

 

OTIPRIO: Sustained-Exposure Topical Antibacterial for Otic Infections

OTIPRIO is a single-dose, physician-administered antibacterial that was approved by the FDA in December 2015 for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery and was approved in March 2018 for the treatment of patients with AOE. OTIPRIO is the only product approved by the FDA for use during TTP surgery and is the only single-dose topical antibacterial approved for the treatment of AOE. We have also completed a successful End-of-Phase 2 review with the FDA for OTIPRIO in patients with acute otitis media with tympanostomy tubes (AOMT). Based on FDA feedback, we believe that registration would require a single, sham controlled, pivotal Phase 3 trial enrolling approximately 200 pediatric patients with AOMT.

We provided promotional support for OTIPRIO using an internal sales force beginning in the first quarter of 2016 which continued into the fourth quarter of 2017. In November 2017, we announced the discontinuation of promotional support for OTIPRIO in order to significantly reduce operating expenses related to the product, however, OTIPRIO continues to be available for purchase by customers. In June 2020, we entered into a co-promotion partnership with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices and in October 2020, we amended that agreement to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

9

 

Our Proprietary Otic Drug Delivery Technologies

To overcome many of the limitations of delivering drugs to the ear, we have developed multiple proprietary formulation technologies designed to deliver drug that is retained in the ear for an extended period of time following a single local administration, which we refer to as “sustained exposure.” One of these technologies utilizes a thermosensitive polymer called poloxamer which transitions from a liquid to a gel at body temperature. The polymer vehicle is combined with drug microparticles to create a suspension that is retained in the ear for an extended period of time. This prolonged residence time provides high and sustained drug exposure.

Potential benefits of our drug delivery technologies for our product and product candidates include:

 

•

Single local administration.

 

•

High drug levels in the target location and minimal systemic exposure.

 

•

Eliminates the need for the patient to remain in a prone position for an extended period of time.

 

•

Simple, office-based administration by an ear, nose and throat physician (ENT).

 

•

Avoids patient compliance concerns.

We have a broad patent portfolio of approximately 70 issued patents and allowed patent applications and at least 68 pending patent applications in active prosecution covering our product, product candidates and indications as well as other potential applications of our drug delivery technologies in major markets around the world.

Competition

The biopharmaceutical market is highly competitive. Successful competitors in the biopharmaceutical market must have the ability to effectively discover, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. Numerous companies are engaged in the development, manufacture and marketing of biopharmaceutical products competitive with those that we are developing. Our potential competitors may have substantially greater manufacturing, financial, research and development, personnel and marketing resources than we have. Our competitors may also have more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities. In addition to product development, testing, approval and promotion, other competitive factors in the biopharmaceutical industry include industry consolidation, product quality and price, product technology, reputation, customer service and access to technical information. As a result, our competitors may be able to develop competing or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. As more companies develop new intellectual property in our market, the possibility of a competitor acquiring patent or other rights that may limit our products or potential products increases, which could lead to litigation.

Any product candidates that we successfully develop and commercialize will compete with existing treatments, including unapproved and off-label drug alternatives that are currently utilized by physicians to treat the indications for which we seek approval, as well as new treatments that may become available in the future.

OTIPRIO

Antibiotic ear drops are currently the primary treatment option for use during TTP surgery even though no ear drop product has been approved by the FDA for this indication. Multiple ear drops are approved and marketed for use in treating patients with AOE and AOMT. Marketed antibiotic ear drops include CIPRODEX® Otic from Novartis Pharmaceuticals Corporation, and Otovel® from Arbor Pharmaceuticals, LLC. The key competitive factors affecting the success of OTIPRIO are likely to be its efficacy, safety, tolerability, dosing regimen, route of administration, convenience and price, and the availability of coverage and adequate reimbursement from government and other third-party payors.

10

 

OTIVIDEX

There are no drugs currently approved by the FDA for the treatment of Ménière’s disease. Current treatments commonly used for Ménière’s disease in the United States include observance of a low-salt diet and off-label use of diuretics, oral steroids, and repeat IT injections of steroid solution. Patients who are unresponsive to treatment may resort to surgical or chemical ablation, which can cause irreversible hearing loss. We are aware that Sound Pharmaceuticals completed a Phase 2b clinical trial with SP-1005 and Auris Medical Holding AG is developing AM-125, a nasal formulation of betahistine, for the treatment of Ménière’s disease.

OTO-313

There are no drugs currently approved by the FDA for the treatment of tinnitus. Current treatments for tinnitus include the use of audio masking devices, such as white noise machines, hearing aids, cognitive behavioral therapy, and the off-label administration of antidepressants, anti-anxiety medications, and steroids. We are aware of other companies that have developed potential pharmaceutical treatments for tinnitus, including Auris Medical Holding AG, which conducted a Phase 3 clinical program evaluating repeat IT injections of Keyzilen® (formerly AM-101) in patients with tinnitus. Both Phase 3 trials failed to achieve the primary endpoint. We are also aware that Autifony Therapeutics terminated a Phase 2 trial for AUT00063 in tinnitus patients following a planned interim analysis, Merz Pharmaceuticals GmbH suspended development of oral neramexane for chronic tinnitus, and Novartis AG completed a Phase 2 clinical trial for chronic tinnitus.

Hearing Loss Programs

There are no drugs currently approved by the FDA for the treatment of hearing loss. Oral steroids and repeat IT steroid injections are often used for the treatment of sudden sensorineural hearing loss (SSNHL), which is a rapidly emergent form of hearing loss. Hearing aids are used by a subset of patients with hearing loss and a limited number of patients with severe hearing loss are treated with cochlear implants. We are aware of a number of companies in clinical development with potential pharmaceutical treatments for various hearing loss indications, including Auris Medical Holding AG, which has reported negative results for a Phase 3 trial for AM-111 in SSNHL and terminated a second Phase 3 trial early, Fennec Pharmaceuticals, which has completed two Phase 3 trials and filed a New Drug Application with the FDA for PEDMARK™ in CIHL, Metarmor, which has conducted a Phase 3 trial with D-MET in noise-induced hearing loss (NIHL), Strekin AG, which is conducting a Phase 3 trial with STR001 in SSNHL, Sound Pharmaceuticals, which has completed a Phase 2 trial with SPI-1005 in patients with NIHL, is enrolling a Phase 2 trial for aminoglycoside-induced hearing loss (AIHL) prevention, and has stated plans to initiate a Phase 2 trial in CIHL, Audion Therapeutics, which has completed a Phase 2 trial with LY3056480 in patients with mild to moderate hearing loss, Sensorion, which has initiated a Phase 2 trial with SENS-401 in SSNHL and has stated plans to initiate a Phase 2 trial in CIHL, Frequency Therapeutics, which has completed a Phase 1/2 trial with FX-322 in patients with hearing loss associated with SSNHL or NIHL and has initiated a Phase 2a trial in a similar patient population as well as two Phase 1b trials in additional hearing loss patient populations, Otologic Pharmaceutics, which has completed a Phase 1 trial with NHPN-010, Decibel Therapeutics, which has initiated a Phase 1b trial with DB-020 in CIHL, Spiral Therapeutics that has initiated a Phase 1 trial with LPT99 in SSNHL, and Pipeline Therapeutics has initiated a Phase 1/2 trial in SSNHL. We are also aware of several companies conducting preclinical development for gene therapy programs targeting congenital hearing loss including Akouos, Inc., Decibel Therapeutics, BridgeBio Pharma, Inc. and Sensorion.

Sales and Marketing

We commercialized OTIPRIO using an internal sales force beginning in the first quarter of 2016 and continued promotional support into the fourth quarter of 2017. In November 2017, we announced the discontinuation of promotional support for OTIPRIO in order to significantly reduce operating expenses related to the product, however, OTIPRIO continues to be available for purchase by customers. We entered into a co-promotion partnership with ALK in June 2020 to support the promotion of OTIPRIO for the treatment of AOE in physician offices, and amended the agreement in October 2020 to also include ALK’s promotion of OTIPRIO for use during TTP surgery in pediatric patients.

11

 

As noted above, we have recently completed enrollment in an additional Phase 3 trial for OTIVIDEX with top-line results expected in the first quarter of 2021. Assuming positive results, submission of a New Drug Application to the FDA is planned for the third quarter of 2021. Otonomy is currently developing its plans for commercialization of OTIVIDEX in the United States that may include collaboration with commercial partners.

Third-Party Payor Coverage and Reimbursement

Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by third-party payors, such as state and federal governments, including Medicare and Medicaid, and commercial insurers. Decisions regarding the extent of coverage and amount of reimbursement to be provided for our products will most likely be made on a plan-by-plan basis.

OTIPRIO

OTIPRIO is billable as a physician-administered drug in the United States using the J Code that was assigned to the product by the Centers for Medicare & Medicaid Services (CMS) and became effective as of January 1, 2017. The Wholesale Acquisition Cost for OTIPRIO is $283.20 per vial. A single vial of OTIPRIO is sufficient for treating a patient during TTP surgery or for the treatment of AOE.

OTIVIDEX, OTO-313, and OTO-413

If approved by the FDA, we intend to apply to CMS for unique J Codes for OTIVIDEX, OTO-313 and OTO-413 to support reimbursement in the physician office setting. If a J Code is granted and accepted by payors then each product is expected to be reimbursed according to its average selling price and in addition to the fee the physician receives for performing the intratympanic injection procedure itself.

Manufacturing

We currently contract with third parties for the manufacture, testing and storage of our product and product candidates and intend to continue to do so in the future. We do not own and have no plans to build our own clinical or commercial manufacturing capabilities. The use of contracted manufacturing is relatively cost-efficient and has eliminated the need for our direct investment in manufacturing facilities. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions.

Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our systems and our contractors are required to be in compliance with these regulations, and this is assessed regularly through monitoring of performance and a formal audit program. To date, our third-party manufacturers have met our manufacturing requirements for clinical trials and our third-party manufacturer for OTIPRIO successfully passed a pre-approval inspection conducted by the FDA. We expect third-party manufacturers to be capable of providing sufficient quantities of our product and product candidates to meet anticipated commercial demands. We believe that there are alternate sources of raw material supply and finished goods manufacturing that can satisfy our requirements, although we cannot be certain that transitioning to such vendors, if necessary, would not result in significant delay or material additional costs.

Poloxamer 407

The basis for the formulation of our product and certain of our product candidates is P407, a thermosensitive polymer. We currently purchase P407 from a single supplier on a purchase-order basis under a supply agreement. Although P407 is available from other sources, changing suppliers could disrupt our supply chain. We believe that we can effectively manage the risk of supply chain disruption by purchasing and storing quantities of P407 sufficient for our clinical and commercial requirements.

12

 

OTIPRIO

OTIPRIO is a suspension containing the antibiotic ciprofloxacin and P407. The raw materials needed for the manufacture of OTIPRIO are commercially available from multiple sources. We have qualified two sources of ciprofloxacin and have a supply agreement in place with one of the vendors. We currently use a single third-party contract manufacturer, Siegfried Irvine, located in Irvine, California, to produce OTIPRIO, and we believe this manufacturer can satisfy our commercial requirements as specified under a commercial supply agreement executed with this manufacturer.

OTIVIDEX

OTIVIDEX is a suspension containing the steroid dexamethasone and P407. We currently purchase dexamethasone from a single supplier on a purchase-order basis and we do not have a long-term supply agreement. Although dexamethasone is commercially available from other sources, we do not anticipate needing an alternative supplier. We believe that we can effectively manage the risk of supply chain disruption by purchasing and storing quantities of dexamethasone sufficient for our clinical, and, if OTIVIDEX is approved for marketing by the applicable regulatory authorities, our commercial requirements. We currently use two third-party contract manufacturers to produce OTIVIDEX that we believe can satisfy our initial commercial requirements.

OTO-313

OTO-313 is a formulation containing gacyclidine. We currently purchase gacyclidine from a single supplier on a purchase-order basis and we do not have a long-term supply agreement. We currently use one third-party contract manufacturer to produce OTO-313 and are currently evaluating our supply chain to ensure support of our future clinical development requirements.

OTO-413

OTO-413 is a formulation containing BDNF. We currently purchase BDNF from a single supplier on a purchase-order basis and we do not have a long-term supply agreement. We are currently evaluating our supply chain to ensure support of our future clinical development requirements.

Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product, product candidates, novel discoveries, product development technologies and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.

As for the product candidates we develop and plan to commercialize, as a normal course of business, we intend to pursue composition and therapeutic use patents, as well as novel indications for our product candidates. We also seek patent protection with respect to novel discoveries, including new active agent, delivery vehicle and delivery target applications. We have also pursued patents with respect to our proprietary manufacturing processes. We have sought and plan to continue to seek patent protection, either alone or jointly with our collaborators, as our collaboration agreements may dictate.

It is possible that our current patents, or patents which we may later acquire, may be successfully challenged or invalidated in whole or in part. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing OTIPRIO or our product candidates. It is also possible that we may not obtain issued patents from our pending patent applications or other inventions we seek to protect. Due to uncertainties inherent in prosecuting patent applications, patent applications are sometimes rejected and we subsequently abandon them. It is also possible that we may develop proprietary products or technologies in the future that are not patentable or that the patents of others will limit or altogether preclude our ability to do business. In addition, any patent issued to us may provide us with little or no competitive advantage, in which case we may abandon such patent or license it to

13

 

another entity. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”

Our patent estate includes patents and applications with claims directed to OTIPRIO, and our OTIVIDEX, OTO-313, OTO-413, and other product candidates. Our patent estate also provides patents and applications with claims directed to a broad range of other active agents as potential future product candidates that are delivered using our proprietary technologies. Our patent estate, on a worldwide basis, includes approximately 70 issued patents and allowed patent applications, and at least 68 pending patent applications in active prosecution with claims relating to our OTIPRIO, OTIVIDEX, OTO-313, OTO-413, other product candidates, future product candidates, manufacturing processes and alternative otic delivery technologies.

For OTIPRIO, we co-own a patent family with the Regents of the University of California (UC) that is directed to the composition and therapeutic use of OTIPRIO. Through an exclusive license agreement, we have acquired UC’s rights in this patent family. This family includes four issued U.S. patents and three pending U.S. applications. The latest expiry date of the U.S. patents, without extensions, is April 2030, and the first three issued U.S. patents have been Orange Book (OB) listed for otitis media with effusion undergoing TTP surgery. The fourth issued patent has been OB listed for AOE. The fifth issued patent is expected to be OB listable for AOMT, if approved by FDA.  Any future U.S. patents issuing from the related applications and directed to OTIPRIO are also expected to be OB listable. This family also includes issued patents in Australia, Canada, China, Europe, Israel, Japan and Korea. Divisional patent applications have been filed in select countries of this family. In addition, we solely own a patent family directed to certain therapeutic uses of OTIPRIO, which includes an issued U.S. patent that has been submitted for OB listing and can extend patent protection of OTIPRIO to August 2034. Furthermore, we solely own a patent family directed to OTIPRIO and its manufacturing methods, which includes an issued U.S. patent that has been OB listed and extends patent protection of OTIPRIO to July 2035; and another issued the U.S. patent that has been submitted for OB listing. Outside of U.S., this patent family includes issued patents in China and Japan and pending applications in Australia, Canada, Europe, and Korea. Finally, we solely own a patent family directed to the packaged OTIPRIO product, and two patent families directed to AOE and AOMT.

For OTIVIDEX, we co-own a patent family with UC directed to the composition and therapeutic use of OTIVIDEX. Through an exclusive license agreement, we have acquired UC’s rights in this patent family. This family includes six issued U.S. patents and one pending U.S. application. The latest expiry date of the U.S. patents, without extensions, is September 2029, and these patents and any future U.S. patent issuing from the related applications are expected to be OB listable. This family also includes issued patents or allowed applications in Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, Mexico, Russia, Singapore, South Africa, Taiwan, and the United Kingdom (UK); and pending applications in Brazil and Thailand. Divisional patent applications have been filed in select countries for this family. We solely own an issued U.S. patent directed to manufacturing methods of OTIVIDEX. The expiry date of this U.S. patent, without extensions, is April 2030.

For OTO-313, we solely own a patent family directed to, among other things, the composition and therapeutic use of OTO-313. This family includes one issued U.S. patent and one pending U.S. application and pending applications in Australia, Canada, China, Europe, Hong Kong, Israel, India, Japan, and Korea. Any future U.S. and foreign patents issuing from those applications are expected to have an expiry date of June 2037. We also solely own a patent family directed to therapeutic use of OTO-313.  Any future U.S. and foreign patents issuing from those applications are expected to have an expiry date of December 2041. In addition, we have licensed from Durect a patent family directed to the therapeutic use of OTO-313. This family includes one issued U.S. patent and one issued Japanese patent. The expiry date of the U.S. patent, without extension, is June 2024, and the patent is expected to be OB listable.

For OTO-413, we co-own a patent family with UC directed to the composition and therapeutic use of OTO-413. Through an exclusive license agreement, we have acquired UC’s rights in this patent family. Any future U.S. or foreign patents issuing from this patent family and directed to OTO-413 are expected to have an expiry date of April 2029. In addition, we solely own three patent families directed to certain aspects of the composition and therapeutic use of OTO-413. Any future U.S. or foreign patents issuing from those patent families and directed to OTO-413 are expected to have an expiry date of January 2039, January 2041 and December 2041, respectively.

14

 

For our future product candidates, we co-own eight other patent families with UC directed to a broad range of other active agents, including but not limited to, anti-TNF agents, auris pressure modulators, CNS modulators, cytotoxic agents, anti-apoptotic agents, bone-remodeling modulators, free radical modulators and ion channel modulators. As above, we have acquired, though an exclusive license, UC’s rights in those co-owned families. Furthermore, to strengthen our protection against potential design-around, we solely own two patent families directed to alternative formulations. Finally, we have acquired from IncuMed LLC, an affiliate of the NeuroSystec Corporation, patent families directed to formulations or devices that deliver active agents, such as the active agent of OTO-313, into the ear for treatment of otic diseases through alternative delivery technologies. We will continue to pursue additional patent protection as well as take appropriate measures to obtain and maintain proprietary protection for our innovative technologies.

Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are effective for 20 years from the earliest effective filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office (USPTO) delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.

In addition to patents, we have obtained trademark registrations for the “OTIPRIO” mark in the United States, Australia, Canada, China, the European Union (EU), Japan, Korea, New Zealand and the UK; we have obtained trademark registrations for the “OTONOMY” mark in the United States; and we have obtained trademark registration for the “OTIVIDEX” mark in the United States, the EU, and the UK. Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”

Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. Although it is not expected to be relevant to our product or any of our product candidates, on April 17, 2015, we filed a request for interference between one of our U.S. pending applications and a U.S. pending application that appears to be controlled by Auris Medical AG (Auris). On July 20, 2015, we received notice from the USPTO that the Patent Trial and Appeal Board (PTAB) declared an interference between our pending application and the Auris patent (issued as U.S. Patent No. 9,066,865 on June 30, 2015). On January 26, 2017, the PTAB determined that all of our patent claims and all but one of the Auris patent claims are not patentable. In addition, the PTAB determined that the written description supporting Auris’s single claim is as of Auris’s filing date of 2014 rather than the 2005 date argued by Auris.  This interference decision does not involve issued U.S. patents covering our product or product candidates. We filed a Notice of Appeal on March 27, 2017, in which we asked the Federal Circuit to reverse PTAB’s decision that our claims are not patentable and that Auris’s single claim is. On April 5, 2017, Auris filed a Notice of Cross-Appeal to ask the

15

 

Federal Circuit to reverse PTAB’s decision that Auris’s other claims are not patentable. In August 2018, the Federal Circuit issued a final ruling in Otonomy’s favor. On March 11, 2019, the PTAB entered the judgment for Otonomy and cancelled the Auris patent. On April 24, 2020, the USPTO issued a Notice of Allowance for our pending application, indicating that all of our claims are allowed. On September 15, 2020, the pending application was issued as U.S. Patent No. 10,772,828. We continue to monitor patent applications filed and being protected by Auris, in case we may need to consider similar or other actions. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”

License and Other Agreements

The Regents of the University of California

In November 2008, we entered into an exclusive license agreement with UC that was subsequently amended in January 2010, June 2010, and November 2012. Under the license agreement, UC granted us an exclusive license under UC’s rights to patents and applications that are co-developed and co-owned with us (see above regarding our patent estate) for the treatment of human otic diseases. As such, we have acquired the entire commercial rights in those patents and applications that cover OTIPRIO, OTIVIDEX and OTO-413, and may apply to other product candidates we develop. Under the agreement, UC reserved the right to use the patents and applications for its and other nonprofit institutions’ research and educational purposes.

Under our agreement with UC, we are obligated to diligently proceed with the development, manufacture and commercialization of licensed products. If we do not satisfy our diligence obligations, UC may either terminate the agreement or convert our license to a non-exclusive license. In addition, we are responsible for diligently prosecuting and maintaining the licensed patents, at our own expense; provided that if we decide to abandon a licensed patent, UC may elect to continue prosecution and maintenance of such patent at its own expense. UC has the first right to prosecute and control any action for infringement of the patents licensed to us under our agreement with UC; provided that if UC does not initiate an enforcement action against a potential infringer within the time limits specified in the agreement, we have the right to do so ourselves.

Our financial obligations under the license agreement include annual license maintenance payments until we commercialize the first product covered under the license agreement, development and regulatory milestone payments of up to $2.7 million per licensed product, of which $1.9 million has been paid for OTIPRIO, $0.8 million has been paid for OTIVIDEX, $0.4 million has been paid for OTO-413, and $0.1 million has been paid for OTO-311 (but such milestone payments are reduced by 75% for any orphan indication product), and a low single-digit royalty on net sales by us or our affiliates of licensed products. In addition, for each sublicense we grant we are obligated to pay UC a fixed percentage of all royalties as well as a sliding scale percentage of non-royalty sublicense fees received by us under such sublicense, with such percentage depending on the licensed product’s stage of development when sublicensed to such third party. We have the right to offset a certain amount of third-party royalties, milestone fees or sublicense fees against the foregoing financial obligations, provided such third-party royalties or fees are paid by us in consideration for intellectual property rights necessary to commercialize a licensed product.

Unless earlier terminated, the agreement will continue in effect until expiration of the longest-lived patent licensed to us thereunder. UC may terminate the license agreement for our uncured breach, or if a claim challenging the validity of the licensed patents is filed by or on behalf of us. We have the right to terminate this agreement for any reason at any time upon prior notice to UC. The termination of our license agreement with UC may affect a portion of our patent portfolio for OTIPRIO, OTIVIDEX and OTO-413, as well as certain other product candidates we may develop. For more information, please see the section entitled “Risk Factors—Risks Related to our Intellectual Property.”

DURECT Corporation

In April 2013, we entered into an exclusive license agreement with Durect as a part of an asset transfer agreement between us and IncuMed LLC, an affiliate of the NeuroSystec Corporation. Under this license agreement, Durect granted us an exclusive (even as to Durect), worldwide, royalty-bearing license under Durect’s rights to certain patents and applications that cover our OTO-313 product candidate, as well as certain related know-how. Included within the rights licensed from Durect is a sublicense from the Institut National de la Santé et de la Recherche Médicale (INSERM) with respect to INSERM’s ownership interest in certain patents and patent applications owned jointly by INSERM and Durect.

16

 

We are obligated to use commercially reasonable efforts to develop and commercialize licensed products containing the active ingredient gacyclidine, and in the event, we do not satisfy this obligation following an opportunity to cure, Durect may elect to either terminate the agreement or convert our license to a non-exclusive license. In addition, we are responsible for prosecuting and maintaining the licensed patents, at our own expense; provided that if we decide to abandon a licensed patent, Durect may elect to continue prosecution and maintenance of such patent at its own expense. We have the first right, but not obligation, to prosecute and control any action for infringement of the patents licensed to us under our agreement with Durect.

We are also subject to certain financial obligations under the license agreement. We are obligated to make one-time development milestone payments of up to $2.3 million for the first licensed product. Upon commercializing a licensed product, we are obligated to pay Durect tiered low single-digit royalties on annual net sales by us or our affiliates or sublicensees of the licensed products, and we have the right to offset a certain amount of third-party license fees or royalties against such royalty payments to Durect, provided such third-party fees or royalties are paid by us in connection with patent rights necessary to sell a licensed product containing the active ingredient gacyclidine. In addition, each sublicense we grant to a third party is subject to payment to Durect of a low double-digit percentage of all non-royalty payments we receive under such sublicense. Additionally, we are also obligated to pay INSERM, on behalf of Durect, a low single-digit royalty payment on net sales by us or our affiliates or sublicensees upon commercialization of the licensed product. The foregoing royalty payment obligation to Durect would continue on a product-by-product and country-by-country basis until expiration or determination of invalidity of the last valid claim within the licensed patents that cover the licensed product, and the payment obligation to INSERM would continue so long as Durect’s license from INSERM remains in effect.

Unless earlier terminated, the agreement will continue in effect until expiration of all our royalty payment obligations thereunder. Durect may terminate the license agreement for our uncured material breach, and either party may terminate the agreement upon written notice in the event of insolvency or bankruptcy of the other party. We have the right to terminate this agreement for any reason at any time upon prior notice to Durect. The termination of our license agreement with Durect would affect a portion of our patent portfolio for OTO-313. For more information, please see the section entitled “Risk Factors—Risks Related to our Intellectual Property.”

Asset Transfer Agreement

In April 2013, we entered into an asset transfer agreement with IncuMed, LLC, an affiliate of NeuroSystec Corporation, pursuant to which we acquired assets and patent rights related to gacyclidine. Pursuant to the asset transfer agreement, we made a one-time payment of $0.2 million and we are obligated to make certain one-time milestone payments in connection with the development and commercialization of products containing the active ingredient gacyclidine, up to a maximum of $5.3 million.

Government Regulation

Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, quality control, manufacture, packaging, storage, recordkeeping, approval, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in a foreign country. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects.

17

 

U.S. Drug Approval Process

In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (FDCA) and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following:

 

•

completion of nonclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s current good laboratory practice (cGLP) regulations;

 

•

submission to the FDA of an IND which must become effective before clinical trials may begin;

 

•

approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated;

 

•

performance of adequate and well-controlled clinical trials in accordance with current good clinical practices (cGCP) to establish the safety and efficacy of the proposed drug or biological product for each indication;

 

•

submission to the FDA of an NDA;

 

•

satisfactory completion of an FDA advisory committee review, if applicable;

 

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity; and

 

•

FDA review and approval of the NDA.

Nonclinical Studies

Nonclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess its potential safety and efficacy. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some nonclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Clinical Trials

Clinical trials involve the administration of the investigational new drug to patients under the supervision of qualified investigators in accordance with cGCP requirements, which include the requirement that all research patients provide their informed consent (assent, if applicable) in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website.

18

 

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

 

•

Phase 1: The drug is initially introduced into healthy human patients with the target disease or condition and tested for safety, dosage tolerability, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.

 

•

Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

•

Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA may impose a partial or full clinical hold or the sponsor may suspend or terminate a clinical trial or development at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk.

Development, or the aspects of development, that are subject to clinical hold may not continue until the sponsor has satisfied FDA requirements for information and has been notified that the hold is being removed. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

As a result of the COVID-19 public health emergency, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, and any disruption of the clinical trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19-pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual’s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial. The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, including new regulatory requirements and changes to existing regulations.

The NDA Approval Process

Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.

The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under the Prescription Drug User Fee Act (PDUFA) guidelines that are currently in effect, the FDA has a goal of ten months from the date of the FDA’s filing of a standard non-priority NDA to review and act on the submission.

19

 

The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity. The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured, which is not under the control of the product sponsor. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP.

The FDA also may require submission of a risk evaluation and mitigation strategy (REMS) plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools.

The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.

The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. Our Fast Track Designation for OTIVIDEX may not result in faster development or approval, if at all.

If the FDA’s evaluation of the NDA and inspection of the manufacturing facilities are favorable, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or nonclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.

Even if the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

20

 

The Section 505(b)(2) NDA

For modifications to products previously approved by the FDA, an applicant may file an NDA under Section 505(b)(2) of the FDCA. This section permits the submission of an NDA where some or all of the data required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Under this section, an applicant may rely on the FDA’s findings of safety and effectiveness in approval of another NDA or on studies published in the scientific literature. The applicant may be required to conduct additional studies or provide additional information to fully demonstrate the safety and effectiveness of its modifications to the approved product.

Upon approval of an NDA, the FDA lists the product in a publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations,” which is commonly known as the “Orange Book.” FDA also lists in the Orange Book patents identified by the NDA applicant as claiming the drug or an approved method of using the drug. Any applicant who submits a Section 505(b)(2) NDA must certify to the FDA with regard to each relevant patent that either (1) no patent information has been submitted to the FDA; (2) the patent has expired; (3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the Section 505(b)(2) NDA is submitted. The last certification is known as a Paragraph IV certification. A notice of Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the Section 505(b)(2) NDA refers. If the NDA holder submits the patent information to the FDA prior to submission of the Section 505(b)(2) application and the NDA holder or patent owner(s) sues the Section 505(b)(2) applicant for infringement within 45 days of its receipt of the certification notice, the FDA is prevented from approving that Section 505(b)(2) application until the earlier of 30 months from the receipt of the notice of the Paragraph IV certification, the expiration of the patent or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. A Section 505(b)(2) applicant that is sued for infringement may file a counterclaim to challenge the listing of the patent or information submitted to FDA about the patent. If we file a Paragraph IV certification with any Section 505(b)(2) application, we cannot assure you that our application will not be significantly delayed as a result of costly patent litigation.

Post-Approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.

The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies to determine compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend significant time, money and effort in the area of production and quality control to maintain cGMP compliance.

21

 

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

 

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

 

•

fines, warning letters or holds on post-approval clinical trials;

 

•

refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;

 

•

product seizure or detention, or refusal to permit the import or export of products; or

 

•

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although doctors may prescribe drugs for off-label purposes.

The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drug and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states.

Hatch-Waxman Exclusivity

Market and data exclusivity provisions under the Federal Food, Drug, and Cosmetic Act (FFDCA) can delay the submission or the approval of certain applications for competing products. The FFDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (ANDA) or a Section 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or Section 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FFDCA also provides three years of marketing exclusivity for an NDA, Section 505(b)(2) NDA or supplement to an existing NDA or Section 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or Section 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

New Legislation and Regulations

From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further

22

 

legislative changes will be enacted or FDA regulations, guidance, policies or interpretations will be changed, or what the impact of such changes, if any, may be.

Pharmaceutical Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we may obtain regulatory approval. Sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication.

In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Whether or not we conduct such studies, our product candidates may not be considered medically necessary or cost-effective. A third-party payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services and questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as OTIPRIO and our drug product candidates and could adversely affect our net revenue and results.

Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.

The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In

23

 

particular, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, which we collectively refer to as the Affordable Care Act (ACA), contains provisions that have the potential to substantially change healthcare delivery and financing, including impacting the profitability of drugs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court. It is unclear how such litigation, other efforts to repeal and replace the ACA, and healthcare measures of the current administration will impact the ACA and our business. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.

The ACA contained provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies’ share of sales to federal health care programs. For example, the ACA revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of covered drugs dispensed to individuals enrolled in Medicaid managed care organizations and subjected manufacturers to new annual fees and taxes for certain branded prescription drugs. In November 2020, the U.S. Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturer. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. It is unclear how these new regulations and healthcare measures of the current Administration will affect current policies and the impact on our business. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Healthcare Law and Regulation

Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescribing of any product candidates for which we may obtain marketing approval. Our business operations and arrangements with investigators, healthcare professionals, consultants, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may constrain the business or financial arrangements and relationships through which we research, manufacture, market, promote, sell and distribute our products that obtain marketing approval. Restrictions under applicable federal and state healthcare laws, include, but are not limited to, the following:

 

•

the federal healthcare Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;

 

•

the federal false claims laws and civil monetary penalties law impose penalties and provide for civil whistleblower or qui tam actions against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

•

the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up

24

 

 

a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;

 

•

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without proper written authorization;

 

•

the federal transparency requirements under the ACA requires manufacturers of drugs, devices, biologicals and medical supplies to annually report to CMS, an agency within HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members; effective January 1, 2022, these reporting obligations will extend to include payments and transfers of value made during the previous year to certain non-physician providers, such as physician assistants and nurse practitioners; and

 

•

analogous state and foreign laws, such as state anti-kickback and false claims laws, that may apply to our business operations, including our sales or marketing arrangements, and claims involving healthcare items or services reimbursed by governmental third-party payors, and in some instances, also such claims reimbursed by non-governmental third-party payors, including private insurers.

Similar to the federal law, certain states also have adopted marketing and/or transparency laws relevant to manufacturers, some of which are broader in scope. Other states impose restrictions on manufacturers’ marketing practices and require tracking and reporting of gifts, compensation, and other remuneration to healthcare professionals and entities. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.  For instance, EU data protection law, in particular the EU General Data Protection Regulation (the GDPR), which became fully applicable in May 2018, includes, among other things, requirements for individuals’ consent, restrictions on the processing of health data, notice obligations, restrictions for the transfer of personal data outside of the EU, security and confidentiality obligations, and significant fines in case of violation.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant administrative, civil, and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to administrative, civil, and/or criminal sanctions, including exclusions from government funded healthcare programs.

Foreign Regulation

In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. The cost of establishing a regulatory compliance system for numerous varying jurisdictions can be very significant. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or

25

 

delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

The U.S. Foreign Corrupt Practices Act and Other Anti-Corruption Laws

We may be subject to a variety of domestic and foreign anti-corruption laws with respect to our regulatory compliance efforts and operations. The U.S. Foreign Corrupt Practices Act, commonly known as the FCPA, is a criminal statute that prohibits an individual or business from paying, offering, promising or authorizing the provision of money (such as a bribe or kickback) or anything else of value (such as an improper gift, hospitality, or favor), directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision in order to assist the individual or business in obtaining, retaining, or directing business or other advantages (such as favorable regulatory rulings). The FCPA also obligates companies with securities listed in the United States to comply with certain accounting provisions. Those provisions require a company such as ours to (i) maintain books and records that accurately and fairly reflect all transactions, expenses, and asset dispositions, and (ii) devise and maintain an adequate system of internal accounting controls sufficient to provide reasonable assurances that transactions are properly authorized, executed and recorded. The FCPA is subject to broad interpretation by the U.S. government. The past decade has seen a significant increase in enforcement activity. In addition to the FCPA, there are a number of other federal and state anti-corruption laws to which we may be subject, including, the U.S. domestic bribery statute contained in 18 USC § 201 (which prohibits bribing U.S. government officials) and the U.S. Travel Act (which in some instances addresses private-sector or commercial bribery both within and outside the United States). Also, a number of the countries in which we conduct activities have their own domestic and international anti-corruption laws, such as the UK Bribery Act 2010. There have been cases where companies have faced multi-jurisdictional liability under the FCPA and the anti-corruption laws of other countries for the same illegal act.

We can be held liable under the FCPA and other anti-corruption laws for the illegal activities of our employees, representatives, contractors, partners, agents, subsidiaries, or affiliates, even if we did not explicitly authorize such activity. Although we will seek to comply with anti-corruption laws, there can be no assurance that all of our employees, representatives, contractors, partners, agents, subsidiaries or affiliates will comply with these laws at all times. Noncompliance with these laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain governments or other persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. In addition, our directors, officers, employees, and other representatives who engage in violations of the FCPA and certain other anti-corruption statutes may face imprisonment, fines, and penalties. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management’s attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our business, results of operations, and financial condition.

Human Capital

As of December 31, 2020, we had 56 full-time employees. Of these employees, 44 were engaged in research and development activities, and 12 were engaged in general and administrative activities. None of our employees is represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our employees. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to remain focused on corporate objectives and perform to achieve our corporate objectives.

In addition, as a result of the COVID-19 pandemic, we have taken steps to protect the health and safety of our employees and community by generally adopting a work from home policy in line with directives from the State of

26

 

California and the applicable local governments, and guidance from the CDC. On-site activities have been restricted to certain essential facility and laboratory support functions and various safety protocols have been implemented.

Channels for Disclosure of Information

Investors, the media and others should note that we may announce material information to the public through filings with the SEC, our website (www.otonomy.com), press releases, public conference calls and public webcasts. We encourage our investors, the media and others to follow the channels of disclosure listed above and review the information disclosed through any such channels as such information could be deemed to be material information. Please note that this list of channels of disclosure may be updated from time to time.

Corporate Information

We were incorporated in Delaware on May 6, 2008. Our principal executive offices are located at 4796 Executive Drive, San Diego, CA 92121. Our telephone number is (619) 323-2200. Our website address is www.otonomy.com.

This Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, (Exchange Act) are available (free of charge) on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

Information contained on, or that can be accessed through, our website or social media sites does not constitute part of this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual references only.

Otonomy, the Otonomy logo, OTIPRIO, OTIVIDEX and other trademarks or service marks of Otonomy are the property of Otonomy. Other service marks, trademarks, and tradenames referred to in this Annual Report on Form 10-K are the property of their respective owners. Except as set forth above and solely for convenience, the trademarks and tradenames in this Annual Report on Form 10-K are generally referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

 

ITEM 1A.Risk Factors

An investment in our securities involves a high degree of risk. You should carefully consider the specific factors discussed below, as well as all other information included in this Annual Report on Form 10-K, including our financial statements, the notes thereto and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any of the following risks actually occurs, our business, financial condition, operating results, prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in our securities.

Risk Factors Summary

Our business is subject to numerous risks and uncertainties, including those outside of our control, that could cause our actual results to be harmed, as fully described below. The principal factors and uncertainties that make investing in our company risky include, among others:

 

•

We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability.

27

 

 

•

We have not yet generated significant product revenue and may never become profitable.

 

•

We will require additional financing to obtain regulatory approval for OTIVIDEX, OTO-313, OTO-413 and any other product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our commercialization efforts, product development, or other operations.

 

•

A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, could materially and adversely affect our business, operations and financial condition.

 

•

We are dependent upon the clinical, regulatory and commercial success of OTIVIDEX for Ménière’s disease.

 

•

In addition to OTIVIDEX, our long-term prospects depend in part upon advancing additional product candidates, such as OTO-313 and OTO-413, through clinical development to regulatory approval and commercialization.

 

•

OTIPRIO and our product candidates, OTIVIDEX, OTO-313, OTO-413 or any future product candidates that obtain regulatory approval, may fail to achieve the broad degree of market acceptance and use necessary for commercial success, and market opportunity for these products may be smaller than we estimate.

 

•

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.

 

•

We may be unable to obtain regulatory approval for our product candidates other than OTIPRIO. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations.

 

•

Use of our product or product candidates could be associated with undesirable side effects or adverse events that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

 

•

OTIPRIO and our product candidates, if approved, will face significant competition in the biopharmaceutical industry, and our failure to effectively compete with competitor drugs, including off-label drug use, and future competitors may prevent us from achieving significant market penetration and expansion.

 

•

We rely on third parties to conduct many of our nonclinical studies and all our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for, or commercialize, our product candidates.

 

•

If our efforts to protect the intellectual property related to our product and product candidates are not adequate, we may not be able to compete effectively in our market.

 

•

Our business and products are subject to extensive government regulation.

Risks Related to Our Financial Condition and Capital Requirements

We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability.

We are a commercial-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred losses in each year since we commenced operations in 2008. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have obtained U.S. regulatory approval and launched a single product, OTIPRIO, but have not yet generated significant revenue. We continue to incur significant research and development expenses related to our clinical trials and product development activities and other selling, general and administrative expenses. We have recorded net losses of $44.7 million, $44.7 million and

28

 

$50.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $504.6 million.

We have not yet generated significant product revenue and may never become profitable.

We expect to continue to incur significant losses for the foreseeable future. Our ability to achieve significant revenue and profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals and successfully commercialize our products. We may never succeed in these activities and may never generate revenue that is significant or large enough to achieve profitability. We launched OTIPRIO in March 2016, but we have not generated significant revenue from sales of OTIPRIO, and in November 2017, we announced the discontinuation of our promotional support for OTIPRIO in TTP surgery. In August 2018, we announced the initiation of a partnership with Mission, and in May 2019, we announced the initiation of a partnership with Glenmark, both for the promotion of OTIPRIO to certain end users involved in the treatment of patients for AOE. In July 2019, we were notified by Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris™ allergy product, and the impact of such delay on its business operations. In August 2019, Mission informed us of its non-renewal of the co-promotion agreement.

In June 2020, we entered into a co-promotion agreement with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients, but there are no assurances that such partnership will be successful or that it will not be terminated earlier than we expect. If the co-promotion agreement with ALK is terminated in the future then we may seek other promotional partners for OTIPRIO, but there are no assurances that we will be able to find a new promotional partner or that the terms and timing of any such arrangements would be acceptable to us. Such partnerships may not generate significant revenue, may not be successful, and may be terminated. In addition, we currently have limited sales and marketing capabilities. If we are unable to enter into arrangements on acceptable terms or at all, or if such arrangements are not successful, we may not be able to successfully commercialize our products or generate product revenue. Any failure or delay in entering promotional partnerships or developing our internal sales, marketing and distribution capabilities could adversely impact the commercialization of our products. If we are not successful in commercializing our products, either on our own or through partnering with one or more third parties, our future product revenue may suffer and we could incur significant additional losses. Even if we achieve profitability in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital and any failure to become and remain profitable may adversely affect the market price of our common stock, our ability to raise capital, and our viability.

We will require additional financing to obtain regulatory approval for OTIVIDEX, OTO-313, OTO-413 and any other product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our commercialization efforts, product development, or other operations.

Since our inception, most of our resources have been dedicated to the development of OTIPRIO and our product candidates, OTIVIDEX, OTO-313 (formerly OTO-311) and OTO-413. In particular, conducting clinical trials for OTIVIDEX, OTO-313 and OTO-413 will require substantial funds. We have funded our operations primarily through the sale and issuance of common stock, convertible preferred stock and convertible notes. As of December 31, 2020, we had cash, cash equivalents and short-term investments of $86.3 million and an outstanding debt balance of $15.2 million, net of debt discounts. We believe that we will continue to expend substantial resources for the foreseeable future for the continued development of OTIVIDEX, OTO-313, OTO-413 and any other product candidates we may choose to pursue. These expenditures will include costs associated with marketing and selling any products approved for sale, manufacturing, preparing regulatory submissions, and conducting nonclinical studies and clinical trials. We cannot estimate with reasonable certainty the actual amounts necessary to successfully complete the development and commercialization of our product candidates.

Our future capital requirements depend on many factors, including:

 

•

the timing of, and the costs involved in, nonclinical and clinical development and obtaining regulatory approvals for OTIVIDEX, OTO-313, OTO-413 or any other product candidates;

29

 

 

•

the cost of manufacturing OTIPRIO and our product candidates;

 

•

the revenue generated by OTIPRIO and our product candidates, if approved;

 

•

the cost of commercialization activities for OTIPRIO and any of our product candidates that may be approved for sale, if any, including marketing, sales and distribution costs;

 

•

the number and characteristics of any other product candidates we develop or acquire;

 

•

our ability to establish and maintain strategic collaborations, licensing, development or commercialization arrangements and the terms and timing of such arrangements;

 

•

the degree and rate of market acceptance of OTIPRIO and any other approved products;

 

•

the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments;

 

•

the expenses needed to attract and retain skilled personnel;

 

•

the costs associated with being a public company;

 

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation;

 

•

the costs associated with legal and regulatory compliance;

 

•

the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments; and

 

•

the cost of litigation, including any product liability or other lawsuits related to our products.

Additional capital may not be available when we need it, on terms that are acceptable to us or at all. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our sales and marketing, manufacturing or distribution capabilities or other activities that may be necessary to commercialize our product or product candidates, nonclinical studies, clinical trials or other development activities.

If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product or product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. In addition, we have a sales agreement in place with Cowen and Company, LLC (Cowen) to sell up to $40.0 million worth of shares of our common stock, from time to time, through an “at the market” equity offering program under which Cowen will act as sales agent or principal. As of December 31, 2020, $40.0 million worth of shares of our common stock remained available for sale under the “at the market” equity offering program. If we raise additional capital through our “at the market” equity offering program, or other public or private equity offerings, the ownership interest of our existing stockholders will be diluted and the terms of any new equity securities may have preferential rights over our common stock. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our product, develop and commercialize our product candidates or operate as a business. Any collaboration agreements we enter into may provide capital in the near-term but limit our potential cash flow and revenue in the future. Any of the foregoing could significantly harm our business, financial condition and prospects.

A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, could materially and adversely affect our business, operations and financial condition.

Outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, could significantly disrupt our business. Such outbreaks pose the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time due to spread of the disease, or due to

30

 

shutdowns that may be requested or mandated by federal, state and local governmental authorities. Business disruptions could include disruptions or restrictions on our ability to travel, as well as temporary closures of our facility, the facilities of our partners, clinical trial sites, service providers, suppliers or contract manufacturers. While it is not possible at this time to estimate the overall impact that the COVID-19 pandemic could have on our business, the continued rapid spread of COVID-19, both across the United States and through much of the world, and the measures taken by the governments of countries and local authorities affected has disrupted and could delay our ongoing clinical trials, and could disrupt and delay our preclinical activities, the manufacture or shipment of both drug substance and finished drug product for preclinical testing and clinical trials and adversely impact our business, financial condition or operating results.

For example, the state of California, where our corporate offices are located, has issued orders for all residents to remain at home, except as needed for essential activities as a result of the COVID-19 pandemic and we have had to implement work from home policies that may continue for an indefinite period. We have taken steps to protect the health and safety of our employees and community, while working to ensure the sustainability of our business operations as this unprecedented situation continues to evolve.  We continue to evaluate the impact COVID-19 may have on our ability to effectively conduct our business operations as planned, and work with healthcare providers supporting our clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies, but there can be no assurance that we will be able to avoid part or all of any impact from the spread of COVID-19 or its consequences.

We have clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. As a result of the pandemic, enrollment of new patients in our OTIVIDEX trial was being managed on a site by site basis according to local conditions for a time and we temporarily paused new patient enrollment in our Phase 1/2 clinical trial of OTO-413 for a short period and then resumed enrollment on a site by site basis. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, we had suspended and subsequently updated our guidance regarding timing of trial results. We may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic. In addition, we have made and we (and our CROs) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020 which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including, among other requirements, the requirements to include in the clinical trial report contingency measures implemented to manage the clinical trial, any disruption of the clinical trial as a result of the COVID-19 pandemic, and analyses and corresponding discussions that address the impact of implemented contingency measures on the safety and efficacy results reported for the clinical trial. To the extent we (or our third party suppliers and manufacturers) are required to implement additional or to modify existing policies and procedures for our clinical studies and/or manufacturing functions, or if the pandemic significantly impacts recruitment of patients or the conduct of our clinical studies, our anticipated timelines for initiating or completing clinical studies and seeking regulatory approval may be substantially delayed, and we may incur additional costs. Also, to the extent FDA and other regulatory authorities experience any delays or limited resources in reviewing our regulatory applications or requests for meetings and/or guidance, and inspection of manufacturing facilities prior to regulatory approval due to the COVID-19 pandemic or other reasons, we may experience significant delays in our anticipated timelines for our clinical studies and/or seeking regulatory approvals, which could adversely affect our business.

Third-party manufacturers which we use for the supply of materials for our product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although we expect no material impact on the clinical supply of our product candidates for our current clinical trials, should our third-party manufacturers experience extended disruptions, we could experience delays in future trials. Further, in June 2020, FDA issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug products manufacturing, including recommendations for manufacturing controls to prevent contamination of drugs. Such guidance and any future guidance or regulatory requirements impacting drug product manufacturing, including delays associated with complying with new requirements, could impact the operations of our contract manufacturers, our business, and our ability to obtain sufficient supplies for our clinical development on a timely basis.

Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which

31

 

may delay our clinical timelines, the development of our product candidates, and regulatory approval for our product candidates.

We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, and any disruption of the clinical trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19-pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual’s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial.

The COVID-19 pandemic continues to rapidly evolve. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to address its impact, including on financial markets or otherwise. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis could have a material negative impact on our business, financial condition and operating results. To the extent that COVID-19 pandemic impacts our business in any way, it may also have the effect of heightening the impact of the risk factors outlined in this section.

Risks Related to Our Product and Product Candidates

We are dependent upon the clinical, regulatory and commercial success of OTIVIDEX for Ménière’s disease.

We have invested substantial resources in the development of OTIVIDEX. We have completed two Phase 3 clinical trials for OTIVIDEX in Ménière’s disease patients. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint while the AVERTS-1 trial, conducted in the United States, did not. Based on a Type C meeting with the FDA, we believe that one additional successful pivotal trial is sufficient to support the U.S. registration of OTIVIDEX in Ménière’s disease. We have completed enrollment in such additional Phase 3 trial with top-line results expected in the first quarter of 2021.

OTIVIDEX is subject to the risks associated with completing such pivotal trial and any future clinical trials required for registration, including risks associated with:

 

•

the successful and timely implementation and completion of such clinical trials of OTIVIDEX;

 

•

the potential impacts of the COVID-19 pandemic;

 

•

the use of, integrity of, patient compliance with, and adequacy of patient reported outcomes in such clinical trials;

 

•

our ability to demonstrate with substantial clinical evidence the safety and efficacy of OTIVIDEX in such clinical trials;

 

•

the successful implementation and completion of any additional clinical safety studies or any additional non-clinical studies that may be required by the FDA;

 

•

the ability to ensure compliance with new or existing laws or regulations; and

 

•

the ability to submit an NDA for regulatory approval to the FDA.

32

 

 

If we are able to successfully complete the clinical trials required for OTIVIDEX registration, its success will still remain subject to the risks associated with obtaining regulatory approval from the FDA and being manufactured and commercialized, including risks associated with:

 

•

the successful completion of all non-clinical studies required to support regulatory approval by the FDA;

 

•

the adequacy and acceptance of the statistical analysis plan;

 

•

the timing of review, as the FDA’s grant of Fast Track designation for OTIVIDEX does not guarantee priority review;

 

•

the FDA’s acceptance of our NDA submission for OTIVIDEX;

 

•

the successful and timely receipt of necessary marketing approval from the FDA to allow us to begin commercializing OTIVIDEX in the United States;

 

•

the ability to manufacture commercial supplies of OTIVIDEX in compliance with cGMP;

 

•

our success in selling OTIVIDEX and achieving broad market acceptance;

 

•

our success in educating physicians and patients about the benefits, administration and use of OTIVIDEX;

 

•

the availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments for Ménière’s disease;

 

•

patient demand for the treatment of Ménière’s disease;

 

•

the availability of coverage and adequate reimbursement for OTIVIDEX;

 

•

our ability to enforce our intellectual property rights in and to OTIVIDEX; and

 

•

a continued acceptable safety profile of OTIVIDEX following approval.

Many of these clinical, regulatory and commercial matters are beyond our control and are subject to other risks described elsewhere in this “Risk Factors” section. Accordingly, we cannot assure you that we will be able to advance OTIVIDEX through final clinical development, or obtain regulatory approval of, manufacture, commercialize or generate significant revenue from OTIVIDEX. If we cannot do so, or are significantly delayed in doing so, our business will be materially harmed.

In addition to OTIVIDEX, our long-term prospects depend in part upon advancing additional product candidates, such as OTO-313 and OTO-413, through clinical development to regulatory approval and commercialization.

Although we are focused upon continued development, regulatory approval and commercialization of OTIVIDEX, the development of OTO-313, OTO-413 and other product candidates for the treatment of inner ear disorders is a key element of our long-term strategy. These programs are currently most subject to the risks associated with nonclinical and clinical development, including the risks associated with:

 

•

generating sufficient data to support the initiation or continuation of clinical trials;

 

•

obtaining regulatory approval to commence clinical trials;

 

•

contracting with the necessary parties to conduct clinical trials;

 

•

enrolling sufficient numbers of subjects or patients in clinical trials;

 

•

the use of, integrity of, patient compliance with, and adequacy of patient reported outcomes in such clinical trials;

 

•

our ability to demonstrate with substantial clinical evidence the safety and efficacy of such product candidates in such clinical trials;

 

•

the ability to ensure compliance with new or existing laws or regulations;

33

 

 

 

•

the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and

 

•

adverse events in the clinical trials.

Even if we successfully advance OTO-313 or OTO-413 through clinical development, or advance other product candidates from our hearing loss programs or any other future product candidate into clinical development, their success will be subject to all the clinical, regulatory and commercial risks described elsewhere in this “Risk Factors” section. Accordingly, we cannot assure you that we will ever be able to develop, obtain regulatory approval of, commercialize or generate significant revenue from OTO-313, OTO-413, any other product candidate from our hearing loss programs or any other future product candidate.

Risks Related to Our Business and Strategy

OTIPRIO and our product candidates, OTIVIDEX, OTO-313, OTO-413 or any future product candidates that obtain regulatory approval, may fail to achieve the broad degree of market acceptance and use necessary for commercial success, and market opportunity for these products may be smaller than we estimate.

OTIPRIO and our product candidates, if approved, may not achieve market acceptance among physicians and patients, and may not be commercially successful. For OTIPRIO, treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery is currently addressed with the off-label use of antibiotic ear drops, but antibiotic ear drops are approved for the AOE indication. We launched OTIPRIO in March 2016, but we have not generated significant revenue from sales of OTIPRIO, and in November 2017, we announced the discontinuation of our promotional support for OTIPRIO in TTP surgery. In August 2018, we announced the initiation of a partnership with Mission, and in May 2019, we announced the initiation of a partnership with Glenmark, both for the promotion of OTIPRIO to certain end users involved in the treatment of patients for AOE. In July 2019, we were notified by Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on its business operations. In August 2019, Mission informed us of its non-renewal of the co-promotion agreement. In June 2020, we entered into a co-promotion agreement with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients, but there are no assurances that such partnership will be successful or that it will not be terminated earlier than we expect.

There are currently no FDA-approved drug treatments for the indications we are pursuing for our product candidates. Our proposed initial indication for OTIVIDEX is the treatment of vertigo associated with Ménière’s disease. Currently, Ménière’s disease patients are routinely prescribed a low-salt diet and off-label use of diuretics. Physicians may also prescribe the off-label use of antihistamines, anticholinergics, phenothiazines and benzodiazepines as well as corticosteroids. Our proposed indication for OTO-313 is the treatment of tinnitus. Currently, physicians may attempt to treat tinnitus symptoms with the off-label use of steroids, anxiolytics, antidepressants, and antipsychotics. Our target indication for OTO-413 is the treatment of speech-in-noise hearing difficulties. A subset of patients with this condition are currently treated with hearing aids. The commercial success of OTIPRIO and our product candidates, if approved, will depend significantly on the adoption and use of the resulting products by physicians for approved indications. The decision to elect treatment with OTIPRIO for middle ear effusion in pediatric patients requiring TTP surgery and AOE, or to elect to utilize OTIVIDEX for Ménière’s disease, OTO-313 for tinnitus or OTO-413 for speech-in-noise hearing difficulties, rather than other products or treatments, may be influenced by a number of factors, including:

 

•

the cost, safety and effectiveness of our products as compared to other products or treatments;

 

•

physician willingness to adopt our product in lieu of other products or treatments;

 

•

ability to gain utilization in facilities responsible for purchasing our products;

 

•

the extent to which physicians recommend our products to their patients;

 

•

patient or caregiver sentiment about the benefits and risks of our products;

 

•

proper training and administration of our products by physicians and medical staff, such that their patients do not experience excessive discomfort during treatment or adverse side effects;

 

•

the procedural risks of IT injection;

34

 

 

 

•

overcoming any biases physicians or patients may have in favor of other products or treatments;

 

•

patient preference for non-injectable treatments;

 

•

patient or caregiver satisfaction with the results and administration of our product and overall treatment experience, including relative convenience and ease of administration;

 

•

the effectiveness of our sales and marketing efforts;

 

•

demand for the treatment of the relevant diseases or disorders;

 

•

product labeling or product insert requirements of the FDA or other regulatory authorities;

 

•

the prevalence and severity of any adverse events;

 

•

the revenue and profitability that our products will offer a physician as compared to other products or treatments;

 

•

the availability of coverage and adequate reimbursement by third-party payors and government authorities and perceptions regarding such availability; and

 

•

general patient or caregiver confidence, which may be impacted by economic and political conditions.

Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties, some of which we commissioned. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Similarly, although the studies we have commissioned are based on information that we believe to be complete and reliable, we cannot guarantee that such information is accurate or complete. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. Further, we have commissioned a number of market studies that are specific to us and to our product candidates and used the results of these studies to help assess our market opportunity. While we believe that our internal assumptions and the bases of our commissioned studies are reasonable, no independent source has verified such assumptions or bases. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for our product candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability.

If our product candidates, if approved for use, fail to achieve the broad degree of market acceptance necessary for commercial success, our operating results and financial condition will be adversely affected. In addition, even if any of our products gain acceptance, the markets for treatment of patients with our target indications may not be as significant as we estimate.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.

Clinical testing is expensive, can take many years to complete and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. The results of nonclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. There is a high failure rate for drugs proceeding through clinical trials, and product candidates in later stages of clinical trials may fail to show the required safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. For instance, our AVERTS-2 Phase 3 clinical trial for OTIVIDEX in Ménière’s disease patients, conducted in Europe, achieved its primary endpoint, while our AVERTS-1 Phase 3 clinical trial, conducted in the United States, did not. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials, and we cannot be certain that we will not face similar

35

 

setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates or support the indications which we are pursuing.

From time to time, we may publicly disclose preliminary, interim or top-line data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously disclosed. As a result, top-line data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could materially affect our business, financial condition, results of operations and growth prospects. If the preliminary or top-line data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could materially affect our business, financial condition, results of operations and growth prospects.

We have in the past experienced delays in our clinical trials and we may in the future. We do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including failure to:

 

•

generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;

 

•

obtain regulatory approval, or feedback on trial design, to commence a clinical trial;

 

•

identify, recruit and train suitable clinical investigators;

 

•

reach agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites;

 

•

obtain and maintain institutional review board (IRB) approval at each clinical trial site;

 

•

identify, recruit and enroll suitable patients to participate in a clinical trial;

 

•

have a sufficient number of patients complete a clinical trial or return for post-treatment follow-up;

 

•

ensure clinical investigators observe trial protocol and comply with Good Clinical Practices (GCP) or continue to participate in a clinical trial;

 

•

address any patient safety concerns that arise during the course of a clinical trial;

 

•

address any conflicts and ensure compliance with new or existing laws or regulations;

 

•

add a sufficient number of clinical trial sites;

 

•

timely manufacture sufficient quantities of product candidate for use in clinical trials; or

 

•

have sufficient capital to fund a clinical trial.

Patient enrollment is a significant factor in the timing of clinical trials. We may not be able to initiate or continue clinical trials for our product candidates on a timely basis if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Patient enrollment is affected by many factors, including the size and nature of the patient population, the proximity of and access by patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials, clinicians’ and patients’ or caregivers’ perceptions as to the potential advantages of the drug candidate being studied in relation to other

36

 

available therapies, including any new drugs or treatments that may be approved for the indications we are investigating, and factors, including quarantine restrictions, due to the COVID-19 pandemic.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such clinical trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such clinical trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

For example, OTIVIDEX was previously subject to Full Clinical Hold that was removed in July 2013 and then subject to Partial Clinical Hold that was removed in June 2014. The removal of Full Clinical Hold allowed us to initiate the Phase 2b clinical trial. As a result of OTIVIDEX being placed on Full Clinical Hold, OTIPRIO was also placed on Full Clinical Hold. The OTIPRIO Full Clinical Hold was removed in November 2012. We cannot assure you that our product candidates will not be subject to new clinical holds or significant delay in the future.

We received questions from the FDA regarding use of the Generalized Poisson model to analyze the daily vertigo count data reported by patients in our ongoing OTIVIDEX Phase 3 clinical trial, and we submitted to the FDA a revised statistical analysis plan that uses a statistical test called the Negative Binomial model for the primary analysis. FDA’s review of the revised statistical analysis plan confirmed our use of the Negative Binomial model for analysis of the primary endpoint in this ongoing trial. However, we cannot guarantee that our revised statistical analysis plan and associated target enrollment plan will be adequate. If the FDA does not agree with how we implemented the statistical analysis plan or our conclusions, we may not receive regulatory approval for our product candidate or we may be required to conduct additional studies that may significantly delay approval, any of which will severely impact our business.

If we experience delays in the initiation or completion of any clinical trial of our product candidates for any reason, or if any clinical trial is terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

We may be unable to obtain regulatory approval for our product candidates other than OTIPRIO. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations.

The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA and by foreign regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market our product candidates, we must provide clinical data that demonstrates with substantial evidence the safety and efficacy of the product for the intended indication. Other than OTIPRIO in the United States, we have not yet obtained regulatory approval to market any of our other product candidates in the United States or any other country. Our business depends upon obtaining these regulatory approvals.

37

 

The FDA can delay, limit or deny approval of our product candidates for many reasons, including:

 

•

our inability to satisfactorily demonstrate that the product candidates are safe and effective for the requested indication;

 

•

the FDA’s disagreement with our trial protocol or the interpretation and analysis of data from nonclinical studies or clinical trials;

 

•

the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the full population for which we seek approval;

 

•

our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks;

 

•

the FDA’s determination that additional nonclinical or clinical trials are required;

 

•

the FDA’s non-approval of the formulation, labeling or the specifications of our product candidates;

 

•

the FDA’s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract, or our inability to manufacture our product candidates pursuant to cGMP; or

 

•

the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval.

Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our business, results of operations and prospects.

Use of our product or product candidates could be associated with undesirable side effects or adverse events that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

Our product or product candidates could be associated with side effects or adverse events which can vary in severity and frequency. Side effects or adverse events associated with the use of our product or product candidates may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval for our product candidates or market our product or product candidates, if approved. Side effects such as toxicity or other safety issues associated with the use of our product or product candidates could affect patient recruitment or the ability of enrolled subjects to complete the trial, require us to perform additional studies, or halt development or sale of our product or product candidates or expose us to product liability lawsuits which will harm our business. We may be required by regulatory agencies to conduct additional nonclinical or clinical trials regarding the safety and efficacy of our product or product candidates which we have not planned or anticipated. We cannot assure you that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.

Some patients in our clinical trials have reported adverse events after being treated with OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. For example, in the Phase 1/2 clinical trial for OTO-313, one patient reported symptoms associated with Grade 2 (moderate) stress cardiomyopathy, a serious adverse event, which was determined not to be treatment related, and six other patients reported Grade 1 (mild) or Grade 2 (moderate) adverse events. If we are successful in commercializing our product or product candidates, the FDA and other foreign regulatory agency regulations will require that we promptly report certain information about adverse medical events

38

 

if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product or product candidates. If we fail to comply with our reporting obligations, the FDA or other foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.

OTIPRIO and our product candidates, if approved, will face significant competition in the biopharmaceutical industry, and our failure to effectively compete with competitor drugs, including off-label drug use, and future competitors may prevent us from achieving significant market penetration and expansion.

The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. If approved, our products must compete with off-label drug use by physicians to treat the indications for which we seek approval, such as, in the case of OTIPRIO, the current use of inexpensive generic antibiotic ear drops to treat middle ear effusion in patients requiring TTP surgery. We are also aware that other companies, such as Akouos, Inc., Arbor Pharmaceuticals, LLC, Audion Therapeutics, Auris Medical Holding AG, Autifony Therapeutics Ltd., BridgeBio Pharma, Inc., Decibel Therapeutics, Inc., Fennec Pharmaceuticals Inc., Frequency Therapeutics, Laboratorios SALVAT S.A., Novartis AG, Otologic Pharmaceutics Inc., Pipeline Therapeutics, Sensorion SA, Sound Pharmaceuticals Inc., Spiral Therapeutics, and Strekin AG are commercializing products or developing potential products for the treatment of various otic indications, including ear infections, tinnitus, Ménière’s disease and hearing loss. Many companies in the biopharmaceutical industry have greater resources to discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. These companies may develop new drugs to treat the diseases and disorders we target or seek to have existing drugs approved for use for new indications that treat the diseases and disorders we target. Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated in potential competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective, easier to administer or less costly than our product or product candidates.

We rely on third parties to conduct many of our nonclinical studies and all our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for, or commercialize, our product candidates.

We do not have the ability to independently conduct many of our nonclinical studies or any of our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations, comply with applicable laws, including with respect to data privacy, or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised or access to such data is impaired due to the failure to adhere to our clinical protocols, regulatory requirements, unauthorized system or data access, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize our product candidates.

39

 

We and the third parties upon whom we rely are required to comply with GCP, which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the regulatory authorities may require us to perform additional clinical trials before reviewing or approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations.

In addition, our clinical trials must be conducted with drug supply produced under cGMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days’ notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs, clinical investigators or other third parties on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects, financial condition or results of operations.

We rely completely on third parties to manufacture our nonclinical, clinical drug supplies and commercial supplies of OTIPRIO and any other approved products.

We outsource the manufacture of OTIPRIO and our product candidates. We do not currently have the infrastructure or internal capability to manufacture supplies of OTIPRIO or our product candidates for use in development and commercialization. If we were to experience an unexpected loss of supply of OTIPRIO or our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, our business would be harmed, and we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, we may be required to manufacture additional supplies of our product candidates to the extent our estimates of the amounts required prove inaccurate, we suffer unexpected losses of product candidate supplies, or to the extent that we are required to have fresh product candidate supplies manufactured to satisfy regulatory requirements or specifications. Any significant delay or discontinuation in the supply of OTIPRIO or a product candidate, or the raw material components thereof, due to the need to replace a contract manufacturer or other third-party manufacturer, could considerably harm our business and ability to generate revenue and delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.

Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance (including compliance with cGMPs), the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. The facilities used by our third-party manufacturers must be accepted by the FDA pursuant to inspections that will be conducted before approval and after we submit our NDA to the FDA. We do not control the implementation of the manufacturing process of, and are completely dependent on, our third-party manufacturers for compliance with the regulatory requirements, for manufacture of both active drug substances and finished drug products. If our third-party manufacturers cannot successfully manufacture material that conforms to applicable specifications in our regulatory applications and the strict regulatory requirements of the

40

 

FDA or foreign regulatory authorities, we will not be able to secure and/or maintain regulatory acceptance of our contract manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers or other third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. The failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of OTIPRIO or our product candidates or any other product candidates or products that we may develop. In addition, if the FDA does not accept these facilities for the manufacture of our product or our product candidates or if it withdraws any such acceptance in the future, we will need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any failure or refusal to supply the components for our product or our product candidates could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected product or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.

We may encounter issues with manufacturing as we commercialize OTIPRIO or our product candidates, if approved.

We have limited experience manufacturing OTIPRIO for commercial use, and our product candidates have never been manufactured for commercial use. There are risks associated with manufacturing for commercial use including, among others, potential problems with forecasting and cost overruns, process reproducibility, storage availability, stability issues, lot consistency and timely availability of materials. We cannot assure you that our contract manufacturers will be able to manufacture any approved product to specifications acceptable to the FDA or foreign regulatory authorities, or to produce it in sufficient quantities to meet the market demand. We have in the past manufactured, and may in the future manufacture, batches of OTIPRIO that do not meet the appropriate specifications and cannot be used. We may also manufacture OTIPRIO or any approved product that remains unused due to obsolescence, expiry or quantities in excess of expected demand. If our contract manufacturers are unable to successfully produce sufficient quantities of any approved product for commercialization, our commercial efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.

We depend on a small number of suppliers for the raw materials necessary to produce OTIPRIO and our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.

We depend on the availability of key raw materials, including poloxamer for OTIPRIO and our product candidates, ciprofloxacin for OTIPRIO, dexamethasone for OTIVIDEX, gacyclidine for OTO-313 and BDNF for OTO-413, from a small number of third-party suppliers. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product and product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce OTIPRIO for required commercial supplies or our product candidates for our clinical trials. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, commercial sales of OTIPRIO and the development of OTIVIDEX, OTO-313, OTO-413 or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.

Our ability to market OTIPRIO is limited to its approved indications, and our product candidates, if approved, will be limited to certain indications. If we want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted.

OTIPRIO is currently approved for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery and for the treatment of AOE and is in development for AOMT. We are developing OTIVIDEX for the treatment of vertigo associated with Ménière’s disease, OTO-313 for the treatment of tinnitus and OTO-413 for the treatment of hearing loss. The FDA and other applicable regulatory agencies will restrict our ability to market and advertise our products to the scope of the approved label for the applicable product and for no

41

 

other indications, which could limit physician and patient adoption. We may attempt to develop new treatment indications for our product or product candidates in the future, but we cannot predict when or if we will receive the regulatory approvals required to promote our product or product candidates for new treatment indications. Failure to receive such approvals prevents us from promoting and commercializing the new treatment indications. In addition, we would be required to conduct additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited.

If our product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions and product liability claims, and our image and reputation within the industry and marketplace could be harmed.

The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. For example, OTIPRIO is approved for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery and for the treatment of AOE, and we cannot promote the use of our product in a manner that is inconsistent with the approved label. Although physicians are able to, in their independent medical judgment, use OTIPRIO on their patients in an off-label manner, such as for the treatment of other otic indications, if we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would materially harm our business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The federal government and regulatory authorities have also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the federal government or regulatory authorities to have engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation with physicians, patients and caregivers, and our position within the industry.

Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims and costly litigation. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.

We have limited sales and marketing experience and may be unable to successfully commercialize our products or generate product revenue.

We have limited experience in the marketing and sale of pharmaceutical products, and there are significant risks involved in managing a sales and marketing organization, including our ability to hire, retain, adequately compensate and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. For example, we discontinued promotional support for OTIPRIO and, as a result, no longer have a sales force. If we decide not to promote our product candidates ourselves, if approved, we may consider promotional partnership arrangements. For instance, in August 2018, we announced the initiation of a partnership with Mission, and in May 2019, we announced the initiation of a partnership with Glenmark, both for the promotion of OTIPRIO to certain end users involved in the treatment of patients for AOE. In July 2019, we were notified by Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy

42

 

product, and the impact of such delay on its business operations. In August 2019, Mission informed us of its non-renewal of the co-promotion agreement.

In June 2020, we entered into a co-promotion agreement with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients, but there are no assurances that such partnership will be successful or that it will not be terminated earlier than we expect. If our ALK partnership is terminated in the future, we may seek other promotional partners for OTIPRIO, but there are no assurances that we can find a new promotional partner or that the terms and timing of any such arrangements would be acceptable to us. Such partnerships may not generate significant revenue, may not be successful, and may be terminated. If we are unable to enter into such arrangements on acceptable terms or at all, or if such arrangements are not successful, we may not be able to successfully commercialize our products or generate product revenue. Any failure or delay in entering promotional partnerships or developing our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products. If we are not successful in commercializing our products, either on our own or through partnering with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.

To expand our development and commercial support capabilities in the future, we may need to increase the size of our organization, and we may experience difficulties in managing this growth.

As we advance our product candidates through the development process and commercialize our product and product candidates, if approved, we may need to expand our development, regulatory, quality, managerial, sales and marketing, operational, finance and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product candidates, if approved. If our operations expand, we expect that we will need to manage additional relationships with various manufacturers and collaborative partners, suppliers and other organizations.

Due to our limited financial resources and our limited experience in managing a company with such growth, we may not be able to effectively manage the expansion of our operations or recruit, train and retain additional qualified personnel. For example, in December 2016, we moved into our current headquarters location in San Diego, California. The physical expansion of our operations has led, and may continue to lead, to significant costs. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations, which could materially impact our business, revenue and operating results.

Coverage and reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. Recent legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for our products, if approved, that could materially affect the opportunity to commercialize.

There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, market acceptance and sales of our products, if approved, in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third-party or government payors for any of our products and may be affected by existing and future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. CMS has established a unique J Code for OTIPRIO that replaces a previously assigned C Code. We also intend to apply for a unique J Code for OTIVIDEX, OTO-313 and OTO-413. We cannot assure you that J Codes will be issued for OTIVIDEX, OTO-313 and OTO-413, if approved. We also cannot assure you that third-party payors will provide reimbursement according to a J Code. If a J Code is not issued or a J Code is issued but not reimbursed by third-party payors, then the cost of these drugs may be absorbed by healthcare providers or charged to patients. If this is the case, our expectations of the pricing we expect to achieve for OTIPRIO, and OTIVIDEX, OTO-313 and OTO-413, if approved, and the related potential revenue, may be significantly diminished. We cannot be certain that coverage and adequate reimbursement will be available for OTIPRIO or any other products, if approved, or that such coverage and reimbursement will be authorized in a timely fashion, even if a unique J Code is assigned for such products. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, OTIPRIO or any of our product candidates, if approved. If reimbursement is not available or is available on a limited basis for any of our products, if approved, we may not be able to successfully commercialize

43

 

any such products. Reimbursement by a third-party or government payor may depend upon a number of factors, including, without limitation, the third-party or government payor’s determination that use of a product is:

 

•

a covered benefit under its health plan;

 

•

safe, effective and medically necessary;

 

•

appropriate for the specific patient;

 

•

cost-effective; and

 

•

neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA or other comparable foreign regulatory authorities. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement or to have pricing set at a satisfactory level. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability.

Assuming we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.

In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. In some foreign countries, particularly in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our products to other available therapies. If reimbursement of any of our products, if approved, is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country.

The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our products profitably, if approved. Among policy-makers and payors in the United States and elsewhere, there has been significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict if or how these or future initiatives may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:

 

•

the demand for any of our products, if approved;

 

•

the ability to set a price that we believe is fair for any of our products, if approved;

 

•

our ability to generate revenues and achieve or maintain profitability;

 

•

the level of taxes that we are required to pay; and

 

•

the availability of capital.

44

 

 

In March 2010, the Affordable Care Act (ACA) became law in the United States. One goal of ACA is to reduce the cost of healthcare and substantially change the way healthcare is financed by both governmental and private insurers. While we cannot fully predict what impact on federal reimbursement policies this legislation will continue to have in general or on our business specifically, ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect our ability to generate revenue, achieve market acceptance of our product or future approved products, attain profitability, or commercialize our product or any future approved products. Provisions of ACA relevant to the pharmaceutical industry include the following:

 

•

an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, not including orphan drug sales;

 

•

an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;

 

•

a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;

 

•

extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

 

•

expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

 

•

expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;

 

•

new requirements to report annually certain financial arrangements with physicians and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any payment or “transfer of value” provided to physicians, as defined by such law, and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year (effective January 1, 2022, these reporting obligations will extend to include payments and transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners);

 

•

expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; and

 

•

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.

There have been judicial and Congressional challenges to certain aspects of the ACA. The U.S. Supreme Court heard oral arguments on the constitutionality of the ACA in November 2020  following a series of federal cases that began with a district court ruling that the ACA is unconstitutional in its entirety because the “individual mandate” provisions of the ACA were repealed by Congress. It is unclear how such litigation, other efforts to repeal and replace the ACA, and healthcare measures of the current administration will impact the ACA and our business. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA or other healthcare reform measures are fully implemented or there is more certainty concerning the future of the ACA or such healthcare reform measures, it will be difficult to predict its full impact and influence on our business.

Recently, the Trump administration announced four executive orders to lower drug prices, including allowing importation of certain drugs, changing how drug rebates are negotiated by middlemen, like pharmacy benefit managers, and directing such rebates to be passed to patients as point-of-sale discounts, and requiring Medicare to pay for certain Part B drugs at the lowest price available in economically comparable countries. In 2020, the Trump

45

 

administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration’s proposals. In September 2020, FDA also issued a final guidance on importation of certain FDA-approved human prescription drugs and a final rule that sets forth requirements for an importation program for certain prescription drugs from Canada, allowing States, Indian Tribes, and, in certain circumstances, pharmacists and wholesalers, to submit proposals for importation for the FDA for review and authorization. In November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturer. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. It is unclear how these new regulations and healthcare measures of the Biden administration will impact on our business. Healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for our product or future approved products. Any such reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve market acceptance of our product or future approved products, attain profitability, or commercialize future approved products.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.

We face an inherent risk of product liability as a result of the clinical testing of our product candidates and face an even greater risk now that OTIPRIO has been commercialized and as other product candidates get approved, if at all. For example, we may be sued if any product we develop allegedly causes or is perceived to cause injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

•

decreased demand for our products;

 

•

injury to our reputation and significant negative media attention;

 

•

withdrawal of clinical trial participants or cancellation of clinical trials;

 

•

costs to defend the related litigation;

 

•

a diversion of management’s time and our resources;

 

•

substantial monetary awards to clinical trial participants or patients;

 

•

regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;

 

•

exhaustion of any available insurance and our capital resources;

 

•

loss of revenue; and

 

•

the inability to commercialize any products we develop.

Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our products. We currently carry product liability insurance with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain

46

 

such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. If we determine that it is prudent to increase our product liability coverage in the future, we may be unable to obtain such increased coverage on acceptable terms, or at all. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.

If we fail to attract and retain senior management and key scientific personnel, we may be unable to successfully develop and commercialize our product candidates.

Our success depends, in part, on our continued ability to attract, retain and motivate highly qualified management, commercial, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals, who all have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved.

We could experience difficulties in attracting, hiring and retaining qualified employees. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all, which may cause our business and operating results to suffer.

If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.

Although a substantial amount of our efforts are focused on the development and regulatory approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize additional product candidates for the treatment of neurotology disorders. We are seeking to do so through our internal research programs and may explore strategic collaborations with third parties for the development or acquisition of new product candidates or products. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified or successfully developed.

Our internal computer systems, or those of our CROs or other contractors or consultants, or our partners, may fail or suffer security breaches, which could result in a material disruption of our drug development programs.

We rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and external parties, collect, store and transmit large amounts of confidential information (including intellectual property, proprietary business information and personal information, including trial data), and operate other critical functions. Despite the implementation of security measures, our internal computer systems and those of our third-party logistics vendors, CROs and other contractors and consultants, and our partners, are vulnerable to damage from computer viruses, unauthorized access or use resulting from malware, denial-of-service attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks, natural disasters, terrorism, war and telecommunication and electrical failures. To our knowledge, we have not experienced a material system failure, accident or security breach to date, nor are we aware of our CROs or other contractors experiencing any such material event negatively impacting ongoing trial data, but if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our commercialization activities or drug development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach (whether to our

47

 

systems or to our CROs or other contractors, consultants, or partners) were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential, proprietary, or other protected information, we could incur liability and penalties and the development and commercialization of our product candidates could be delayed.

Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.

Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. For example, in February 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-02, Leases (Topic 842), which aims to increase lease transparency and comparability among organizations. Further, we early adopted Accounting Standards Update No. 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, effective January 1, 2020, which removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business.

Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, (ii) manufacturing standards, (iii) federal, state and foreign healthcare fraud and abuse laws, (iv) privacy and data protection laws, and any laws regulating data security, or (v) laws that require the reporting of financial information or data accurately. Specifically, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, education, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, as well as various compliance policies and procedures, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters are located in San Diego, which in the past has experienced earthquakes. We do not carry earthquake insurance. The San Diego area has also experienced serious wildfires. If a natural disaster or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged

48

 

critical infrastructure, such as product development and research efforts for our current product candidates and finance records, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Furthermore, integral parties in our supply chain and distribution chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn may cause extreme volatility and disruptions in the capital and credit markets and could result in a variety of risks to our business and our ability to raise additional capital when needed on acceptable terms, if at all. Additionally, our obligations to repay principal and interest on our indebtedness make us vulnerable to economic or market downturns. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers and third-party payors to delay making payments for our services.

Events, including the UK’s 2016 vote in favor of exiting the EU, or “Brexit,” and the UK’s withdrawal, and similar geopolitical developments or the perception that any of them could occur, may lead to worldwide economic and legal uncertainty, including significant volatility in global stock markets and currency exchange rates, and increasingly divergent laws and regulations.

Any of the foregoing could harm our business, and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.

Our business is subject to economic, political, regulatory, operational and other risks associated with international operations.

Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located outside the United States, and we conduct some of our clinical trials outside the United States. Accordingly, our ability to operate our business and our future results could be harmed by a variety of factors, including:

 

•

economic weakness, including inflation, or political instability in non-U.S. economies and markets;

 

•

differing and changing regulatory or legal requirements in non-U.S. countries;

 

•

challenges enforcing our contractual and intellectual property rights, especially in non-U.S. countries that may not respect and protect intellectual property rights to the same extent as the United States;

 

•

difficulties in compliance with non-U.S. laws and regulations;

 

•

changes in non-U.S. laws, regulations and customs, tariffs and trade barriers;

 

•

changes in currency exchange rates and non-U.S. currency controls;

 

•

changes in a country’s or region’s political or economic environment;

 

•

trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;

 

•

negative consequences from changes in tax laws;

49

 

 

 

•

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

 

•

workforce uncertainty and labor unrest;

 

•

difficulties associated with staffing and managing international operations;

 

•

potential liability under the FCPA, UK Bribery Act, GDPR or comparable non-U.S. laws; and

 

•

business interruptions resulting from (i) geopolitical actions, including annexation, war and terrorism, (ii) natural disasters, including earthquakes, typhoons, floods and fires or (iii) outbreaks of health epidemics and pandemics.

Risks Related to Our Intellectual Property

If our efforts to protect the intellectual property related to our product and product candidates are not adequate, we may not be able to compete effectively in our market.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product, product candidates and technology. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market.

The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, it is possible that certain patentable aspects of our inventions may not be protected in a manner consistent with the best interests of our business. Defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. If we or our current licensors, or any future licensors or licensees, fail to file patent applications, or maintain, enforce or protect our patents, such patent rights may be reduced or eliminated. If our current licensors, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law or rules in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or foreign countries with claims that cover our product or product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product or product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product or product candidates, provide exclusivity for our product or product candidates, or prevent others from designing around our patents. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product or product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product or product candidates.

Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its effective filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product or product candidates, we may be open to competition from generic versions of our product or product candidates. Further, if we encounter delays in our development

50

 

efforts, including our clinical trials, the period of time during which we could market our product or product candidates under patent protection would be reduced.

Some of our patents and patent applications are entitled to effective filing dates prior to March 16, 2013. For U.S. patent applications for which patent claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the U.S. Patent and Trademark Office (USPTO) to determine who was the first to invent any of the subject matter covered by those patent claims. An unfavorable outcome could require us either to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management.

In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product and product candidates, and our product development processes (such as manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have a material adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques, and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.

In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product and product candidates, and third parties involved in our clinical trials, to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by such employees, consultants, advisors, etc., or made known to them by us during the course of our relationship with them be kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or advisors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.

51

 

For our U.S. patent and patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or the America Invents Act (AIA), was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after March 16, 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product or product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.

Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provided opportunities for third parties to challenge any issued patent in the USPTO. This applies to all our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action.

Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and any patents that we might obtain in the future.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product or product candidates, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business.

We may not be able to protect our intellectual property rights throughout the world.

Filing and prosecuting patent applications and defending patents on our product and product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. For example, China has a heightened requirement for

52

 

patentability, and specifically requires a detailed description of medical uses of a claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in those countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain other countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.

Third-party claims alleging intellectual property infringement may adversely affect our business.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, patents and proprietary rights of competitors. Our research, development and commercialization activities, including the commercialization of OTIPRIO, may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties, including our competitors. There are also patent applications, owned by third parties including competitors, that have been filed but not issued that, if issued as patents, may be asserted against us. Numerous U.S. and foreign issued patents and pending patent applications, exist in the otic field in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product or product candidates may give rise to claims of infringement of the patent rights of third parties. We cannot assure you that our product or product candidates will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already issued and that a third party, for example a competitor in the otic market, might assert are infringed by our product or product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product or product candidates, could be found to be infringed by our product or product candidates.

Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop our product candidates and commercialize our product and product candidates, if approved. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Regardless of the merits of any third-party claims, our defense against such claims, or other related actions we may take, could cause us to incur substantial expenses, and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i) pay substantial damages, including treble damages and attorneys’ fees if we are found to have willfully infringed the third party’s patents; (ii) obtain one or more licenses from the third party; (iii) pay royalties to the third party; and/or (iv) redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would

53

 

be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our product candidates and commercialize our product and product candidates, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

Engaging in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming.

Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors’ patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings. For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product or product candidates, the defendant could counterclaim that the patent covering our product or product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.

In addition, within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the pharmaceutical industry. The AIA introduced procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including challenges to those patents perceived by our competitors as blocking entry into the market for their products, and the outcome of such challenges.

Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product or product candidates. They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate scope to cover our product and product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administrative panel to affect the validity or enforceability of a claim, for example if a priority claim is found to be improper. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product and product candidates. Such a loss of patent protection could have a material adverse impact on our business.

Enforcing our or our licensors’ intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also

54

 

absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.

Although not involving issued U.S. patents covering our product or any of our product candidates, on April 17, 2015, we filed a request for interference between one of our U.S. pending applications and a U.S. pending application controlled by Auris Medical Holding AG (Auris). On July 20, 2015, we received notice from the USPTO that the Patent Trial and Appeal Board (PTAB) declared an interference between our pending application and the Auris patent (issued as U.S. Patent No. 9,066,865 on June 30, 2015). On January 26, 2017, the PTAB determined that all of the Otonomy patent claims and all but one of the Auris patent claims were not patentable. We filed a Notice of Appeal on March 27, 2017, in which we asked the Federal Circuit to reverse PTAB’s decision that our claims are not patentable and that Auris’s single claim is. On August 1, 2018, the Federal Circuit agreed with us that the PTAB had erred in its rulings for Auris. The court reversed the PTAB’s decision against Otonomy and remanded the case for the PTAB to enter judgment for Otonomy. On March 11, 2019, the PTAB entered the judgment for Otonomy and cancelled the Auris patent. On April 24, 2020, the USPTO issued a Notice of Allowance for our pending application, indicating that all of our claims are allowed. On September 15, 2020, the pending application was issued as U.S. Patent No. 10,772,828.

If we fail to comply with our obligations in any of the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of license agreements under which we are granted intellectual property rights that are crucial to our business. A portion of our patent portfolio for our product and certain product candidates was co-developed and is co-owned with UC which licensed its rights to us through an exclusive worldwide license agreement. Under our existing license agreement with UC, we are subject to various obligations, including development and commercialization diligence obligations, and patent prosecution and maintenance obligations, as well as financial obligations such as potential development milestone payments, sublicensing income payments, and royalty payments. If we fail to comply with any of these obligations or otherwise breach other terms of our license agreement, and fail to cure such breach, UC may have the right to terminate the license or, in the instance where we fail to meet our diligence obligations, UC may instead elect to change our exclusive license to a non-exclusive license. The loss of the license from UC would affect a portion of the patent portfolio for OTIPRIO and OTIVIDEX, as well as certain other product candidates we may develop. While we could still proceed with development and, if approved, commercialization of OTIPRIO, OTIVIDEX and other product candidates as co-owner of the licensed patents, third parties, such as our competitors, could enter into the market by obtaining a license from UC under UC’s rights to such patents.

In addition, a portion of our patent portfolio for our OTO-313 product candidate is exclusively in-licensed from Durect, which license includes a sublicense to patents jointly owned by Durect and INSERM. Under our existing license agreement with Durect, we are subject to various obligations, including development and commercialization diligence obligations and pre-commercial launch progress reporting obligations, as well as financial obligations such as potential development milestone payments, sublicensing income payments, and royalty payments to both Durect and INSERM. If we fail to comply with the diligence obligations or otherwise materially breach our license agreement and fail to remedy such failure or cure such breach, Durect may have the right to terminate the license or, in the instance of our failure to meet the diligence obligations, Durect may instead elect to convert our exclusive license to a non-exclusive license. In particular, the loss of the license from Durect would affect a portion of the patent portfolio for OTO-313, which would adversely affect our ability to proceed with any development or potential commercialization of OTO-313 and could subject us to claims of patent infringement by Durect if OTO-313 is covered by the licensed patents.

55

 

Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:

 

•

the scope of rights granted under the license agreement and other interpretation-related issues;

 

•

our right to sublicense intellectual property rights to third parties under collaborative development relationships; and

 

•

our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product and product candidates, and what activities satisfy those diligence obligations.

While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the patents licensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Generally, the loss of any one of our current licenses, or any other license we may acquire in the future, could materially harm our business, prospects, financial condition and results of operations.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We have received confidential and proprietary information from third parties. In addition, we employ individuals, consultants and independent contractors who were previously employed at other biotechnology or pharmaceutical companies. Although we require all employees to enter into confidentiality and proprietary information agreements, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential or proprietary information of these third parties or their former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants, independent contractors or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.

Risks Related to Government Regulation

Our business and products are subject to extensive government regulation.

We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, principally by the FDA, the U.S. Drug Enforcement Administration (DEA), the CDC, the U.S. Department of Health and Human Services, and its various agencies, and also from state and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act (FFDCA), the Public Health Service Act, and the Controlled Substances Act, among others, may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, disgorgement, contractual damages, and/or exclusion from future participation in the Medicare and Medicaid programs. After our products receive regulatory approval or clearance, we, and our direct and indirect suppliers, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in the implementation of Risk Evaluation and Mitigation Strategies (REMS), programs, completion of government mandated clinical trials, and government enforcement action relating to labeling, advertising, marketing and promotion, as well as regulations governing cGMPs.

56

 

The regulatory approval process is highly uncertain and we may not obtain regulatory approval for the commercialization of OTIVIDEX, OTO-313, OTO-413 or any other product candidates.

The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. We are not permitted to market our product candidates in the United States until we receive approval of an NDA from the FDA. Obtaining regulatory approval of a product can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:

 

•

warning letters and adverse publicity;

 

•

civil and criminal penalties;

 

•

injunctions;

 

•

withdrawal of approved products;

 

•

product seizure or detention;

 

•

product recalls;

 

•

total or partial suspension of production; and

 

•

refusal to approve pending NDAs or supplements to approved NDAs.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled nonclinical studies and clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways, and insufficient or adverse results from nonclinical studies can affect the ability to conduct clinical trials. For example, following completion of a Phase 1b clinical trial, the OTIVIDEX program was put on Full Clinical Hold due to adverse findings in a nonclinical study evaluating the safety of repeated doses of OTIVIDEX. OTIVIDEX was subsequently removed from Full Clinical Hold in July 2013, allowing for initiation of the Phase 2b single-dose clinical trial, and placed on Partial Clinical Hold prohibiting the initiation of multiple-dose clinical trials in the United States pending the submission and review of additional nonclinical data. We submitted additional nonclinical data to the FDA and OTIVIDEX was removed from Partial Clinical Hold in June 2014. As a result of OTIVIDEX being placed on Full Clinical Hold, OTIPRIO was also placed on Full Clinical Hold. The OTIPRIO Full Clinical Hold was removed in November 2012. We cannot assure you that our product candidates will not be subject to new clinical holds in the future.

Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.

Regulatory approval is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional nonclinical studies and clinical trials. The number of nonclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including the following:

 

•

a product candidate may not be deemed safe, effective, pure or potent;

 

•

FDA officials may not find the data from nonclinical studies and clinical trials sufficient;

 

•

the FDA might not accept or approve our third-party manufacturers’ processes or facilities; or

57

 

 

 

•

the FDA may change its approval policies or adopt new regulations.

If OTIVIDEX, OTO-313, OTO-413 or any other product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain regulatory approval, our business and results of operations will be materially and adversely harmed.

For our product, and if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, or the limiting or withdrawal of regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.

If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, our product and any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, for our product, and if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include prompt submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product or our product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers’ processes, or failure to comply with regulatory requirements, may result in, among other things:

 

•

restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;

 

•

fines, warning letters or holds on clinical trials;

 

•

refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals;

 

•

product seizure or detention, or refusal to permit the import or export of products; and

 

•

injunctions or the imposition of civil or criminal penalties.

Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.

Our relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and information privacy and security laws regulating health, personal and other information. If we are unable to comply, or have not fully complied, with such laws, we could face penalties.

We are subject to various U.S. federal and state health care laws, including those intended to prevent healthcare fraud and abuse.

The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate),

58

 

directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare, and Medicaid Remuneration has been broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors.

Federal false claims laws, including the federal False Claims Act (FCA), and civil monetary penalties law impose penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Many states also have similar laws that apply to their state health care programs as well as private payors.

Additionally, state and federal authorities have aggressively targeted medical technology and pharmaceutical companies for, among other things, alleged violations of these healthcare fraud and abuse statutes, based on, for example, improper research or consulting contracts and other services agreements with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices.

The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH Act), and their implementing regulations, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.

Additionally, U.S. and international laws and regulations could impact our ability to store and process personal data, use certain vendors or service providers, and utilize personal data from certain jurisdictions. Because the global privacy and data protection landscape is rapidly evolving, we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions.

For example, in the United States, HIPAA imposes certain obligations, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without proper written authorization. Similarly, the California Consumer Privacy Act of 2018 (CCPA) took effect on January 1, 2020. The CCPA gives California residents the right to access and require deletion of their personal information, the right to opt out of certain personal information sharing, and the right to detailed information about how their personal information is collected, used and shared. The CCPA provides civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the CCPA includes exemptions for certain clinical trials data, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. In November 2020, California passed the California Privacy Rights Act (CPRA), which amends and expands the CCPA. The CCPA and the CPRA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. The CCPA has prompted a wave of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.

Several foreign jurisdictions, including the EU, its member states, the UK, Japan and Australia, among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. Additionally, certain countries have passed or are considering passing laws that require local data residency and/or restrict the

59

 

international transfer of data. These laws have the potential to increase costs of compliance, risks of noncompliance and penalties for noncompliance.

For example, the collection and use of health data in the EU is governed by the General Data Protection Regulation (GDPR). The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. Guidance, interpretation and application under the GDPR are still developing and may change over time. Failure to comply with the GDPR and the applicable national data protection laws of the EU member states may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we control and/or process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable EU laws and regulations are not successful, it could adversely affect our business in the EU.

The GDPR introduces obligations around the transfer of personal data outside of the European Economic Area (EEA). There are several ways a company can compliantly transfer such information. On July 16, 2020, the Court of Justice of the European Union (CJEU) invalidated the U.S.-EU Privacy Shield framework that had been in place since 2016, which allowed companies like us to meet certain European legal requirements for the transfer of personal data from the EEA to the United States, and imposed additional obligations on companies when relying on the model clauses approved by the EU Commission. This CJEU decision may result in different EEA data protection regulators applying differing standards for, and require ad hoc verification of measures taken with respect to, certain personal data flows from the EEA to the U.S.  The invalidation of the U.S.-EU Privacy Shield framework will require us to take additional steps to legitimize any personal data transfers that are impacted by this decision. This could result in increased costs of compliance and limitations on our business in the EU.

Since the approval of OTIPRIO, our operations have been subject to the federal transparency requirements under the federal Physician Payment Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments and other transfers of value provided to physicians, as defined by law, and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.  Additionally, in 2018 the “Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act” was enacted which, under the provision entitled “Fighting the Opioid Epidemic with Sunshine,” in part, extends the reporting and transparency requirements for physicians under the Physician Payments Sunshine Act to physician assistants, nurse practitioners and other mid-level practitioners, with reporting requirements going into effect in 2022 for payments made in 2021.

If any of our business activities, including but not limited to our relationships with healthcare providers or payors, violate any of the aforementioned laws and analogous state and foreign laws and regulations that may apply to pharmaceutical business practices, we may be subject to significant administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.

In addition, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.

60

 

Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.

From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our product and product candidates. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:

 

•

changes to manufacturing methods;

 

•

recall, replacement, or discontinuance of one or more of our products; and

 

•

additional recordkeeping.

Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

61

 

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations which can harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, the UK Bribery Act 2010, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. U.S. economic sanctions and export control laws and regulations prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.

We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for any unauthorized exports and reexports of our products and for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.

Risks Related to Ownership of Our Securities

The price of our common stock has been, is, and may continue to be highly volatile, which may make it difficult for stockholders to sell our common stock when desired or at attractive prices.

Our stock is currently traded on the Nasdaq Global Select Market, but we can provide no assurance that we will be able to maintain an active trading market on the Nasdaq Global Select Market or any other exchange in the future. Moreover, the trading price of our common stock may fluctuate substantially. These price fluctuations may be rapid and severe and may leave investors little time to react. Broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Sharp drops in the market price of our common stock may also expose us to securities class-action litigation.

The stock market in general and the market for pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:

 

•

regulatory or legal developments;

 

•

results from or delays in clinical trials of our product candidates or product candidates of companies that are perceived to be similar to us;

 

•

announcements of regulatory approval or disapproval of our product candidates;

 

•

commercialization of our products, if approved;

 

•

FDA or other regulatory actions affecting us or our industry;

 

•

introductions and announcements of new products or product candidates by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;

 

•

our financial results or those of companies that are perceived to be similar to us;

 

•

changes in the structure of healthcare payment systems;

62

 

 

 

•

announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;

 

•

market conditions in the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts’ reports or recommendations;

 

•

actual or anticipated quarterly variations in our results of operations or those of our competitors;

 

•

changes in financial estimates or guidance, including our ability to meet our revenue, operating profit or loss and cash balance estimates or guidance;

 

•

sales of substantial amounts of our stock by insiders and large stockholders, or the expectation that such sales might occur;

 

•

general economic, industry and market conditions;

 

•

the impact of any natural disasters or public health crises, such as the COVID-19 pandemic;

 

•

additions or departures of key personnel;

 

•

intellectual property, product liability or other litigation against us;

 

•

expiration or termination of our potential relationships with strategic and co-promotion partners;

 

•

limited trading volume of our common stock; and

 

•

the other factors described in this “Risk Factors” section.

If securities or industry analysts do not continue to publish research or publish unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will be influenced in part on the research and reports that equity research analysts publish about us and our business. Although certain equity research analysts currently cover us, we do not have any control of the analysts or the content and opinions included in their reports or whether any such analysts will continue to, or whether new analysts will, cover us for any given period of time. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analyst ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.

Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders, including our directors, executive officers or principal stockholders, sell, or the market perceives that they intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.

As of December 31, 2020, certain holders of approximately 2,205,178 shares of our common stock, including shares issuable upon the exercise of outstanding options, are entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.

If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, the market price of our common stock may decline.

We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any

63

 

shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. In September 2018, our shelf registration statement on Form S-3 (File No. 333-227269) was declared effective by the SEC, pursuant to which we may offer debt securities, preferred stock, common stock and certain other securities from time to time. In July 2020, we sold in a public offering 17,275,000 shares of our common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and we sold pre-funded warrants to purchase 4,000,000 shares of our common stock.

On August 1, 2019, we filed a prospectus supplement in connection with an “at-the-market” offering under our Sales Agreement with Cowen, under which we may sell shares of common stock for up to an aggregate of $40.0 million. If in the future we issue additional shares of common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, the market price of our common stock may decline.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:

 

•

We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.

 

•

We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.

 

•

We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

 

•

We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.

 

•

The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.

 

•

We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.

Concentration of ownership of our common stock among our existing principal stockholders may effectively limit the voting power of other stockholders.

As of December 31, 2020, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in aggregate, beneficially owned approximately 29.9% of our outstanding common stock. Accordingly, these stockholders, acting together, may significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions.

64

 

These stockholders may therefore delay or prevent a change of control, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the market price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

Anti-takeover provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult, which could discourage takeover attempts and lead to management entrenchment, and the market price of our common stock may be lower as a result.

Certain provisions in our certificate of incorporation and bylaws may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock. Our board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.

Our charter documents contain other provisions that could have an anti-takeover effect, including provisions that:

 

•

establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms;

 

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

 

•

provide that our directors may only be removed for cause;

 

•

eliminate cumulative voting in the election of directors;

 

•

authorize our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;

 

•

provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship;

 

•

permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;

 

•

prohibit stockholders from calling a special meeting of stockholders;

 

•

require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;

 

•

authorize our board of directors, by a majority vote, to amend the bylaws; and

 

•

require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.

In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. These provisions may also prevent changes in our management or limit the price that certain investors are willing to pay for our stock.

65

 

Our amended and restated certificate of incorporation and our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following:

 

•

any derivative action or proceeding brought on our behalf;

 

•

any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders;

 

•

any action or proceeding asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws; and

 

•

any action or proceeding asserting a claim governed by the internal-affairs doctrine.

This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.

Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings.

It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our common stock has been and will likely continue to be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years and we may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.

We have not declared or paid cash dividends on our common stock to date and we do not intend to pay dividends on our capital stock in the foreseeable future. The declaration of dividends is subject to the discretion of our board of directors and will depend on various factors, including our operating results, financial condition, future prospects and any other factors deemed relevant by our board of directors. You should not rely on an investment in our company if you require dividend income from your investment in our company. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. There is no guarantee that our capital stock will appreciate in value or even maintain the price at which you purchased your shares.

66

 

Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.

As of December 31, 2020, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $382.8 million and $124.8 million, respectively. Of the federal NOLs, approximately $142.2 million were generated after January 1, 2018, and therefore do not expire. Our U.S. federal and state NOLs will expire in various years beginning in 2030, if not utilized. Under the 2017 legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act), as modified by the CARES Act, the deductibility of our federal NOLs generated in tax years beginning after December 31, 2020 will be limited to 80% of taxable income in such years. As of December 31, 2020, we had federal and California research and development tax credit carryforwards of approximately $12.0 million and $5.8 million, respectively. The federal research and development tax credit carryforwards expire in various years beginning in 2030, if not utilized. The California research credit will carry forward indefinitely. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change federal NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result of future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results in the event that we attain profitability.

The enactment of tax reform policies could adversely affect our business and financial condition.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

We have incurred and will continue to incur costs as a result of operating as a public company, and our management has been and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.

As a public company listed in the United States, we incur and will continue to incur significant legal, accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act) and regulations implemented by the SEC, and The Nasdaq Stock Market (Nasdaq) may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

67

 

As a public company in the United States, we are required, pursuant to the Sarbanes-Oxley Act, to maintain effective disclosure controls and procedures and internal control over financial reporting. We are also required to provide an annual management report on the effectiveness of our disclosure controls and procedures over financial reporting. We need to disclose any material weaknesses identified by our management in our internal control over financial reporting, and at any time when we are not a non-accelerated filer, we will need to provide a statement that our independent registered public accounting firm has issued an opinion on our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC, is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Our current controls, and any new controls that we develop may become inadequate because of changes in conditions in our business or the degree of compliance with these policies or procedures may deteriorate and significant deficiencies or material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, may provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting that are required to be included in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial information and operating results, which could result in a negative market reaction and effect on the trading price of our common stock.

We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.

We are a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. For as long as we remain a “smaller reporting company,” we are permitted and intend to continue to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not “smaller reporting companies.” These exemptions include:

 

•

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s discussion and analysis of financial condition and results of operations” disclosure; and

 

•

reduced disclosure obligations regarding executive compensation.

We cannot predict whether investors will find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be reduced or more volatile.

We have broad discretion in the use of the net proceeds from our public offerings, including our “at the market” offering, and may not use them effectively.

We have broad discretion as to how to spend and invest the proceeds from our public offerings, including our “at-the-market” offering with Cowen, and we may spend or invest these proceeds in a way with which our stockholders disagree. Accordingly, investors will need to rely on our judgment with respect to the use of these proceeds and these uses may not yield a favorable return to our stockholders. In addition, until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value.

Item 1B. UNRESOLVED STAFF COMMENTS

None.

68

 

Item 2. PROPERTIES

Our corporate headquarters are located in San Diego, California, where we lease and occupy approximately 62,000 square feet of space, which we believe is adequate to meet our existing needs. The current term of our lease on this facility expires in September 2027. We have an option to extend this lease by an additional five years.

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 4. MINE SAFETY DISCLOSURE

Not applicable.

69

 

PART II

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information for Common Stock

Our common stock began trading on The NASDAQ Global Select Market under the symbol “OTIC” on August 13, 2014. Prior to that date, there was no public trading market for our common stock.

Holders of Record

On February 5, 2021, the closing sale price of our common stock on The NASDAQ Global Select Market was $5.47. As of February 5, 2021, there were approximately 19 holders of record of our common stock. The actual number of stockholders is greater than this number of holders of record and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust or by other entities.

Dividend Policy

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

Recent Sale of Unregistered Securities

There were no sales of unregistered securities during the period covered by this Annual Report on Form 10-K, other than those previously reported in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

Use of Proceeds

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

70

 

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in the section entitled “Risk Factors” and in other parts of this Annual Report on Form 10-K.

Overview

We are a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. We pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and has been utilized to develop a pipeline of product candidates including three clinical-stage programs (OTIVIDEX for Ménière’s disease, OTO-313 for tinnitus, and OTO-413 for hearing loss) as well as several preclinical development programs including a gene therapy collaboration targeting the most common form of congenital hearing loss. We estimate, based on an external market report commissioned by us, that approximately 39 million patients in the United States suffer from the hearing and balance disorders that we are targeting in our clinical and preclinical programs, including moderate or severe vertigo (approximately 11 million), tinnitus (approximately 8 million) or hearing loss (approximately over 20 million). We also developed, registered and commercialized in the United States an otic antibiotic called OTIPRIO that is being marketed by a co-promotion partner, ALK.

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease. Two Phase 3 trials in Ménière’s disease patients were completed in the second half of 2017. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029), while the AVERTS-1 trial, conducted in the United States, did not (p value = 0.62). Based on a Type C meeting with the FDA, we believe that one additional successful pivotal trial is sufficient to support the United States registration of OTIVIDEX in Ménière’s disease. We have completed enrollment in such additional Phase 3 trial with top-line results expected by the end of February 2021.

OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective NMDA receptor antagonist, in development for the treatment of tinnitus. In July 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity. We plan to initiate a Phase 2 clinical trial for OTO-313 in the first quarter of 2021, with top-line results expected in mid-2022.

OTO-413 is a sustained-exposure formulation of BDNF in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. In December 2020, we announced positive top-line results from a Phase 1/2 clinical trial of OTO-413, demonstrating that a single intratympanic injection of OTO-413 was well-tolerated and showed therapeutic activity across multiple speech-in-noise hearing tests. We plan to initiate an expansion of the Phase 1/2 trial in the second quarter of 2021 to evaluate a refined study protocol in additional hearing loss patients, with top-line results expected in mid-2022.

We also have multiple preclinical stage programs addressing additional hearing loss pathologies including a gene therapy for treatment of congenital hearing loss (OTO-825), an otoprotectant for prevention of cisplatin-induced hearing loss (OTO-510), and a hair cell repair and regeneration program for treatment of severe hearing loss (OTO-6XX). In October 2019, we entered into a strategic collaboration with AGTC to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with congenital hearing loss caused by a mutation in the GJB2 gene. In July 2020, we entered into an exclusive license agreement with Kyorin that provides us with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for our OTO-6XX program.

In addition, we developed, received FDA approval for and commercially launched OTIPRIO (ciprofloxacin otic suspension) for use during TTP surgery in pediatric patients. OTIPRIO was also approved by the FDA for the

71

 

treatment of AOE. In June 2020, we entered into a co-promotion agreement with ALK to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

We have a limited operating history. Since our inception in 2008, we have devoted substantially all our efforts to developing and commercializing OTIPRIO, developing our current product candidates, and providing general and administrative support for these operations. In July 2020, we sold in a public offering 17,275,000 shares of our common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and we sold pre-funded warrants to purchase 4,000,000 shares of our common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, we had cash, cash equivalents and short-term investments of $86.3 million and an outstanding debt balance of $15.2 million.

We have never been profitable, and as of December 31, 2020, we had an accumulated deficit of $504.6 million. Our net losses were $44.7 million, $44.7 million and $50.4 million for the years ended December 31, 2020 2019 and 2018, respectively. Substantially all our net losses have resulted from research and development expenses related to our clinical trials and product development activities, commercialization expenses to launch OTIPRIO in the U.S. market, and other general and administrative expenses.

We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to develop, seek regulatory approval, and, if approved, commercialize our product candidates. In the near term, we anticipate our expenses will continue to be substantial as we:

 

•

conduct clinical development of OTIVIDEX, OTO-313 and OTO-413;

 

•

conduct nonclinical development of OTO-825, OTO-510 and OTO-6XX;

 

•

contract to manufacture our product candidates;

 

•

evaluate opportunities for development of additional product candidates;

 

•

maintain and expand our intellectual property portfolio;

 

•

hire additional staff as necessary to execute our product development plan; and

 

•

operate as a public company.

We believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations for a period of at least twelve months from the date of this Annual Report on Form 10-K. When additional financing is required, we anticipate we will seek funding through public or private equity or debt financings or other sources, such as potential collaboration arrangements. We may not be able to raise capital on terms acceptable to us, or at all. Our failure to raise capital could have a negative impact on our financial condition and our ability to pursue our business strategies.

In November 2008, we entered into an exclusive license agreement with the Regents of the University of California (UC). Under the license agreement, UC granted us an exclusive license under their rights to patents and applications that are co-developed and co-owned with us for the treatment of human otic diseases. Our financial obligations under the license agreement include development and regulatory milestone payments of up to $2.7 million per licensed product, of which $1.9 million has been paid for OTIPRIO, $0.8 million has been paid for OTIVIDEX, $0.4 million has been paid for OTO-413, and $0.1 million has been paid for OTO-311 (but such milestone payments are reduced by 75% for any orphan indication product), and a low single-digit royalty on net sales by us or our affiliates of licensed products. In addition, for each sublicense we grant we are obligated to pay UC a fixed percentage of all royalties as well as a sliding-scale percentage of non-royalty sublicense fees received by us under such sublicense, with such percentage depending on the licensed product’s stage of development when sublicensed to such third party. We have the right to offset a certain amount of third-party royalties, milestone fees or sublicense fees against the foregoing financial obligations, provided such third-party royalties or fees are paid by us in consideration for intellectual property rights necessary to commercialize a licensed product.

72

 

In April 2013, we entered into an exclusive license agreement with DURECT Corporation (Durect), as part of an asset transfer agreement between us and IncuMed LLC, an affiliate of the NeuroSystec Corporation. Under this license agreement, Durect granted us an exclusive, worldwide, royalty-bearing license under Durect’s rights to certain patents and applications covering our OTO-313 product candidate, as well as certain related know-how. Under this license agreement and the asset transfer agreement, we are obligated to make one-time milestone payments of up to $7.5 million for the first licensed product. Upon commercializing a licensed product, we are obligated to pay Durect tiered, low single-digit royalties on annual net sales by us or our affiliates or sublicensees of the licensed products, and we have the right to offset a certain amount of third-party license fees or royalties against such royalty payments to Durect. In addition, each sublicense we grant to a third party is subject to payment to Durect of a low double-digit percentage of all non-royalty payments we receive under such sublicense. Additionally, we are also obligated to pay the Institut National de la Santé et de la Recherche Médicale (INSERM), on behalf of Durect, for a low single-digit royalty payment on net sales by us or our affiliates or sublicensees upon commercialization of the licensed product. The foregoing royalty payment obligation to Durect would continue on a product-by-product and country-by-country basis until expiration or determination of invalidity of the last valid claim within the licensed patents that cover the licensed product, and the payment obligation to INSERM would continue so long as Durect’s license from INSERM remains in effect.

Given the unprecedented and evolving nature of the COVID-19 pandemic, there continues to be significant uncertainty about the progression and ultimate impact of the pandemic on our business operations. We have taken steps to mitigate the impact of the COVID-19 pandemic on our clinical trials, including developing processes to ensure the integrity of data collection from enrolled patients and supporting the increasing number of sites able to enroll new patients, among other activity. Nonetheless, we do not know the full extent of potential future delays or impacts on our business operations, our preclinical programs and clinical trials, healthcare systems, our financial condition, or the global economy as a whole resulting from the COVID-19 pandemic.

Financial Operations Overview

Revenue

In December 2015, OTIPRIO was approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery. In March 2016, we began sales of OTIPRIO in the United States to our network of specialty distributors who fill orders received from hospitals and ambulatory surgery centers who are the primary end user customers of OTIPRIO for use during TTP surgery. We also entered into co-promotion partnerships to support the promotion of OTIPRIO for the treatment of AOE in physician offices and in October 2020 amended the current co-promotion agreement with ALK to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

We recognize revenue on sales of OTIPRIO upon delivery to our distributors. Product sales are recorded net of estimated chargebacks, government rebates and distributor fees.

Prior to March 2016 we had not generated revenue. We do not expect to generate any revenue from any of our product candidates unless and until we obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties.

Operating Expenses

Cost of product sales

Cost of product sales consists primarily of direct and indirect costs related to the manufacturing of OTIPRIO, including third-party manufacturing costs, allocation of overhead costs and royalty payments based on OTIPRIO sales.

Research and development expenses

Our research and development expenses primarily consist of costs associated with the nonclinical and clinical development of our product candidates.

73

 

Our research and development expenses include:

 

•

employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;

 

•

external development expenses incurred under arrangements with third parties, such as fees paid to CROs in connection with nonclinical studies and clinical trials, costs of acquiring and evaluating clinical trial data such as investigator grants, patient screening fees, laboratory work and statistical compilation and analysis, and fees paid to consultants;

 

•

costs to acquire, develop and manufacture clinical trial materials, including fees paid to contract manufacturers;

 

•

payments related to licensed product candidates and technologies;

 

•

costs related to compliance with drug development regulatory requirements; and

 

•

facilities expenses which include allocated expenses for amortization of ROU assets, depreciation and other overhead expenses, and direct costs for laboratory and other supplies.

We expense our internal and third-party research and development expenses as incurred.

The following table summarizes our research and development expenses (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Third-party development costs:

 

 

 

 

 

 

 

 

 

 

 

 

OTIPRIO

 

$

—

 

 

$

—

 

 

$

137

 

OTIVIDEX

 

 

4,383

 

 

 

7,709

 

 

 

5,160

 

OTO-313

 

 

1,527

 

 

 

2,951

 

 

 

2,262

 

OTO-413

 

 

2,385

 

 

 

4,557

 

 

 

5,264

 

Total third-party development costs

 

 

8,295

 

 

 

15,217

 

 

 

12,823

 

Other unallocated internal research and development

   costs

 

 

19,702

 

 

 

17,588

 

 

 

19,021

 

Total research and development costs

 

$

27,997

 

 

$

32,805

 

 

$

31,844

 

 

We expect our research and development expenses to continue to be substantial for the foreseeable future as we advance our product candidates through their respective development programs. The process of conducting nonclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for our product candidates. The probability of success will be affected by numerous factors, including nonclinical data, clinical data, competition, manufacturing capability and commercial viability. We are responsible for all of the research and development costs for our programs.

Completion dates and completion costs can vary significantly for each of our clinical development programs and are difficult to predict. We therefore cannot estimate with any degree of certainty the costs we will incur in connection with development of our product candidates. We anticipate that we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments, and our ongoing assessments as to each current or future product candidate’s commercial potential. We may need to raise substantial additional capital in the future to complete the development of and, if approved, commercialize, our product candidates. We may enter into collaborative agreements in the future in order to conduct clinical trials and gain regulatory approval of our product candidates, particularly in markets outside of the United States. We cannot forecast which programs or product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and overall capital requirements.

74

 

The costs of clinical trials may vary significantly over the life of a program owing to the following:

 

•

per patient trial costs;

 

•

the number of sites included in the trials;

 

•

the countries in which the trials are conducted;

 

•

changes in regulatory and legal requirements for clinical trials;

 

•

the length of time required to enroll eligible patients;

 

•

the number of patients that participate in the trials;

 

•

the number of doses that patients receive;

 

•

the drop-out or discontinuation rates of patients;

 

•

potential additional safety monitoring or other studies requested by regulatory agencies;

 

•

the duration of patient follow-up;

 

•

the phase of development of the product candidate;

 

•

the manufacturing process and complexity of, expiration of, and amount of the drug product required for the clinical trials;

 

•

the efficacy and safety profile of the product candidate; and

 

•

the impacts of COVID-19.

Selling, general and administrative expenses

Our selling, general and administrative expenses consist primarily of employee-related expenses, including salaries, benefits, travel and stock-based compensation expense, as well as other related costs for our employees and consultants in executive, administrative, finance and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development, costs associated with prosecuting and maintaining our patent portfolio and corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of our business, and OTIPRIO product support expenses and profit-sharing fees payable to our co-promotion partners, which are reduced by payments received from them.

We expect our selling, general and administrative expenses to be substantial as we support development of our product candidates, and as we incur ongoing expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with stock exchange listing and SEC requirements, directors’ and officers’ liability insurance premiums, and investor relations-related expenses.

Other Income (Expense)

Other income (expense) primarily consists of interest income earned on cash and cash equivalents and short-term investments and interest expense related to our long-term debt and finance leases.

Critical Accounting Policies and Significant Judgments and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to net product sales, accrued expenses and stock-based compensation. We base our estimates on our historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of

75

 

assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are most critical to the judgments and estimates used in the preparation of our financial statements.

Clinical Trial Expense Accruals

We estimate expenses resulting from our obligations under contracts with vendors, CROs and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.

We record clinical trial expenses in the period in which services are performed and efforts are expended. We accrue for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We estimate accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, we may adjust our clinical accruals if actual results differ from our estimates. We estimate accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. Our clinical trial accruals are dependent upon accurate reporting by CROs and other third-party vendors. Although we do not expect our estimates to differ materially from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2020, 2019 and 2018 there were no material adjustments to our prior period estimates of accrued expenses for clinical trials.

Stock-based Compensation

We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes-Merton option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years.

Recent Accounting Pronouncements

See Note 2 to our financial statements included in Part II, Item 8, “Financial Statements,” of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our business.

Other Information

Net Operating Loss and Research and Development Tax Credit Carryforwards

As of December 31, 2020, we had U.S. federal and state NOLs of approximately $382.8 million and $124.8 million, respectively. Of the federal NOLs, approximately $142.2 million were generated after January 1, 2018, and therefore do not expire. Our U.S. federal and state NOLs will expire in various years beginning in 2030, if not utilized. Under the 2017 legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act), as modified by the CARES Act, the deductibility of our federal NOLs generated in tax years beginning after December 31, 2020 will be limited to 80% of taxable income in such years. As of December 31, 2020, we had federal and California research and development tax credit carryforwards of approximately $12.0 million and $5.8 million, respectively. The federal research and development tax credit carryforwards expire in various years beginning in 2030, if not utilized. The California research credit will carry forward indefinitely. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change federal NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past

76

 

and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result of future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results in the event that we attain profitability.

As of December 31, 2020, we had a full valuation allowance against our net deferred tax assets.

Reduced Reporting Requirements

We are a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. For as long as we remain a “smaller reporting company,” we are permitted and intend to continue to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not “smaller reporting companies.” These exemptions include:

 

•

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s discussion and analysis of financial condition and results of operations” disclosure; and

 

•

reduced disclosure obligations regarding executive compensation.

Additionally, we intend to rely on certain exemptions and reduced reporting requirements available to us as a non-accelerated filer, including those relating to providing an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act.

Results of Operations

Comparison of the Years Ended December 31, 2020 and 2019

The following table sets forth the significant components of our results of operations for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years Ended December 31,

 

 

 

 

 

 

 

2020

 

 

2019

 

 

Change

 

Research and development

 

 

27,997

 

 

 

32,805

 

 

 

(4,808

)

Selling, general and administrative

 

 

14,575

 

 

 

11,690

 

 

 

2,885

 

 

Research and development expenses. The decrease of $4.8 million in research and development expenses resulted from a number of activities including: (i) a decrease of $3.3 million in OTIVIDEX clinical trial and development costs primarily due to lower activity during 2020 as a result of COVID-19 related delays; (ii) a decrease of $2.2 million in development costs for our OTO-413 hearing loss program due to the completion of manufacturing and nonclinical studies in 2019, partially offset by an increase in clinical trial and development costs in 2020; and (iii) a decrease of $1.4 million in OTO-313 clinical trial and development costs primarily due to the completion of enrollment in the quarter ended March 31, 2020. These decreases were partially offset by an increase of $2.1 million in personnel costs and other operating expenses.

Selling, general and administrative expenses. The increase of $2.9 million in selling, general and administrative expenses was primarily related to an increase of $1.9 million in professional services due to the discontinuation of cost reimbursement received from our OTIPRIO co-promotion partners in 2019 and an increase of $1.0 million in personnel costs, including stock-based compensation expense, and other operating expenses.

77

 

Comparison of the Years Ended December 31, 2019 and 2018

The following table sets forth the significant components of our results of operations for the years ended December 31, 2019 and 2018 (in thousands):

 

 

 

Years Ended December 31,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

Research and development

 

 

32,805

 

 

 

31,844

 

 

 

961

 

Selling, general and administrative

 

 

11,690

 

 

 

20,008

 

 

 

(8,318

)

 

Research and development expenses. The increase of $1.0 million in research and development expenses resulted from a number of activities including: (i) a $2.5 million increase in OTIVIDEX clinical trial and development costs related to the Phase 3 trial initiated in the third quarter of 2018; (ii) a $0.7 million increase in OTO-313 clinical trial and development costs related to the Phase 1/2 trial initiated in the second quarter of 2019; and (iii) an increase of $0.5 million in other research and development costs, including professional services. These increases were partially offset by: (i) a decrease of $0.7 million in clinical trial and development costs for our OTO-413 hearing loss program; and (ii) a $2.0 million net decrease in personnel costs, including stock-based compensation expense associated with the Option Exchange in 2018.

Selling, general and administrative expenses. The decrease of $8.3 million in selling, general and administrative expenses was a result of a $5.3 million reduction in personnel costs, primarily due to a decrease in stock-based compensation expense associated with the Option Exchange in 2018, and a $3.0 million decrease in outside service expense as a result of OTIPRIO cost reimbursement recognized from our co-promotion partners in 2019.

Liquidity and Capital Resources

We have incurred significant losses and negative cash flows from operations since our inception. As of December 31, 2020, we had an accumulated deficit of $504.6 million and we expect to continue to incur significant losses for the foreseeable future. We expect our research and development and selling, general and administrative expenses to continue to be substantial for the foreseeable future and, as a result, we will need additional capital to fund our operations, which we may obtain through one or more public or private equity or debt financings, or other sources such as potential collaboration arrangements.

As of December 31, 2020, we had cash, cash equivalents and short-term investments of $86.3 million. We have principally financed our operations through sales and issuances of our equity securities, debt financing as well as private placements of redeemable convertible preferred stock and convertible notes.

The following table sets forth a summary of the primary sources and uses of cash for the years ended December 31, 2020, 2019 and 2018 (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Net cash (used in) provided by:

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(38,874

)

 

$

(36,925

)

 

$

(38,434

)

Investing activities

 

 

(20,215

)

 

 

28,296

 

 

 

37,984

 

Financing activities

 

 

64,663

 

 

 

195

 

 

 

15,165

 

Net increase (decrease) in cash, cash equivalents

   and restricted cash

 

$

5,574

 

 

$

(8,434

)

 

$

14,715

 

 

Operating activities. The primary uses of cash were to fund increased levels of development activities for our product candidates and to support the commercialization of OTIPRIO. We expect to continue the use of cash for development of our product candidates for the foreseeable future.

Net cash used in operating activities was $38.9 million in 2020 compared to $36.9 million in 2019. The increase in the utilization of cash was primarily due to a decrease in accrued expenses compared to an increase in the

78

 

prior year.  Net cash used in operating activities was $36.9 million in 2019 compared to $38.4 million in 2018.  The decrease in the utilization of cash was primarily due to a decrease in operating losses compared to the prior year.

Investing activities. The primary source of cash from investing activities was from maturities of short-term investments and the primary use of cash from investing activities was for purchases of short-term investments and capital expenditures.

Net cash used in investing activities was $20.2 million in 2020 compared to net cash provided of $28.3 million in 2019 and net cash provided of $38.0 million in 2018. The increase in net cash used in investing activities in 2020 compared to 2019 was primarily due to net purchases of short-term investments. The decrease in net cash provided by investing activities in 2019 compared to 2018 was primarily due to net maturities of short-term investments used to fund operations.

Financing activities. The primary source of net cash provided by financing activities was net proceeds from the sale of our equity securities.

Net cash provided by financing activities was $64.7 million in 2020 compared to $0.2 million in 2019 and $15.2 million in 2018. Net cash provided by financing activities in 2020 consisted of $64.2 million related to the issuance of common stock and pre-funded warrants and $0.5 million in net proceeds for shares issued for stock option exercises and under our employee stock purchase plan. Net cash provided by financing activities in 2019 consisted of $0.2 million in net proceeds for shares issued for stock option exercises and under our employee stock purchase plan. Net cash provided by financing activities in 2018 consisted primarily of net proceeds of $14.8 million from a loan and $0.4 million in net proceeds for shares issued for stock option exercises and under our employee stock purchase plan.

At the Market Offering Program

In August 2019, we entered into a sales agreement (Sales Agreement) with Cowen to sell shares of our common stock having aggregate sales proceeds of up to $40.0 million, from time to time, through an “at the market” equity offering program under which Cowen will act as sales agent or principal. Under the Sales Agreement, we set the parameters for the sale of shares, including the number or dollar value of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that Cowen will be entitled to compensation for its services that will equal 3.0% of the gross sales price per share of all shares sold through Cowen under the Sales Agreement. The Sales Agreement shall automatically terminate upon the issuance and sale of placement shares equaling sales proceeds of $40.0 million and may be terminated earlier by either us or Cowen upon five days’ notice. We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. Through December 31, 2020, we have not sold any shares under the Sales Agreement.

Term Loan

Oxford Loan

On December 31, 2018 (the Closing Date), we entered into a Loan and Security Agreement with Oxford Finance LLC (the Loan Agreement). The Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for working capital and general corporate purposes. We have the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment fee of 1.00%. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan was fully funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). We paid a facility fee of 0.75% and customary closing fees on the Closing Date.

79

 

The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate). Interest on the Term Loan is payable monthly in arrears. During the year ended December 31, 2020, the terms of the Term Loan were amended to extend the interest-only period from 24 months to 36 months following the Closing Date, followed by consecutive equal monthly payments of principal and interest in arrears through the Maturity Date. The extension was accounted for as a modification, with no material effect on our financial statements or financial position. The outstanding principal amount of the Term Loan, together with accrued and unpaid interest, is due on December 1, 2023. The net outstanding Term Loan balance was $15.2 million as of December 31, 2020.

Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the effective interest method.

Our obligations under the Loan Agreement are secured by substantially all of our assets, excluding intellectual property and subject to certain other exceptions and limitations.

The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting our ability to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable, increase the applicable rate of interest by 5.00%, and exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include payment defaults, breaches of covenants or representations and warranties, material adverse changes, certain bankruptcy events, cross defaults with certain other indebtedness, and judgment defaults.

Funding Requirements

We expect to continue to incur significant losses for the foreseeable future as we: (i) develop and seek regulatory approvals for our product candidates OTIVIDEX, OTO-313 and OTO-413; and (ii) work to develop additional product candidates through research and development programs. We are subject to all the risks incident in the development of new therapeutic products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.

We believe that our existing cash, cash equivalents and short-term investments that include proceeds from our long-term debt will be sufficient to fund our operations for a period of at least twelve months from the date of this Annual Report on Form 10‑K. When additional financing is required, we anticipate that we will seek funding through public or private equity or debt financings or other sources, such as potential collaboration arrangements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any collaboration agreements we enter into may provide capital in the near-term but limit our potential cash flow and revenue in the future. Any of the foregoing could significantly harm our business, financial condition and prospects.

80

 

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including:

 

•

the timing and costs of completing the remaining clinical development and obtaining regulatory approval for OTIVIDEX in Ménière’s disease;

 

•

the design, initiation, progress, size, timing, costs and results of nonclinical studies and clinical trials for our other product candidates, including OTO-313 and OTO-413;

 

•

the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;

 

•

the revenue generated by OTIPRIO and our product candidates, if approved;

 

•

the costs related to manufacturing commercial supplies of OTIPRIO;

 

•

the timing and costs associated with manufacturing our product candidates for clinical trials, nonclinical studies and for commercial sale;

 

•

the cost of building and maintaining sales, marketing and distribution capabilities for any products for which we may receive regulatory approval and commercialize, including related facilities expansion costs;

 

•

the number and characteristics of product candidates that we pursue;

 

•

the potential acquisition and in-licensing of other technologies, products or assets;

 

•

the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments;

 

•

the cost of preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation;

 

•

the cost associated with legal and regulatory compliance;

 

•

our need to expand our development activities, including our need and ability to hire and adequately compensate additional employees;

 

•

the potential impacts of the COVID-19 pandemic;

 

•

the costs associated with being a public company;

 

•

the effect of competing technological and market developments; and

 

•

the cost of litigation, including potential patent litigation.

If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

81

 

Item 8. FINANCIAL STATEMENTS

Otonomy, Inc.

Index to Financial Statements

 

 

82

 

Report of Independent Registered Public Accounting Firm

 

The Board of Directors and Stockholders of Otonomy, Inc.

 

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Otonomy, Inc. (the “Company”) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Clinical Trial Expense Accrual

Description of the Matter

As of December 31, 2020, the Company recorded $1.5 million for accrued clinical trial costs. As described in Note 2 of the Form 10-K, the Company records accruals for estimated costs of clinical trial activities, resulting from the Company’s obligations under contracts with vendors, contract research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Estimated accruals are determined based on reviewing contractual terms and through communications with internal clinical personnel and external service providers including Contract Research Organizations (“CRO”) as to the progress or state of its trials.

Auditing management’s accounting for accrued clinical trial expenses was especially challenging as calculating the liability for clinical trial activity includes determining the progress or stage of completion of the activities included in the individual clinical trial agreements based on internal and external information, and involves a high volume of data.

83

 

How We Addressed the Matter in Our Audit

To test the adequacy of the Company’s clinical trial expense accruals, we performed audit procedures that included, amongst others, obtaining supporting evidence of the status of significant clinical trials based on communications with both internal and external clinical trial service providers.  For instance, we attended internal clinical trial and project status meetings with accounting personnel and clinical project managers to corroborate the status of clinical trial activities. To verify the appropriate measurement of accrued clinical trial costs, we reviewed significant agreements, confirmed fees and status directly with the CRO, selected a sample of transactions to compare the recorded expense against related invoices and contracts, recalculated the clinical expense and accrual and tested a sample of payments made subsequent to year-end to evaluate the completeness of the clinical trial expense accruals.

 

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2010.

San Diego, California

February 11, 2021

84

 

Otonomy, Inc.

Balance Sheets

(in thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

30,767

 

 

$

25,194

 

Short-term investments

 

 

55,576

 

 

 

35,476

 

Prepaid and other current assets

 

 

2,372

 

 

 

2,480

 

Total current assets

 

 

88,715

 

 

 

63,150

 

Restricted cash

 

 

702

 

 

 

701

 

Property and equipment, net

 

 

2,766

 

 

 

3,702

 

Right-of-use assets

 

 

14,082

 

 

 

15,465

 

Total assets

 

$

106,265

 

 

$

83,018

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

849

 

 

$

1,161

 

Accrued expenses

 

 

2,953

 

 

 

5,442

 

Accrued compensation

 

 

3,927

 

 

 

2,593

 

Leases, current

 

 

3,265

 

 

 

3,302

 

Total current liabilities

 

 

10,994

 

 

 

12,498

 

Long-term debt, net

 

 

15,158

 

 

 

14,967

 

Leases, net of current

 

 

13,847

 

 

 

15,320

 

Total liabilities

 

 

39,999

 

 

 

42,785

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000,000 shares authorized at

   December 31, 2020 and 2019; no shares issued or outstanding at

   December 31, 2020 and 2019

 

 

—

 

 

 

—

 

Common stock, $0.001 par value; 200,000,000 shares authorized at

   December 31, 2020 and 2019; 48,318,970 and 30,814,211 shares issued

   and outstanding at December 31, 2020 and 2019, respectively

 

 

48

 

 

 

31

 

Additional paid-in capital

 

 

570,841

 

 

 

500,084

 

Accumulated other comprehensive income

 

 

1

 

 

 

11

 

Accumulated deficit

 

 

(504,624

)

 

 

(459,893

)

Total stockholders’ equity

 

 

66,266

 

 

 

40,233

 

Total liabilities and stockholders’ equity

 

$

106,265

 

 

$

83,018

 

 

See accompanying notes.

85

 

Otonomy, Inc.

Statements of Operations

(in thousands, except share and per share data)

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Product sales, net

 

$

273

 

 

$

600

 

 

$

745

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,188

 

 

 

912

 

 

 

946

 

Research and development

 

 

27,997

 

 

 

32,805

 

 

 

31,844

 

Selling, general and administrative

 

 

14,575

 

 

 

11,690

 

 

 

20,008

 

Total costs and operating expenses

 

 

43,760

 

 

 

45,407

 

 

 

52,798

 

Loss from operations

 

 

(43,487

)

 

 

(44,807

)

 

 

(52,053

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

326

 

 

 

1,723

 

 

 

1,689

 

Interest expense

 

 

(1,570

)

 

 

(1,591

)

 

 

(4

)

Total other (expense) income, net

 

 

(1,244

)

 

 

132

 

 

 

1,685

 

Net loss

 

 

(44,731

)

 

 

(44,675

)

 

 

(50,368

)

Net loss per share, basic and diluted

 

$

(1.10

)

 

$

(1.45

)

 

$

(1.65

)

Weighted-average shares used to compute net loss per share, basic

   and diluted

 

 

40,845,844

 

 

 

30,726,786

 

 

 

30,610,244

 

 

See accompanying notes.

86

 

Otonomy, Inc.

Statements of Comprehensive Loss

(in thousands)

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Net loss

 

$

(44,731

)

 

$

(44,675

)

 

$

(50,368

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

 

(10

)

 

 

34

 

 

 

77

 

Comprehensive loss

 

$

(44,741

)

 

$

(44,641

)

 

$

(50,291

)

 

See accompanying notes.

 

 

 

87

 

 

Otonomy, Inc.

Statements of Stockholders’ Equity

(in thousands, except share data)

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2017

 

 

30,558,726

 

 

$

31

 

 

$

482,198

 

 

$

(100

)

 

$

(364,850

)

 

$

117,279

 

Issuance of common stock upon exercise

   of stock options

 

 

18,800

 

 

 

—

 

 

 

32

 

 

 

—

 

 

 

—

 

 

 

32

 

Issuance of common stock under

   employee stock purchase plan

 

 

107,886

 

 

 

—

 

 

 

303

 

 

 

—

 

 

 

—

 

 

 

303

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

12,414

 

 

 

—

 

 

 

—

 

 

 

12,414

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(50,368

)

 

 

(50,368

)

Unrealized gain on available-for-sale securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

77

 

 

 

—

 

 

 

77

 

Balance at December 31, 2018

 

 

30,685,412

 

 

 

31

 

 

 

494,947

 

 

 

(23

)

 

 

(415,218

)

 

 

79,737

 

Issuance of common stock upon exercise

   of stock options

 

 

2,912

 

 

 

—

 

 

 

5

 

 

 

—

 

 

 

—

 

 

 

5

 

Issuance of common stock under

   employee stock purchase plan

 

 

125,887

 

 

 

—

 

 

 

242

 

 

 

—

 

 

 

—

 

 

 

242

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

4,890

 

 

 

—

 

 

 

—

 

 

 

4,890

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(44,675

)

 

 

(44,675

)

Unrealized gain on available-for-sale securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

34

 

 

 

—

 

 

 

34

 

Balance at December 31, 2019

 

 

30,814,211

 

 

 

31

 

 

 

500,084

 

 

 

11

 

 

 

(459,893

)

 

 

40,233

 

Issuance of common stock and pre-

   funded warrants, net of issuance

   costs

 

 

17,275,000

 

 

 

17

 

 

 

64,170

 

 

 

—

 

 

 

—

 

 

 

64,187

 

Issuance of common stock upon exercise

   of stock options

 

 

92,035

 

 

 

—

 

 

 

206

 

 

 

—

 

 

 

—

 

 

 

206

 

Issuance of common stock under

   employee stock purchase plan

 

 

137,724

 

 

 

—

 

 

 

270

 

 

 

—

 

 

 

—

 

 

 

270

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

6,111

 

 

 

—

 

 

 

—

 

 

 

6,111

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(44,731

)

 

 

(44,731

)

Unrealized loss on available-for-sale securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(10

)

 

 

—

 

 

 

(10

)

Balance at December 31, 2020

 

 

48,318,970

 

 

$

48

 

 

$

570,841

 

 

$

1

 

 

$

(504,624

)

 

$

66,266

 

 

See accompanying notes.

 

 

 

88

 

 

Otonomy, Inc.,

Statements of Cash Flows

(in thousands)

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(44,731

)

 

$

(44,675

)

 

$

(50,368

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

1,062

 

 

 

1,149

 

 

 

1,186

 

Stock-based compensation

 

 

6,111

 

 

 

4,890

 

 

 

12,414

 

Accretion of discounts on short-term investments

 

 

(29

)

 

 

(787

)

 

 

(506

)

Amortization of debt discount

 

 

191

 

 

 

189

 

 

 

—

 

Deferred rent

 

 

—

 

 

 

—

 

 

 

103

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid and other assets

 

 

108

 

 

 

536

 

 

 

(493

)

Accounts payable

 

 

(374

)

 

 

127

 

 

 

68

 

Accrued expenses

 

 

(2,419

)

 

 

1,656

 

 

 

(166

)

Accrued compensation

 

 

1,334

 

 

 

(42

)

 

 

(672

)

Right-of-use assets and lease liabilities, net

 

 

(127

)

 

 

32

 

 

 

—

 

Net cash used in operating activities

 

 

(38,874

)

 

 

(36,925

)

 

 

(38,434

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of short-term investments

 

 

(68,581

)

 

 

(85,004

)

 

 

(104,270

)

Maturities of short-term investments

 

 

48,500

 

 

 

114,000

 

 

 

142,750

 

Purchases of property and equipment

 

 

(134

)

 

 

(700

)

 

 

(496

)

Net cash (used in) provided by investing activities

 

 

(20,215

)

 

 

28,296

 

 

 

37,984

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock and pre-funded

   warrants, net of issuance costs

 

 

64,187

 

 

 

—

 

 

 

—

 

Proceeds from issuance of long-term debt, net of cash issuance costs

 

 

—

 

 

 

—

 

 

 

14,830

 

Proceeds from short-term debt

 

 

1,126

 

 

 

—

 

 

 

—

 

Principal payments on short-term debt

 

 

(1,126

)

 

 

—

 

 

 

—

 

Proceeds from issuance of common stock under employee stock

   purchase plan

 

 

270

 

 

 

242

 

 

 

303

 

Proceeds from exercise of stock options

 

 

206

 

 

 

5

 

 

 

32

 

Payments of debt issuance costs

 

 

—

 

 

 

(52

)

 

 

—

 

Net cash provided by financing activities

 

 

64,663

 

 

 

195

 

 

 

15,165

 

Net change in cash, cash equivalents and restricted cash

 

 

5,574

 

 

 

(8,434

)

 

 

14,715

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

25,895

 

 

 

34,329

 

 

 

19,614

 

Cash, cash equivalents and restricted cash at end of period

 

$

31,469

 

 

$

25,895

 

 

$

34,329

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

30,767

 

 

$

25,194

 

 

$

33,633

 

Restricted cash at end of period

 

 

702

 

 

 

701

 

 

 

696

 

Cash, cash equivalents and restricted cash at end of period

 

$

31,469

 

 

$

25,895

 

 

$

34,329

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

1,373

 

 

$

1,394

 

 

$

4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing

   activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property and equipment in accounts payable and

   accrued expenses

 

$

67

 

 

$

76

 

 

$

7

 

Debt issuance costs in accounts payable and accrued expenses

 

$

—

 

 

$

—

 

 

$

66

 

Debt issuance costs

 

$

—

 

 

$

—

 

 

$

771

 

 

See accompanying notes.

89

 

Otonomy, Inc.,

Notes to Financial Statements

1. Description of Business and Basis of Presentation

Description of Business

Otonomy, Inc. (Otonomy or the Company) was incorporated in the state of Delaware on May 6, 2008. Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The Company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss and tinnitus.

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone that has completed two Phase 3 trials for the treatment of Ménière’s disease, with a third Phase 3 trial that has completed enrollment of patients with top-line results expected by the end of February 2021. OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine that has completed a Phase 1/2 clinical trial in tinnitus patients with positive top-line results, and the Company expects to initiate a Phase 2 clinical trial in the first quarter of 2021. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) for hearing loss, with positive top-line results announced for a Phase 1/2 clinical trial that the Company intends to continue with an expansion of the trial expected to start in the second quarter of 2021. Otonomy also has multiple preclinical stage programs addressing additional hearing loss pathologies including a gene therapy for treatment of congenital hearing loss (OTO-825), an otoprotectant for prevention of cisplatin-induced hearing loss (OTO-510), and a hair cell repair and regeneration program for severe hearing loss (OTO-6XX). In October 2019, the Company entered into a strategic collaboration with Applied Genetic Technologies Corporation (AGTC), to co-develop and co-commercialize a gene therapy to restore hearing in patients with hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. In July 2020, the Company entered into an exclusive license agreement with Kyorin Pharmaceutical Co., Ltd. (Kyorin) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for the OTO-6XX program.

In addition, the Company developed, received United States Food and Drug Administration (FDA) approval and commercially launched OTIPRIO for use during tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis externa (AOE). In June 2020, the Company entered into a co-promotion agreement with ALK-Abelló, Inc. (ALK) to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

Basis of Presentation

The Company follows Accounting Standards Codification (ASC) Topic 205-40, Presentation of Financial Statements—Going Concern, which requires that management evaluate whether there are relevant conditions and events that in aggregate raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating activities since inception. In July 2020, the Company sold in a public offering 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase 4,000,000 shares of its common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, the Company had cash, cash equivalents and short-term investments of $86.3 million, outstanding debt of $15.2 million and an accumulated deficit of $504.6 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory approvals for OTIVIDEX, OTO-313, OTO-413 and its other product candidates; and (ii) works to develop additional product candidates through research and development programs.

90

 

When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or other sources, such as potential collaboration agreements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all.  If the Company is not able to secure adequate additional funding, if or when necessary, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.  The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for a period of at least twelve months from the date of this report.

2. Summary of Significant Accounting Policies

Use of Estimates

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available checking, savings and money market accounts.

The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s corporate headquarters.

Short-term Investments

The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 8 – Fair Value).

Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis, and whenever events or changes

91

 

in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records unrealized gains and losses on available-for-sale debt securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders’ equity on the balance sheets. The Company does not hold equity securities in its investment portfolio.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value.

Inventory

Inventory is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost to sell. During the year ended December 31, 2020, the Company recorded an inventory write down of $0.3 million to cost of product sales. During the years ended December 31, 2019 and 2018, no such write downs were recorded.

Property and Equipment, Net

Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred.

Impairment of Long-Lived Assets

The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2020, 2019 and 2018.

Right-of-Use Assets and Lease Liabilities

The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. The Company determines if an arrangement is or contains a lease at each commencement date. Accounting Standards Codification (ASC) 842, Leases (ASC 842) establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02) provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases.

Operating leases are included in ROU assets, Leases, current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on the balance sheets. The Company has elected a policy not to recognize short-term leases (one year or less) on the balance sheets. ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease

92

 

payments over the lease term at the commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Clinical Trial Expense Accruals

The Company estimates expenses resulting from its obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.

The Company records clinical trial expenses in the period in which services are performed and efforts are expended. The Company accrues for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company estimates accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, the Company may adjust its clinical accruals if actual results differ from its estimates.

Revenue Recognition

The Company recognizes revenue by performing the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under ASC Topic 606, Revenue from Contracts with Customers (ASC 606) and when it is probable the Company will collect the consideration exchanged for the goods or services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of OTIPRIO, typically upon delivery by the Company to these distributors. The Company has determined the delivery of OTIPRIO to its customers constitutes a single performance obligation and no other performance obligations are present. The Company’s customer contracts have standard payment terms. The Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.

Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are not permitted. To date, product returns have been immaterial.

Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year or the amount is immaterial.

Concentration of Major Customers

The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest customers for each of the periods presented:

 

93

 

 

 

 

2020

 

 

2019

 

 

2018

 

First largest

 

 

41

%

 

 

38

%

 

 

44

%

Second largest

 

 

29

%

 

 

33

%

 

 

33

%

Third largest

 

 

24

%

 

 

24

%

 

 

21

%

 

Collaborative Arrangements

The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, Collaborative Arrangements (ASC 808).

Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.

Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the statements of operations.

Research and Development

Research and development expenses include the costs associated with the Company’s research and development activities, including salaries, benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.

Selling, General and Administrative

Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s partners under its co-promotion agreements.

Stock-Based Compensation

The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-based vesting conditions, stock-based compensation expense is recognized using the straight-line method.  For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

Income Taxes

The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

94

 

The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources.

Net Loss Per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

As of December 31, 2020, 2019 and 2018, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of outstanding options to purchase 9,842,744, 7,495,129 and 5,019,964 shares of the Company’s common stock, respectively.

Risks and Uncertainties Related to COVID-19

In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 pandemic could pose significant risks to the Company’s business; however, the ultimate impact of the pandemic is highly uncertain.

The Company has clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, the Company had suspended and subsequently updated its guidance regarding timing of trial results. The Company may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic.  In addition, the Company has made and it (and its contract research organizations (CROs)) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020, among other activity.  Third-party manufacturers which the Company uses for the supply of materials for its product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although the Company expects no material impact on the clinical supply of its product candidates for its current clinical trials, should its third-party manufacturers experience extended disruptions, the Company could experience delays in future trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which may delay the development of the Company’s product candidates.

The Company continues to evaluate the impact COVID-19 may have on its ability to effectively conduct its business operations as planned, and work with healthcare providers supporting its clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies and may take further actions as may be required by federal, state or local authorities or that the Company determines are in the best interests of public health and safety and that of patients, employees, partners, and stockholders.  Nonetheless,

95

 

the Company does not yet know and cannot predict the full extent of potential delays or impacts on its business, its preclinical programs and clinical trials, healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the COVID-19 pandemic will have on the Company’s business, strategy, collaborations, financial condition, liquidity and future results of operations.

 

Recent Accounting Pronouncements

Not Yet Adopted

In June 2016, ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable. ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect on its financial position, results of operations or cash flows.

Recently Adopted

Effective January 1, 2020, the Company early adopted ASU No. 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, other comprehensive income).

ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 is effective for the Company beginning January 1, 2020. There was no cumulative effect to be recognized in connection with the early adoption of ASU 2019-12 and the adoption did not have a material impact on the Company’s financial statements or disclosures.

3. Available-for-Sale Securities

The Company invests in available-for-sale debt securities consisting of money market funds, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities. Available-for-sale debt securities are classified as part of either cash and cash equivalents or short-term investments in the balance sheets. Available-for-sale debt securities with maturities of three months or less from the date of purchase have been classified as cash equivalents, and were $23.3 million and $22.1 million as of December 31, 2020 and 2019, respectively.

Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and were as follows (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Market Value

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

55,085

 

 

$

2

 

 

$

(1

)

 

$

55,086

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

—

 

 

 

490

 

 

 

$

55,575

 

 

$

2

 

 

$

(1

)

 

$

55,576

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 

 

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 

 

As of December 31, 2020, the Company had four securities in a gross unrealized loss position, all of which have been in such position for less than twelve months. At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized

96

 

loss positions until their amortized cost basis has been recovered. The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2020. All the Company’s available-for-sale debt securities mature within one year.

The Company obtains the fair value of its available-for-sale debt securities from a professional pricing service. The fair values of available-for-sale debt securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank.

4. Balance Sheet Details

Prepaid and Other Current Assets

Prepaid and other current assets are comprised of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Inventory

 

$

227

 

 

$

478

 

Other

 

 

2,145

 

 

 

2,002

 

Total

 

$

2,372

 

 

$

2,480

 

Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

4,265

 

 

$

4,179

 

Manufacturing equipment

 

 

1,075

 

 

 

1,111

 

Computer equipment and software

 

 

989

 

 

 

943

 

Leasehold improvements

 

 

768

 

 

 

768

 

Office furniture

 

 

1,548

 

 

 

1,548

 

 

 

 

8,645

 

 

 

8,549

 

Less: accumulated depreciation and amortization

 

 

(5,879

)

 

 

(4,847

)

Total

 

$

2,766

 

 

$

3,702

 

 

Depreciation expense was $1.1 million, $1.1 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued clinical trial costs

 

$

1,477

 

 

$

3,443

 

Accrued other

 

 

1,476

 

 

 

1,999

 

Total

 

$

2,953

 

 

$

5,442

 

 

5. Commitments and Contingencies

Operating Leases

In December 2016, the Company moved into its current headquarters location in San Diego, California. The lease commenced in December 2016 and has an initial term of 130 months, with an option by the Company to

97

 

extend the lease term for an additional five years. The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee. The Company is responsible for payment of taxes and operating expenses for the building, in addition to monthly base rent in the initial amount of approximately $232,000, with 3% annual increases, which monthly base rent was abated for the first ten months of the lease term. The total estimated base rent payments over the life of the lease are estimated to be approximately $32.7 million. Upon execution of the lease in May 2015, the Company provided a security deposit in the form of a letter of credit in the amount of approximately $0.7 million. Cash collateralizing the letter of credit is classified as noncurrent restricted cash on the balance sheets. The Company has determined that the lease is an operating lease for accounting purposes.

Intellectual Property Licenses

The Company has acquired exclusive rights to develop patented rights, information rights and related know-how for OTIPRIO, OTIVIDEX, OTO-311, OTO-313 and OTO-413 and potential future product candidates under licensing agreements with third parties. The licensing rights obligate the Company to make payments to the licensors for license fees, milestones and royalties. The Company is also responsible for patent prosecution costs, in the event such costs are incurred.

The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements covering OTIPRIO, OTIVIDEX, OTO-313 and OTO-413 as follows (in thousands):

 

Development

 

$

1,250

 

Regulatory

 

 

10,275

 

Commercialization

 

 

1,000

 

Total

 

$

12,525

 

 

Under one of these agreements, the Company has achieved eight development milestones and one regulatory milestone, totaling $3.2 million, related to its clinical trials for OTIPRIO, OTIVIDEX, OTO-311 and OTO-413.

If the Company receives positive results from the OTIVIDEX Phase 3 trial and submits an NDA to the FDA in 2021, the Company may be obligated to make a regulatory milestone payment of $1.0 million under one of the Company’s license agreements. This potential payment is included in the table above.

 

In addition, the Company is obligated to pay royalties of less than five percent on net sales of OTIPRIO and on sales of any other commercial products developed using these licensed technologies. Such royalty expense for OTIPRIO is recorded to cost of product sales. The Company may also be obligated to pay to the licensors a percentage of fees received if and when the Company sublicenses the technology. As of December 31, 2020, the Company has not entered into any sublicense agreements for the licensed technologies.

In July 2020, the Company entered into an exclusive license agreement to develop, manufacture and commercialize a novel compound as a potential treatment, OTO-6XX, for severe hearing loss. Under the terms of the agreement, the Company acquired worldwide rights to the compound for an upfront payment of $0.5 million with an additional $0.5 million due upon demonstration of preclinical efficacy. If the Company advances a product containing the compound into full development, the Company may be obligated to make payments for development and commercial milestones and pay a royalty on worldwide net sales. The license agreement was accounted for as an asset acquisition and the upfront cash payment of $0.5 million was expensed to research and development during the year ended December 31, 2020 as there is no future alternative use for the assets.

98

 

The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable royalty and milestone obligations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

License and other fees

 

$

500

 

 

$

—

 

 

$

—

 

Milestone fees

 

 

250

 

 

 

100

 

 

 

—

 

Total license and related fees

 

$

750

 

 

$

100

 

 

$

—

 

 

Other Royalty Arrangements

The Company entered into an agreement related to OTIPRIO under which the Company is obligated to pay royalties of less than one percent on net product sales of OTIPRIO. The royalties are recorded as selling, general and administrative expense. The royalties are payable until the later of: (i) the expiration of the last to expire patent owned by the Company in such country covering OTIPRIO; or (ii) 10 years after the first commercial sale of OTIPRIO after receipt of regulatory approval for OTIPRIO in such country.

In October 2014, the Company entered into an exclusive license agreement with Ipsen that enables the Company to use clinical and nonclinical gacyclidine data generated by Ipsen to support worldwide development and regulatory filings for OTO-313. Under this license agreement, the Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees, up to a maximum cumulative royalty totaling $10.0 million.

Litigation

From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company as of December 31, 2020 which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

6. Debt

Term Loan

 

On December 31, 2018 (the Closing Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), among the Company, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time.

 

The Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for working capital and general corporate purposes. The Company has the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment fee of 1.00%. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan was fully funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). The Company paid a facility fee of 0.75% and customary closing fees on the Closing Date.

 

The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate). Interest on the Term Loan is payable monthly in arrears. During the year ended December 31, 2020, the terms of the Term Loan were amended to extend the interest-only period from 24 months to 36 months following the Closing Date, followed by consecutive equal monthly payments of principal and interest in arrears through the Maturity Date. The extension was accounted for as a modification, with no material effect on the Company’s financial statements or financial position. The outstanding principal amount of the Term Loan, together with accrued and unpaid interest, is due on December 1, 2023.

 

99

 

 

Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the effective interest method.

 

The Company’s obligations under the Loan Agreement are secured by substantially all its assets, excluding intellectual property and subject to certain other exceptions and limitations.

 

The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained compliance with all such covenants to date. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable, increase the applicable rate of interest by 5.00%, and exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include payment defaults, breaches of covenants or representations and warranties, material adverse changes, certain bankruptcy events, cross defaults with certain other indebtedness, and judgment defaults.

 

Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.6 million for the year ended December 31, 2020. Accrued interest, included in accounts payable, was $0.1 million as of December 31, 2020. The outstanding Term Loan balance was $15.2 million as of December 31, 2020, inclusive of accretion of the final payment and net unamortized debt discount.

 

The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2020 for the next three fiscal years were as follows:

 

2021

 

$

—

 

2022

 

 

7,826

 

2023

 

 

7,774

 

Subtotal

 

 

15,600

 

Unamortized discount

 

 

(442

)

Total long-term debt, net

 

$

15,158

 

PPP Loan

On April 10, 2020 the Company obtained an unsecured $1.1 million loan through JPMorgan Chase Bank, N.A. under the Paycheck Protection Program (the PPP Loan) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Loan bore an interest rate of 0.98% and notionally matured two years from the date of issuance. Following the issuance of new, retroactive guidance on the program from the Small Business Administration on April 23, 2020, the Company repaid the PPP Loan principal and accrued interest in full. Interest expense related to the PPP Loan was de minimis for the year ended December 31, 2020.

7. Leases

Operating Leases

100

 

The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from 48 months to 130 months. The facility lease has an option for the Company to extend the lease term for an additional five years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the lease liability. The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee.

On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at the end of the lease term based upon the then fair market value of the equipment. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The Company evaluated the lease in accordance with ASC 842 and recorded this lease as an operating lease in the balance sheets.

The ROU assets associated with all the Company’s operating leases are recognized in the balance sheets. Rent expense was $3.1 million during the years ended December 31, 2020, 2019 and 2018.

 

Finance Leases

On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to purchase the equipment at the end of the lease term that is expected to be exercised. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The associated ROU asset is recognized within property and equipment, net in the balance sheets and is being amortized over three years in accordance with the Company’s standard depreciation and amortization policies.

 

 

 

Years Ended December 31,

 

Lease expenses:

 

2020

 

 

2019

 

Operating lease expenses

 

$

3,137

 

 

$

3,137

 

Variable lease expenses

 

 

793

 

 

 

942

 

Total lease expenses

 

$

3,930

 

 

$

4,079

 

 

 

Lease Maturities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Leases

 

 

Finance Leases

 

 

Total

 

2021

 

$

3,247

 

 

$

18

 

 

$

3,265

 

2022

 

 

3,333

 

 

—

 

 

 

3,333

 

2023

 

 

3,433

 

 

—

 

 

 

3,433

 

2024

 

 

3,536

 

 

—

 

 

 

3,536

 

2025

 

 

3,642

 

 

—

 

 

 

3,642

 

Thereafter

 

 

6,642

 

 

—

 

 

 

6,642

 

Total minimum lease payments

 

 

23,833

 

 

 

18

 

 

 

23,851

 

Imputed interest

 

 

(6,739

)

 

 

—

 

 

 

(6,739

)

Total

 

 

17,094

 

 

 

18

 

 

 

17,112

 

Less: leases, current

 

 

(3,247

)

 

 

(18

)

 

 

(3,265

)

Leases, net of current

 

$

13,847

 

 

$

—

 

 

$

13,847

 

 

 

8. Fair Value

The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:

Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

101

 

As of December 31, 2020 and 2019, the Company held no assets or liabilities measured at fair value on a nonrecurring basis and no liabilities measured at fair value on a recurring basis. The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurement at Reporting Date Using

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

23,278

 

 

$

23,278

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

55,086

 

 

 

55,086

 

 

 

—

 

 

 

—

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

490

 

 

 

—

 

 

 

$

78,854

 

 

$

78,364

 

 

$

490

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

22,121

 

 

$

22,121

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

35,476

 

 

 

35,476

 

 

 

—

 

 

 

—

 

 

 

$

57,597

 

 

$

57,597

 

 

$

—

 

 

$

—

 

 

9. Stockholders’ Equity

Common Stock Reserved for Future Issuance

Shares of common stock reserved for future issuance are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Common stock options issued and outstanding

 

 

9,842,744

 

 

 

7,495,129

 

Pre-funded warrants to purchase common stock

 

 

4,000,000

 

 

 

—

 

Common stock options available for future grant

 

 

2,553,854

 

 

 

3,548,214

 

Common stock reserved for issuance under ESPP

 

 

2,301,704

 

 

 

1,977,215

 

Total common stock reserved for future issuance

 

 

18,698,302

 

 

 

13,020,558

 

Sale of Common Stock and Pre-funded Warrants

In July 2020, the Company sold 17,275,000 shares of its common stock at a public offering price of $3.25 per share and sold pre-funded warrants to purchase 4,000,000 shares of its common stock at a public offering price of $3.249 per pre-funded warrant. After deducting underwriting discounts and commissions and offering expenses, the Company received net proceeds from the offering of $64.2 million. The public offering price for the pre-funded warrants was equal to the public offering price of the common stock, less the $0.001 per share exercise price of each pre-funded warrant. Per their terms, the outstanding pre-funded warrants to purchase shares of common stock may not be exercised if certain holders’ ownership of the Company’s common stock would exceed 4.99% following such exercise. The pre-funded warrants are exercisable immediately and do not contain an expiration date. The pre-funded warrants include a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. The pre-funded warrants are recorded as a component of stockholders’ equity within additional paid-in capital. The pre-funded warrants are included in the computation of basic net loss per share as the exercise price is negligible and may be exercised at any time until the pre-funded warrants are exercised in full. During the year ended December 31, 2020, none of the pre-funded warrants were exercised; accordingly, as of December 31, 2020, all of the pre-funded warrants remained issued and outstanding.

10. Stock-Based Compensation and Equity Plans

2014 Equity Incentive Plan

The Company granted awards under its 2010 Equity Incentive Plan (the 2010 Plan) until June 2014. In July 2014, the Company’s board of directors adopted and the Company’s stockholders approved its 2014 Equity

102

 

Incentive Plan (the 2014 Plan), which became effective in August 2014. In connection with the adoption of the 2014 Plan, the Company terminated the 2010 Plan for future use and provided that no further equity awards were to be granted under the 2010 Plan. All outstanding awards under the 2010 Plan continue to be governed by their existing terms.

The 2014 Plan permits the grant of incentive stock options to the Company’s employees and the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants. Options granted under the 2014 Plan are generally scheduled to vest over four years, subject to continued service, and subject to certain acceleration of vesting provisions, expire no later than 10 years from the date of grant. Options granted under the 2014 Plan must have a per share exercise price equal to at least 100% of the fair market value of a share of the common stock as of the date of grant.

Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 2,415,948 shares so that the total available for future issuance as of January 1, 2021 was 4,969,802 shares.

As of December 31, 2020, 2,553,854 options were available for grant under the 2014 Plan. The following table summarizes stock option activity for the year ended December 31, 2020 (in thousands except per share amounts and years):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-

Average

Remaining

Contractual

Term

(In Years)

 

 

Aggregate

Intrinsic Value

 

Outstanding as of December 31, 2019

 

 

7,495

 

 

$

4.43

 

 

 

 

 

 

 

 

 

Granted

 

 

3,099

 

 

$

3.46

 

 

 

 

 

 

 

 

 

Exercised

 

 

(92

)

 

$

2.23

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(659

)

 

$

4.93

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options vested and expected to vest as of

   December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options exercisable as of December 31, 2020

 

 

5,160

 

 

$

4.84

 

 

 

5.7

 

 

$

10,890

 

 

The following table summarizes certain information regarding stock options (in thousands, except per share data):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Weighted-average grant date fair value per share of

   options granted during the period

 

$

2.68

 

 

$

1.64

 

 

$

4.36

 

Cash received from options exercised during the

   period

 

 

206

 

 

 

5

 

 

 

32

 

Intrinsic value of options exercised during the period

 

 

59

 

 

 

2

 

 

 

76

 

 

Performance-based Awards

In February 2018, the Company granted its chief executive officer a stock option for the purchase of 250,000 shares of the Company’s common stock which is subject to time-based vesting and certain performance-based conditions. Specifically, subject to continued service the option was scheduled to vest upon achievement of a clinical development milestone. On the grant date, the Company determined the fair value of the award and

103

 

determined achievement of the milestone was probable of occurrence and recognized stock-based compensation expense, based upon the grant date fair value, over the implicit service period. The milestone was achieved, and the option grant vested and was fully expensed as of December 31, 2018.

Option Exchange

On December 20, 2017, the Company commenced an option exchange program (Option Exchange) which allowed eligible employees to exchange certain outstanding stock options (Eligible Options), whether vested or unvested, with an exercise price greater than $12.00 per share, for new stock options.  Non-employee members of the Company’s board of directors were not eligible to participate in the Option Exchange. The Option Exchange expired on January 19, 2018.  The closing price of the Company’s common stock on that date was $5.675 per share.

Pursuant to the terms and conditions of the Option Exchange, the Company accepted for exchange Eligible Options to purchase a total of 1,992,000 shares of the Company’s common stock, representing approximately 81.51% of the total shares of common stock underlying the Eligible Options. All surrendered options were canceled effective as of the expiration of the Option Exchange and in exchange on January 19, 2018, the Company granted new options to purchase an aggregate of 1,570,328 shares of the Company’s common stock with an exercise price of $5.675 per share pursuant to the terms of the Option Exchange and the 2014 Plan.

These new options vest over one to three years, subject to the terms of the Option Exchange and expire eight years from the date of grant. The Company determined this option exchange was an option modification. The exchange of these stock options was treated as a modification for accounting purposes. The difference in the fair value of the canceled options immediately prior to the cancelation and the fair value of the modified options resulted in incremental value, of approximately $0.6 million, which was calculated using the Black-Scholes-Merton option pricing model. Total stock-based compensation expense to be recognized over the requisite service period is equal to the remaining unrecognized expense for the exchanged option, as of the exchange date, plus the incremental value of the modification to the award.

2014 Employee Stock Purchase Plan

In July 2014, the Company’s board of directors adopted and the stockholders approved the Company’s 2014 Employee Stock Purchase Plan (the ESPP), which became effective upon adoption by the Company’s board of directors. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The offering periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and December 1 approximately twenty-four months later, and include six-month purchase periods.

The number of shares available for issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of (i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 724,784 shares so that the total available for future issuance as of January 1, 2021 was 3,026,488 shares.

As of December 31, 2020, the Company had issued 595,555 shares of common stock under the ESPP and had 2,301,704 shares available for future issuance.

104

 

Stock-Based Compensation Expense

The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-Scholes-Merton option pricing model:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Stock Options:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

1.5

%

 

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

96.7

%

 

 

98.1

%

 

 

100.6

%

Expected term (in years)

 

 

6.1

 

 

 

6.1

 

 

 

5.4

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

0.1

%

 

 

2.0

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

69.8

%

 

 

69.5

%

 

 

116.0

%

Expected term (in years)

 

 

1.3

 

 

 

1.3

 

 

 

1.3

 

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the option grants.

Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.

Expected Volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.

Expected Term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.

Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Cost of product sales

 

$

13

 

 

$

12

 

 

$

12

 

Research and development

 

 

2,456

 

 

 

2,085

 

 

 

4,447

 

Selling, general and administrative

 

 

3,642

 

 

 

2,793

 

 

 

7,955

 

Total stock-based compensation

 

$

6,111

 

 

$

4,890

 

 

$

12,414

 

 

As of December 31, 2020, unrecognized compensation cost related to stock options was $9.8 million which is expected to be recognized over a remaining weighted-average vesting period of 2.5 years. As of December 31, 2020, unrecognized compensation cost related to ESPP rights was $0.4 million which is expected to be recognized over a remaining weighted-average vesting period of 1.2 years.

11. Collaboration Agreements

AGTC collaboration

In October 2019, the Company announced a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. Under the collaboration agreement, the Company and AGTC equally share the program costs and any revenue or other proceeds related to the program. As of December 31, 2020, the Company recognized a net receivable of $0.1 million from AGTC.

105

 

Co-Promotion Agreements

The Company entered into a co-promotion agreement with ALK in June 2020, with Mission Pharmacal Company (Mission) in August 2018 and with Glenmark Therapeutics Inc., USA (Glenmark) in April 2019 (each, a Co-Promotion Agreement) to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed the Company of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on its business operations. In September 2019, the Company reached a settlement with Glenmark regarding the financial and contractual terms impacted by this decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed the Company of its non-renewal of the co-promotion agreement.

ALK, Mission and Glenmark (each, a Partner) each agreed to reimburse the Company for certain expenses, including a proportion of product support expenses. All such payments are accounted for as reductions to selling, general and administrative expense. Each Partner has been entitled to a share of gross profits totaling more than 50% from the sale of OTIPRIO to each Partner’s accounts. The Company’s payments to each Partner for its portion of the gross profit is recognized as selling, general and administrative expense. The Company is the principal in the product sale of OTIPRIO and recognizes all revenue and related cost of product sales. For the years ended December 31, 2020 and 2019, the Company recognized reductions in selling, general and administrative expenses related to the Co-Promotion Agreements of $0.3 million and $2.6 million, respectively.

12. Income Taxes

Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed a preliminary IRC Section 382/383 analysis, regarding the limitation of net operating loss and research and development credit carryforwards as of December 31, 2020 and does not believe there to have been an ownership change during the year then ended. The Company will continue to consider changes in ownership that may cause losses of tax attributes in the future.

Significant components of the Company’s deferred tax assets are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

88,013

 

 

$

78,768

 

Research and development credits

 

 

9,985

 

 

 

8,920

 

Depreciation and amortization

 

 

10,212

 

 

 

12,608

 

Accrued expenses

 

 

850

 

 

 

381

 

Lease liabilities

 

 

3,816

 

 

 

4,349

 

Stock compensation

 

 

3,856

 

 

 

4,395

 

Other, net

 

 

234

 

 

 

181

 

Total deferred tax assets

 

 

116,966

 

 

 

109,602

 

Less: valuation allowance

 

 

(113,826

)

 

 

(105,990

)

Total deferred tax assets, net of valuation allowance

 

 

3,140

 

 

 

3,612

 

Deferred tax liability:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(3,140

)

 

 

(3,612

)

Total deferred tax liability

 

 

(3,140

)

 

 

(3,612

)

Total

 

$

—

 

 

$

—

 

Due to the Company’s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company’s net deferred tax assets, as it is more likely than not that such net assets will not be realized. A valuation allowance of approximately $113.8 million and $106.0 million has been established as of December 31, 2020 and 2019, respectively.

106

 

At December 31, 2020, the Company had federal and state net operating loss carryforwards of approximately $382.8 million net of IRC Section 382 limitations and $124.8 million, respectively. Of the federal net operating loss carryforwards, approximately $142.2 million were generated after January 1, 2018, and therefore do not expire. Federal net operating losses that occur after January 1, 2018 are subject to a taxable income limitation of 80% in accordance with the Tax Cuts and Jobs Act of 2017 (the TCJA). The remaining federal and state net operating loss carryforwards will begin to expire in 2030, unless previously utilized. As of December 31, 2020, the Company also had federal and California research and development credit carryforwards of approximately $12.0 million net of IRC Section 383 limitations and $5.8 million, respectively. The federal research and development credit carryforwards will begin expiring in 2030, unless previously utilized. The California research credit will carry forward indefinitely.

The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those currently reported for the years ended December 31 (in thousands):

 

 

 

2020

 

 

2019

 

 

2018

 

Federal statutory rate

 

$

(9,393

)

 

$

(9,382

)

 

$

(10,578

)

State tax (net of federal benefit)

 

 

334

 

 

 

299

 

 

 

(4,383

)

Permanent items, other

 

 

9

 

 

 

189

 

 

 

(2,092

)

Stock compensation

 

 

1,595

 

 

 

2,470

 

 

 

2,570

 

Other adjustments

 

 

687

 

 

 

523

 

 

 

—

 

Research and development credits

 

 

(1,774

)

 

 

(1,595

)

 

 

(2,308

)

Uncertain tax positions

 

 

710

 

 

 

638

 

 

 

907

 

Change in valuation allowance

 

 

7,832

 

 

 

6,858

 

 

 

15,884

 

Provision for income taxes

 

$

0

 

 

$

0

 

 

$

0

 

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Balance at the beginning of the year

 

$

10,739

 

 

$

10,052

 

 

$

9,098

 

Adjustments related to prior year tax positions

 

 

(21

)

 

 

(80

)

 

 

242

 

Increases related to current year tax positions

 

 

796

 

 

 

767

 

 

 

712

 

 

 

$

11,514

 

 

$

10,739

 

 

$

10,052

 

The Company’s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has no accruals for interest or penalties in the balance sheets as of December 31, 2020 and 2019 and has not recognized interest or penalties in the statements of operations for the years ended December 31, 2020, 2019 and 2018.

Due to the valuation allowance recorded against the Company’s net deferred tax assets, future changes in unrecognized tax benefits will not impact the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.

The Company is subject to taxation in the United States for federal and state purposes. Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination by the IRS and state tax authorities for all years since inception. The Company is not currently under examination by the federal or any state tax authority.

107

 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

Item 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Management, with the participation of our Chief Executive Officer and our Chief Financial and Business Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2020, our Chief Executive Officer and our Chief Financial and Business Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria established in “Internal Control—Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2020. This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting due to our status as a non-accelerated filer.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting

Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.

Item 9B. OTHER INFORMATION

None.

108

 

Part III

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2021 annual meeting of stockholders (Proxy Statement), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2020, and is incorporated in this report by reference.

Item 11. EXECUTIVE COMPENSATION

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

109

 

PART IV

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

The following documents are filed as a part of this Annual Report on Form 10-K:

(1) Financial Statements:

Our Financial Statements are listed in the “Index to Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.

(2) Financial Statement Schedules:

Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes herein.

(3) Exhibits:

The following exhibits, as required by Item 601 of Regulation S-K are attached or incorporated by reference as stated below.

 

 

110

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

Description

 

Incorporation by Reference

 

 

 

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

    2.1#

 

Asset Transfer Agreement between the Registrant and IncuMed, LLC, dated April 30, 2013.

  

S-1

  

333-197365

 

2.1

 

7/11/2014

 

 

 

 

 

 

 

 

 

 

 

    3.1

 

Amended and Restated Certificate of Incorporation of the Registrant.

 

S-1/A

 

333-197365

 

3.2

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

    3.2

 

Amended and Restated Bylaws of the Registrant.

 

8-K

 

001-36591

 

3.1

 

7/9/2020

 

 

 

 

 

 

 

 

 

 

 

    4.1

 

Third Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated April 23, 2014.

  

S-1

 

333-197365

 

4.1

 

7/11/2014

 

 

 

 

 

 

 

 

 

 

 

    4.2

 

Specimen common stock certificate of the Registrant.

 

S-1/A

 

333-197365

 

4.2

 

7/28/2014

 

 

 

 

 

 

 

 

 

 

 

    4.3

 

Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.

 

10-K

 

001-36591

 

4.3

 

2/27/2020

 

 

 

 

 

 

 

 

 

 

 

    4.4

 

Form of Pre-Funded Warrant.

 

8-K

 

001-36591

 

4.1

 

7/10/2020

 

 

 

 

 

 

 

 

 

 

 

  10.1+

 

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.

  

S-1/A

 

333-197365

 

10.1

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.2+

 

Amended and Restated 2010 Equity Incentive Plan and forms of agreement thereunder.

  

S-1/A

 

333-197365

 

10.2

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.3+

 

2014 Equity Incentive Plan and forms of agreements thereunder.

 

S-1/A

 

333-197365

 

10.3

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.4+

 

2014 Employee Stock Purchase Plan and form of agreement thereunder.

  

S-1/A

 

333-197365

 

10.4

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.5+

 

Executive Incentive Compensation Plan.

 

S-1/A

 

333-197365

 

10.5

 

7/28/2014

 

 

 

 

 

 

 

 

 

 

 

  10.6+

 

Executive Employment Agreement between the Registrant and David A. Weber, Ph.D., dated July 30, 2014.

  

S-1/A

 

333-197365

 

10.6

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.7+

 

Executive Employment Agreement between the Registrant and Paul E. Cayer, dated July 31, 2014.

  

S-1/A

 

333-197365

 

10.7

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.8+

 

Executive Employment Agreement between the Registrant and Robert Michael Savel, II, dated July 31, 2014.

  

S-1/A

 

333-197365

 

10.9

 

8/1/2014

 

 

 

 

 

 

 

 

 

 

 

  10.9+

 

Executive Employment Agreement between the Registrant and Kathie Bishop, Ph.D., dated January 4, 2017.

  

10-Q

 

001-36591

 

10.1

 

5/4/2017

 

 

 

 

 

 

 

 

 

 

 

  10.10#

 

License and Commercialization Agreement between the Registrant and DURECT Corporation, dated April 30, 2013.

  

S-1

 

333-197365

 

10.11

 

7/11/2014

 

 

 

 

 

 

 

 

 

 

 

  10.11#

 

License Agreement between the Registrant and The Regents of the University of California, dated November 5, 2008, as amended on January 27, 2010, June 9, 2010 and November 7, 2012.

 

S-1

 

333-197365

 

10.12

 

7/11/2014

 

 

 

 

 

 

 

 

 

 

 

  10.12

 

Lease Agreement between the Registrant and ARE-SD Region No. 34, LLC, dated May 11, 2015.

 

10-Q

 

001-36591

 

10.2

 

5/12/2015

 

 

 

 

 

 

 

 

 

 

 

111

 

Exhibit

Number

 

Description

 

Incorporation by Reference

 

 

 

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

  10.13

 

Loan and Security Agreement among the Registrant, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time, dated December 31, 2018.

 

8-K

 

001-36591

 

10.1

 

1/3/2019

 

 

 

 

 

 

 

 

 

 

 

  10.14

 

Sales Agreement, dated as of August 1, 2019, between the Registrant and Cowen and Company, LLC.

 

8-K

 

001-36591

 

1.1

 

8/1/2019

 

 

 

 

 

 

 

 

 

 

 

  23.1

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  24.1

 

Power of Attorney, incorporated by reference to the signature page hereto.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.1

 

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.2

 

Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.1*

 

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.2*

 

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document.

 

The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover page interactive data file (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101).

 

 

 

 

 

 

 

 

 

*

The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Otonomy, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.

112

 

#

Portions of the exhibit have been omitted pursuant to an order granted by the Securities and Exchange Commission for confidential treatment.

+

Indicates management contract or compensatory plan.

Item 16. FORM 10-K SUMMARY

None.

113

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 11, 2021

 

OTONOMY, INC.

 

 

By:

 

/s/ David A. Weber

 

 

David A. Weber, Ph.D.

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints David A. Weber, Ph.D. and Paul E. Cayer, and each of them acting individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ David A. Weber

David A. Weber, Ph.D.

 

President, Chief Executive Officer and Director

(Principal Executive Officer)

 

February 11, 2021

 

 

 

 

 

/s/ Paul E. Cayer

Paul E. Cayer

 

Chief Financial and Business Officer

(Principal Financial and Accounting Officer)

 

February 11, 2021

 

 

 

 

 

/s/ Jay Lichter

Jay Lichter, Ph.D.

 

Chairman of the Board of Directors

 

February 11, 2021

 

 

 

 

 

/s/ James Breitmeyer

James Breitmeyer, M.D., Ph.D.

 

Director

 

February 11, 2021

 

 

 

 

 

/s/ Vickie Capps

Vickie Capps

 

Director

 

February 11, 2021

 

 

 

 

 

/s/ Ciara Kennedy

Ciara Kennedy, Ph.D.

 

Director

 

February 11, 2021

 

 

 

 

 

/s/ Iain McGill

Iain McGill

 

Director

 

February 11, 2021

 

 

 

 

 

/s/ Theodore R. Schroeder

Theodore R. Schroeder

 

Director

 

February 11, 2021

 

114

 EX-23.1 2 otic-ex231_10.htm EX-23.1 otic-ex231_10.htm

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-3 No. 333-227269) of Otonomy, Inc.;

 

(2)

Registration Statement (Form S-8 Nos. 333-236716, 333-230055, 333-223522, 333-216401, 333-209990, 333-202851 and 333-198116) pertaining to the 2014 Equity Incentive Plan, the 2014 Employee Stock Purchase Plan and the Amended and Restated 2010 Equity Incentive Plan;

of our report dated February 11, 2021, with respect to the financial statements of Otonomy, Inc., included in this Annual Report (Form 10-K) of Otonomy, Inc. for the year ended December 31, 2020.

/s/ Ernst & Young LLP

San Diego, California

February 11, 2021

 

 EX-31.1 3 otic-ex311_11.htm EX-31.1 otic-ex311_11.htm

 

Exhibit 31.1

CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, David A. Weber, Ph.D., certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Otonomy, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 11, 2021

 

/s/ David A. Weber

David A. Weber, Ph.D.

President and Chief Executive Officer

 

 

 EX-31.2 4 otic-ex312_7.htm EX-31.2 otic-ex312_7.htm

 

Exhibit 31.2

CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Paul E. Cayer, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Otonomy, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 11, 2021

 

/s/ Paul E. Cayer

Paul E. Cayer

Chief Financial and Business Officer

 

 

 EX-32.1 5 otic-ex321_9.htm EX-32.1 otic-ex321_9.htm

 

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, David A. Weber, Ph.D., President and Chief Executive Officer of Otonomy, Inc. (the “Company”), hereby certify that:

 

1.

The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 11, 2021

 

By:

 

/s/ David A. Weber

Name:

 

David A. Weber, Ph.D.

Title:

 

President and Chief Executive Officer

 

 

 EX-32.2 6 otic-ex322_8.htm EX-32.2 otic-ex322_8.htm

 

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, Paul E. Cayer, Chief Financial and Business Officer of Otonomy, Inc. (the “Company”), hereby certify that:

 

1.

The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 11, 2021

 

By:

 

/s/ Paul E. Cayer

Name:

 

Paul E. Cayer

Title:

 

Chief Financial and Business Officer

 

 

 EX-101.SCH 7 otic-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Description of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Available-for-Sale Securities link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Fair Value link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-Based Compensation and Equity Plans link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Description of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Available-for-Sale Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Fair Value (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Stock-Based Compensation and Equity Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Available-for-Sale Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Balance Sheet Details - Prepaid and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Balance Sheet Details - Property and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Balance Sheet Details - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Balance Sheet Details - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Leases - Summary of Lease Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Fair Value - Additional information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stock-Based Compensation and Equity Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Collaboration Agreements - Additional information (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 otic-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 otic-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 otic-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Operating leases imputed interest. Finance leases imputed interest. Future minimum lease payments due next twelve months. Future minimum lease payments due in two years. Future minimum lease payments due in three years. Future minimum lease payments due in four years. Future minimum lease payments due in five years. Future minimum lease payments due after year five. Imputed interest. Lease liabilities. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Document Annual Report Document Annual Report Document Transition Report Document Transition Report Lease liabilities current. Lease liabilities non-current. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Available For Sale Securities Debt Securities Current Prepaid and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Restricted cash Restricted Cash Noncurrent Property and equipment, net Property Plant And Equipment Net Right-of-use assets Operating Lease Right Of Use Asset Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Accrued compensation Employee Related Liabilities Current Leases, current Lease Liabilities Current Total current liabilities Liabilities Current Long-term debt, net Long Term Debt Noncurrent Leases, net of current Lease Liabilities Non Current Total liabilities Liabilities Commitments and Contingencies Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued or outstanding at December 31, 2020 and 2019 Preferred Stock Value Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and 2019; 48,318,970 and 30,814,211 shares issued and outstanding at December 31, 2020 and 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares Issued Common Stock Shares Issued Common stock, Shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Product sales, net Revenue From Contract With Customer Excluding Assessed Tax Type of Revenue [Extensible List] Type Of Revenue Extensible List Costs and operating expenses: Costs And Expenses [Abstract] Cost of product sales Cost Of Goods And Services Sold Type of Cost, Good or Service [Extensible List] Type Of Cost Good Or Service Extensible List Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total costs and operating expenses Costs And Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest income Interest Income Other Interest expense Interest Expense Other Total other (expense) income, net Nonoperating Income Expense Net loss Net Income Loss Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares used to compute net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive loss: Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized (loss) gain on available-for-sale securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Additional Paid-in Capital [Member] Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Other Comprehensive Loss [Member] Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance, shares Shares Outstanding Issuance of common stock and pre-funded warrants, net of issuancecosts Stock Issued During Period Value New Issues Issuance of common stock and prefunded warrants, net of issuance costs (unaudited), shares Stock Issued During Period Shares New Issues Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under employee stock purchase plan Stock Issued During Period Value Share Based Compensation Issuance of common stock under employee stock purchase plan, shares Stock Issued During Period Shares Share Based Compensation Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Ending balance Ending balance, shares Amount of increase (Decrease) in the net amount of right of use assets and lease liabilities, net. Proceeds from issuance of common stock and prefunded warrants, net of issuance costs. Proceeds from issuance of common stock under employee stock purchase plan. Debt issuance costs incurred during noncash transaction included in accounts payable and accrued expenses. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation Allocated Share Based Compensation Expense Accretion of discounts on short-term investments Accretion Amortization Of Discounts And Premiums Investments Amortization of debt discount Amortization Of Debt Discount Premium Deferred rent Straight Line Rent Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Accrued compensation Increase Decrease In Employee Related Liabilities Right-of-use assets and lease liabilities, net Increase Decrease In Right Of Use Assets And Lease Liabilities Net Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of short-term investments Payments To Acquire Available For Sale Securities Maturities of short-term investments Proceeds From Maturities Prepayments And Calls Of Shortterm Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs Proceeds From Issuance Of Common Stock And Prefunded Warrants Net Of Issuance Costs Proceeds from issuance of long-term debt, net of cash issuance costs Proceeds From Issuance Of Long Term Debt Proceeds from short-term debt Proceeds From Short Term Debt Principal payments on short-term debt Repayments Of Short Term Debt Proceeds from issuance of common stock under employee stock purchase plan Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan Proceeds from exercise of stock options Proceeds From Stock Options Exercised Payments of debt issuance costs Payments Of Debt Issuance Costs Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net change in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash and cash equivalents at end of period Restricted cash at end of period Restricted Cash And Cash Equivalents Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Supplemental disclosure of non-cash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Purchase of property and equipment in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Debt issuance costs in accounts payable and accrued expenses Debt Issuance Costs Incurred During Noncash Transaction Included In Accounts Payable And Accrued Expenses Debt issuance costs Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Accounting Policies [Abstract] Description of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Available-for-Sale Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Long Term Debt [Abstract] Debt Long Term Debt [Text Block] Leases [Abstract] Leases Leases Of Lessee Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Fair Value Disclosures [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation and Equity Plans Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Collaborative arrangement disclosure. Collaborative Arrangement Disclosure [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Segment Reporting Segment Reporting Policy Policy [Text Block] Concentrations of Credit Risk Concentration Risk Credit Risk Cash, Cash Equivalents and Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Short-Term Investments Investment Policy [Text Block] Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Inventory Inventory Policy [Text Block] Property and Equipment, Net Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Right-of-Use Assets and Lease Liabilities Lessee Leases Policy [Text Block] Disclosure of accounting policy for clinical trial expense accruals. Clinical Trial Expense Accruals Clinical Trial Expense Accruals Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Concentration of Major Customers Major Customers Policy Policy [Text Block] Collaborative Arrangements Collaborative Arrangement Accounting Policy Research and Development Research And Development Expense Policy Selling, General and Administrative Selling General And Administrative Expenses Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Disclosure of accounting policy for risks and uncertainties related to COVID-19. Risks and Uncertainties Related to COVID-19 Risks And Uncertainties Related To C O V I D19 Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Sales to Largest Customers Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block] Schedule of Available-for-Sale Debt Securities Available For Sale Securities [Text Block] Prepaid and Other Current Assets Schedule Of Other Current Assets Table [Text Block] Property and Equipment, Net Property Plant And Equipment [Text Block] Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of Additional Milestone Payments under Intellectual Property License Agreements Other Commitments Table [Text Block] Costs recognized under license agreements. Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations Costs Recognized Under License Agreements Table [Text Block] Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations Schedule Of Maturities Of Long Term Debt Table [Text Block] Summary of Lease Expenses Lease Cost Table [Text Block] Schedule of future minimum lease payments under non cancellable leases. Future Minimum Annual Obligations under Finance and Operating Lease Commitments Schedule Of Future Minimum Lease Payments Under Non Cancellable Leases Table [Text Block] Fair Value Assets Measured on a Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Schedule of Shares of Common Stock Reserved for Future Issuance Schedule Of Stock By Class [Text Block] Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Certain Information Regarding Stock Options Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block] Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Summary of Non-cash Stock Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Components of Deferred Tax Assets Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Reconciliation of Expected Recovery of Income Taxes Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Unrecognized Tax Benefit Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Net proceeds after deducting underwriters commission. Description of business and basis of presentation. Description Of Business And Basis Of Presentation [Table] Description Of Business And Basis Of Presentation [Table] Description Of Business And Basis Of Presentation [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO [Member] I P O [Member] Description Of Business And Basis Of Presentation [Line Items] Description Of Business And Basis Of Presentation [Line Items] Cash, cash equivalents and short-term investments Cash Cash Equivalents And Short Term Investments Common stock sold in public offering Debt outstanding Shortterm Debt Average Outstanding Amount Warrants to purchase common stock Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Net proceeds after deducting underwriters commission Net Proceeds After Deducting Underwriters Commission Summary of significant accounting policies line items. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Options to Purchase Common Stock [Member] Employee Stock Option [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Number of operating segment Number Of Operating Segments Inventory write-down Inventory Write Down Property and equipment useful lives Property Plant And Equipment Useful Life Impairment of long-lived assets Impairment Of Long Lived Assets Held For Use Risks And Uncertainties [Abstract] Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table] Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Sales Revenue, Net [Member] Sales Revenue Net [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Customer one. Customer One [Member] Customer One [Member] Customer two. Customer Two [Member] Customer Two [Member] Customer three. Customer Three [Member] Customer Three [Member] Entity Wide Revenue Major Customer [Line Items] Entity Wide Revenue Major Customer [Line Items] Concentration risk percentage Concentration Risk Percentage1 Potentially dilutive securities excluded from the calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Debt Security Category Information By Category Of Debt Security [Axis] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain] Available-for-sale Securities [Member] Availableforsale Securities [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Money market funds and certificate of deposit. Money Market Funds and Certificates of Deposit [Member] Money Market Funds And Certificate Of Deposit [Member] Schedule of Available-for-sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Cash equivalents Cash Equivalents At Carrying Value Available For Sale Securities [Abstract] U.S. Treasury Securities [Member] U S Treasury Securities [Member] Certificates Of Deposit [Member] Certificates Of Deposit [Member] Amortized Cost Available For Sale Securities Amortized Cost Unrealized Gains Available For Sale Securities Gross Unrealized Gains Unrealized Losses Available For Sale Securities Gross Unrealized Loss Market Value Available For Sale Securities Number of available-for-sale securities in unrealized loss positions for less than twelve months Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year Other-than-temporary declines in the value of any available-for-sale securities Other Than Temporary Impairment Losses Investments Availableforsale Securities Maximum maturity of available-for-sale debt securities Debt Securities Available For Sale Term Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Inventory Inventory Net Other Other Prepaid Expense Current Total Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Laboratory equipment. Laboratory Equipment [Member] Laboratory Equipment [Member] Manufacturing Equipment [Member] Machinery And Equipment [Member] Computers and software. Computer Equipment and Software [Member] Computers And Software [Member] Leasehold Improvements [Member] Leasehold Improvements [Member] Office Furniture [Member] Furniture And Fixtures [Member] Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total Depreciation expense Accrued clinical trial costs. Payables And Accruals [Abstract] Accrued clinical trial costs Accrued Clinical Trial Costs Accrued other Other Accrued Liabilities Current Total Lease commencement month and year. Period for right to terminate agreement. Initial monthly base rent. Annual percentage increase in monthly base rent. Lease abatement period. Other Commitments [Table] Other Commitments [Table] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Restricted cash. Restricted Cash [Member] Restricted Cash [Member] Building [Member] Building [Member] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Intellectual Property [Member] Intellectual Property [Member] Other Commitments Other Commitments [Axis] Other Commitments Other Commitments [Domain] Development. Development [Member] Development [Member] Category of Item Purchased Long Term Purchase Commitment By Category Of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased Long Term Purchase Commitment Category Of Item Purchased [Domain] Regulatory. Regulatory [Member] Regulatory [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Upfront payment. Upfront Payment [Member] Upfront Payment [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] License agreement. License Agreement [Member] License Agreement [Member] Royalty Agreements [Member] Royalty Agreements [Member] Data License Agreement [Member] Licensing Agreements [Member] Other Commitments [Line Items] Other Commitments [Line Items] Construction commencement period Lease Commencement Month And Year Operating lease term Lessee Operating Lease Term Of Contract Additional operating lease term Lessee Operating Lease Renewal Term Period after which company has the right to terminate lease if it is acquired by a third party and pays early termination fee Period For Right To Terminate Agreement Monthly base rent for first year Initial Monthly Base Rent Lease rate increase, percentage Annual Percentage Increase In Monthly Base Rent Abatement period of monthly base rent Lease Abatement Period Estimated base rent payments over the life of lease Operating Leases Rent Expense Minimum Rentals Security deposit in the form of letter of credit Security Deposit Cash milestones that may be incurred under license agreements. Commercialization. Commercialization [Member] Commercialization [Member] Cash Payments Cash Milestones Under License Agreements Number of milestones achieved. Milestone costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Number of milestones achieved Number Of Milestones Achieved Milestone fees Milestone Fees Cash milestones potential payment under license agreements. Milestones potential cash payment Cash Milestones Potential Payment Under License Agreements Maximum percentage of royalty on net sales. Maximum percentage of royalties on sales Maximum Percentage Of Royalty On Net Sales Additional payments due upon demonstration. Payment to acquire worldwide rights Payments To Acquire Intangible Assets Additional payments due upon demonstration Additional Payments Due Upon Demonstration Non-milestone costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Total costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. License and other fees License And Other Fees Total license and related fees License And Related Fees Royalty period. Royalty period Royalty Period Description of royalty payment. Maximum cumulative royalties obligation threshold. Description of royalties payable Description Of Royalty Payment Maximum cumulative royalties paid under license agreement Maximum Cumulative Royalties Obligation Threshold Percentage of debt prepayment fee. Debt Instrument [Table] Debt Instrument [Table] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Secured term loan credit facility. Secured Term Loan Credit Facility [Member] Secured Term Loan Credit Facility [Member] Extinguishment of Debt Extinguishment Of Debt [Axis] Extinguishment of Debt, Type Extinguishment Of Debt Type [Domain] Thereafter second anniversary of closing date. Thereafter Second Anniversary of Closing Date [Member] Thereafter Second Anniversary Of Closing Date [Member] Occurrence and during continuance of event of default. Occurrence and During Continuance of Event of Default [Member] Occurrence And During Continuance Of Event Of Default [Member] Accounts Payable [Member] Accounts Payable And Accrued Liabilities [Member] Unsecured Loan [Member] Unsecured Debt [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Loan under paycheck protection program. PPP Loan [Member] Paycheck Protection Program [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] JPMorgan Chase Bank, N.A. [Member] JPMorgan Chase Bank, N.A. [Member] J P Morgan Chase Bank N A [Member] Unusual Risk or Uncertainty, Nature Unusual Risk Or Uncertainty By Nature [Axis] Unusual Risk or Uncertainty, Nature Unusual Risk Or Uncertainty Nature [Domain] CARES Act Of 2020 [Member] CARES Act Of 2020 [Member] C A R E S Act Of2020 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt instrument, face amount Debt Instrument Face Amount Percentage of debt prepayment fee Percentage Of Debt Prepayment Fee Facility fee percentage Line Of Credit Facility Commitment Fee Percentage Debt instrument, maturity date Debt Instrument Maturity Date Debt instrument reference rate. Line of credit facility interest only payments period. Line of credit facility interest only payments extension period. Line of credit facility minimum interest rate. Interest rate description Line Of Credit Facility Interest Rate Description Debt instrument, reference rate Debt Instrument Reference Rate Debt instrument, basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Debt instrument, interest rate at period end Line Of Credit Facility Interest Rate At Period End Debt instrument, minimum interest rate Line Of Credit Facility Minimum Interest Rate Interest frequency payments Line Of Credit Facility Frequency Of Payments Interest only payment term Line Of Credit Facility Interest Only Payments Period Interest only payment extension term Line Of Credit Facility Interest Only Payments Extension Period Debt repayment fee percentage. Repayment fee percentage Debt Repayment Fee Percentage Debt discount, amount Debt Instrument Unamortized Discount Debt instrument, covenant description Debt Instrument Covenant Description Increase in applicable rate of interest Debt Instrument Interest Rate Increase Decrease Interest expense, including amortization of the debt discount Interest Expense Debt Accrued interest Interest Payable Current Term Loan outstanding 2021 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months 2022 Long Term Debt Maturities Repayments Of Principal In Year Two 2023 Long Term Debt Maturities Repayments Of Principal In Year Three Subtotal Debt Instrument Carrying Amount Unamortized discount Total long-term debt, net Long Term Debt Early repayment of long term debt, Date. Loans amount Long Term Loans From Bank Interest rate Debt Instrument Interest Rate Stated Percentage Loan term Long Term Debt Term Date of early repayment of loan in full Early Repayment Of Long Term Debt Date Lease expiration year Lessee Lease Description [Table] Lessee Lease Description [Table] Computer Equipment [Member] Computer Equipment [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Operating lease, description Lessee Operating Lease Description Operating lease, option to extend Lessee Operating Lease Existence Of Option To Extend Operating lease, option to extend description Lessee Operating Lease Option To Extend Operating lease term ending year Lease Expiration Year Operating lease, option to terminate Lessee Operating Lease Existence Of Option To Terminate Operating lease, option to terminate description Lessee Operating Lease Option To Terminate Rent expense Operating Leases Rent Expense Net Finance lease, right of use asset, amortization term. Finance lease, description Lessee Finance Lease Description Finance lease initial term Lessee Finance Lease Term Of Contract1 Finance lease right-of-use asset amortization term Finance Lease Right Of Use Asset Amortization Term Lease expenses: Lease Cost [Abstract] Operating lease expenses Operating Lease Cost Variable lease expenses Variable Lease Cost Total lease expenses Lease Cost Future minimum payments due. Operating Leases, 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months Operating Leases, 2022 Lessee Operating Lease Liability Payments Due Year Two Operating Leases, 2023 Lessee Operating Lease Liability Payments Due Year Three Operating Leases, 2024 Lessee Operating Lease Liability Payments Due Year Four Operating Leases, 2025 Lessee Operating Lease Liability Payments Due Year Five Operating Leases, Thereafter Lessee Operating Lease Liability Payments Due After Year Five Operating Leases, Total minimum lease payments Lessee Operating Lease Liability Payments Due Operating Leases, Imputed interest Operating Leases Imputed Interest Operating Leases, Total Operating Lease Liability Operating Leases, Less: leases, current Operating Lease Liability Current Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease Liability Current Statement Of Financial Position Extensible List Operating Leases, Leases, net of current Operating Lease Liability Noncurrent Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List Finance Leases, 2021 Finance Lease Liability Payments Due Next Twelve Months Finance Leases, 2022 Finance Lease Liability Payments Due Year Two Finance Leases, 2023 Finance Lease Liability Payments Due Year Three Finance Leases, 2024 Finance Lease Liability Payments Due Year Four Finance Leases, 2025 Finance Lease Liability Payments Due Year Five Finance Leases, Thereafter Finance Lease Liability Payments Due After Year Five Finance Leases, Total minimum lease payments Finance Lease Liability Payments Due Finance Leases, Imputed interest Finance Leases Imputed Interest Finance Leases, Total Finance Lease Liability Finance Leases, Less: leases, current Finance Lease Liability Current Finance Leases, Leases, net of current Finance Lease Liability Noncurrent 2021 Future Minimum Lease Payments Due Next Twelve Months 2022 Future Minimum Lease Payments Due In Two Years 2023 Future Minimum Lease Payments Due In Three Years 2024 Future Minimum Lease Payments Due In Four Years 2025 Future Minimum Lease Payments Due In Five Years Thereafter Future Minimum Lease Payments Due After Year Five Total minimum lease payments Future Minimum Payments Due Imputed interest Imputed Interest Total Lease Liabilities Less: leases, current Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements Nonrecurring [Member] Fair Value Measurements Nonrecurring [Member] Fair Value Measurements, Recurring [Member] Fair Value Measurements Recurring [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets measured at fair value Assets Fair Value Disclosure Liabilities measured at fair value Liabilities Fair Value Disclosure Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value Inputs Level1 [Member] Level 2 [Member] Fair Value Inputs Level2 [Member] Level 3 [Member] Fair Value Inputs Level3 [Member] Money Market Funds [Member] Money Market Funds [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Money market funds Cash And Cash Equivalents Fair Value Disclosure Short-term investments Certificates of deposit Certificates Of Deposit At Carrying Value Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand and fourteen Employee Stock Purchase Plan. 2014 Employee Stock Purchase Plan [Member] Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Award Date Award Date [Axis] Award Date Award Date [Domain] Available future grant year. Available Future Grant Year [Member] Available Future Grant Year [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Options to Purchase Common Stock [Member] Prefunded warrants member. Pre-funded Warrants [Member] Prefunded Warrants [Member] Class of Stock [Line Items] Class Of Stock [Line Items] Total common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Difference in offering price of warrants to offering price of common stock. Ownership percentage of common stock Prefunded warrants exercised Shares issued, price per Share Shares Issued Price Per Share Warrants to purchase common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net proceeds after deducting underwriters commission Difference in offering price of warrants to offering price of common stock Difference In Offering Price Of Warrants To Offering Price Of Common Stock Ownership percentage of common stock Ownership Percentage Of Common Stock Prefunded warrants exercised Prefunded Warrants Exercised Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Equity incentive plan two thousand fourteen. Equity Incentive Plan 2014 [Member] Equity Incentive Plan Two Thousand Fourteen [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Performance-based Awards [Member] Performance Shares [Member] Transaction Type Transaction Type [Axis] Transaction Transaction [Domain] Option Exchange [Member] Exchange Traded [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share based compensation vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Contractual term of options Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Exercise price, percentage of fair market value Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Share-based compensation arrangement by share-based payment award number of additional shares authorized annually. Share based compensation arrangement by share based payment award additional shares authorized annually percentage of common stock outstanding. Annual increase in common shares reserved for issuance, percentage of total shares of common stock Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Annually Percentage Of Common Stock Outstanding Changes in share issuance, description Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description Annual increase in common shares reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Annually Common shares reserved for issuance Options available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Outstanding as of beginning of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding as of end of period Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Options exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted- Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Outstanding as of beginning of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Outstanding as of end of period Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Options exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted-Average Remaining Contractual Term (In Years) Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Outstanding Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Options vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Options exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract] Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Options exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Weighted-average grant date fair value per share of options granted during the period Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Cash received from options exercised during the period Intrinsic value of options exercised during the period Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Stock option granted Share-based compensation arrangement by share-based payment award, program expiration date. Share-based compensation arrangement by share-based payment award, closing price per share. Exchange of outstanding stock options, exercise price Option exchange program, expiration date Share Based Compensation Arrangement By Share Based Payment Award Program Expiration Date Exchange of outstanding stock options under option exchange program, closing price per share Share Based Compensation Arrangement By Share Based Payment Award Closing Price Per Share Share-based compensation arrangement by share-based payment award, percentage of shares purchased for award. Number of shares purchased Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award Percentage of number of common stock purchased Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Purchased For Award Common stock exercise price Incremental fair value options Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost Employee stock purchase plan offering period description. Duration of offering period permitted with respect to the plan for eligible employees to purchase shares of company's common stock. Eligible compensation contribution Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Offering periods under plan Share Based Compensation Arrangement By Share Based Payment Award Duration Of Offering Period Offering period description Employee Stock Purchase Plan Offering Period Description Number of common stock issued pursuant to ESPP purchases Stock Issued During Period Shares Employee Stock Purchase Plans Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Employee Stock Purchase Plan [Member] Employee Stock [Member] Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of Product Sales [Member] Cost Of Sales [Member] Research and Development [Member] Research And Development Expense [Member] Selling, General and Administrative [Member] Selling General And Administrative Expenses [Member] Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans other than options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Unrecognized compensation costs related to stock options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Remaining weighted-average vesting period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unrecognized compensation cost related to stock options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Remaining weighted-average vesting period Employee Service Share Based Compensation Nonvested Awards Other Than Options Compensation Cost Not Yet Recognized Period For Recognition Amount of net payment to be received from collaboration agreement party. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] AGTC Collaboration. AGTC Collaboration [Member] A G T C Collaboration [Member] Glenmark Co Promotion Agreement. Glenmark Co-Promotion Agreement [Member] Glenmark Co Promotion Agreement [Member] Mission co-promotion agreement. Mission Co-Promotion Agreement [Member] Mission Co Promotion Agreement [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Net receivable Amount Of Net Payment To Be Received From Collaboration Agreement Party Payment of committed amount in settlement. Payment of committed amount in settlement Payment Of Committed Amount In Settlement Profit sharing percentage. Share of gross profits, percentage Profit Sharing Percentage Decrease in selling general and administrative expenses. Decrease in selling general and administrative expenses Decrease In Selling General And Administrative Expenses Deferred tax assets depreciation and amortization. Deferred tax liabilities right of use assets. Deferred tax assets: Deferred Tax Assets Net [Abstract] Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Research and development credits Deferred Tax Assets Tax Credit Carryforwards Research Depreciation and amortization Deferred Tax Assets Depreciation And Amortization Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Lease liabilities Deferred Tax Liabilities Leasing Arrangements Stock compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Other, net Deferred Tax Assets Other Total deferred tax assets Deferred Tax Assets Gross Less: valuation allowance Deferred Tax Assets Valuation Allowance Total deferred tax assets, net of valuation allowance Deferred Tax Assets Net Deferred tax liability: Deferred Tax Liabilities Net [Abstract] Right-of-use assets Deferred Tax Liabilities Right Of Use Assets Total deferred tax liability Deferred Income Tax Liabilities Total Deferred Tax Liabilities Income taxes. Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Internal Revenue Service (IRS) [Member] Internal Revenue Service I R S [Member] California Franchise Tax Board [Member] California Franchise Tax Board [Member] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] State and Local Jurisdiction [Member] State And Local Jurisdiction [Member] Income Taxes [Line Items] Income Taxes [Line Items] Valuation allowance Percentage of taxable income limitation. Net operating loss carryforwards Operating Loss Carryforwards Percentage of taxable income limitation Percentage Of Taxable Income Limitation Net operating loss carryforwards, expiration Operating Loss Carryforwards Limitations On Use Tax credit carryforwards Tax Credit Carryforward Amount Tax credit carryforwards, expiration Tax Credit Carryforward Limitations On Use Income tax reconciliation other permanent items. Federal statutory rate Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate State tax (net of federal benefit) Income Tax Reconciliation State And Local Income Taxes Permanent items, other Income Tax Reconciliation Other Permanent Items Stock compensation Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Other adjustments Income Tax Reconciliation Other Adjustments Research and development credits Income Tax Reconciliation Tax Credits Research Uncertain tax positions Income Tax Reconciliation Tax Contingencies Change in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Provision for income taxes Income Tax Expense Benefit Increase (decrease) related to prior year tax positions. Balance at the beginning of the year Unrecognized Tax Benefits Adjustments related to prior year tax positions Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions Increases related to current year tax positions Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Unrecognized Tax Benefits Unrecognized tax benefit, income tax penalties and interest accrued Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Unrecognized tax benefits, income tax penalties and interest expense Unrecognized Tax Benefits Income Tax Penalties And Interest Expense EX-101.PRE 11 otic-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 otic-10k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001493566 2020-01-01 2020-12-31 0001493566 2021-02-05 0001493566 2020-06-30 0001493566 2020-12-31 0001493566 2019-12-31 0001493566 2019-01-01 2019-12-31 0001493566 2018-01-01 2018-12-31 0001493566 us-gaap:CommonStockMember 2017-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001493566 us-gaap:RetainedEarningsMember 2017-12-31 0001493566 2017-12-31 0001493566 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001493566 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001493566 us-gaap:CommonStockMember 2018-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001493566 us-gaap:RetainedEarningsMember 2018-12-31 0001493566 2018-12-31 0001493566 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001493566 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001493566 us-gaap:CommonStockMember 2019-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001493566 us-gaap:RetainedEarningsMember 2019-12-31 0001493566 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001493566 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001493566 us-gaap:CommonStockMember 2020-12-31 0001493566 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001493566 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001493566 us-gaap:RetainedEarningsMember 2020-12-31 0001493566 us-gaap:IPOMember 2020-07-01 2020-07-31 0001493566 2020-07-01 2020-07-31 0001493566 2020-07-31 0001493566 srt:MinimumMember 2020-01-01 2020-12-31 0001493566 srt:MaximumMember 2020-01-01 2020-12-31 0001493566 otic:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001493566 otic:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001493566 otic:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001493566 otic:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001493566 otic:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001493566 otic:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001493566 otic:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001493566 otic:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001493566 otic:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001493566 us-gaap:AvailableforsaleSecuritiesMember otic:MoneyMarketFundsAndCertificateOfDepositMember 2020-12-31 0001493566 us-gaap:AvailableforsaleSecuritiesMember otic:MoneyMarketFundsAndCertificateOfDepositMember 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-12-31 0001493566 us-gaap:CertificatesOfDepositMember 2020-01-01 2020-12-31 0001493566 us-gaap:USTreasurySecuritiesMember 2019-01-01 2019-12-31 0001493566 otic:LaboratoryEquipmentMember 2020-12-31 0001493566 otic:LaboratoryEquipmentMember 2019-12-31 0001493566 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001493566 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001493566 otic:ComputersAndSoftwareMember 2020-12-31 0001493566 otic:ComputersAndSoftwareMember 2019-12-31 0001493566 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001493566 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001493566 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001493566 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001493566 us-gaap:BuildingMember 2016-12-01 2016-12-31 0001493566 2016-12-31 0001493566 2016-12-01 2016-12-31 0001493566 otic:RestrictedCashMember 2015-05-31 0001493566 otic:DevelopmentMember 2020-12-31 0001493566 otic:RegulatoryMember 2020-12-31 0001493566 otic:CommercializationMember 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember otic:RegulatoryMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember otic:DevelopmentMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember 2020-01-01 2020-12-31 0001493566 us-gaap:IntellectualPropertyMember otic:RegulatoryMember 2020-12-31 0001493566 otic:UpfrontPaymentMember otic:LicenseAgreementMember 2020-07-01 2020-07-31 0001493566 otic:LicenseAgreementMember 2020-07-01 2020-07-31 0001493566 us-gaap:RoyaltyAgreementsMember 2020-01-01 2020-12-31 0001493566 us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0001493566 us-gaap:LicensingAgreementsMember 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember 2020-12-31 0001493566 otic:ThereafterSecondAnniversaryOfClosingDateMember otic:SecuredTermLoanCreditFacilityMember 2020-01-01 2020-12-31 0001493566 otic:SecuredTermLoanCreditFacilityMember 2020-01-01 2020-12-31 0001493566 srt:MinimumMember otic:SecuredTermLoanCreditFacilityMember 2020-01-01 2020-12-31 0001493566 otic:OccurrenceAndDuringContinuanceOfEventOfDefaultMember otic:SecuredTermLoanCreditFacilityMember 2020-01-01 2020-12-31 0001493566 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2020-12-31 0001493566 otic:JPMorganChaseBankNAMember otic:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember otic:CARESActOf2020Member 2020-04-10 0001493566 otic:JPMorganChaseBankNAMember otic:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember otic:CARESActOf2020Member 2020-01-01 2020-12-31 0001493566 srt:MinimumMember 2020-12-31 0001493566 srt:MaximumMember 2020-12-31 0001493566 us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001493566 us-gaap:ComputerEquipmentMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001493566 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2020-12-31 0001493566 us-gaap:EmployeeStockOptionMember 2019-12-31 0001493566 otic:PrefundedWarrantsMember 2020-12-31 0001493566 otic:PrefundedWarrantsMember 2019-12-31 0001493566 otic:AvailableFutureGrantYearMember us-gaap:EmployeeStockOptionMember 2020-12-31 0001493566 otic:AvailableFutureGrantYearMember us-gaap:EmployeeStockOptionMember 2019-12-31 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-12-31 0001493566 otic:PrefundedWarrantsMember 2020-07-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember 2020-01-01 2020-12-31 0001493566 srt:MinimumMember otic:EquityIncentivePlanTwoThousandFourteenMember 2020-01-01 2020-12-31 0001493566 srt:MaximumMember otic:EquityIncentivePlanTwoThousandFourteenMember 2020-01-01 2020-12-31 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember us-gaap:SubsequentEventMember 2021-01-01 2021-01-01 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember us-gaap:SubsequentEventMember 2021-01-01 0001493566 otic:EquityIncentivePlanTwoThousandFourteenMember 2020-12-31 0001493566 us-gaap:PerformanceSharesMember us-gaap:CommonStockMember 2018-02-01 2018-02-28 0001493566 srt:MinimumMember us-gaap:EmployeeStockOptionMember us-gaap:ExchangeTradedMember 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:ExchangeTradedMember 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:EmployeeStockOptionMember otic:EquityIncentivePlanTwoThousandFourteenMember us-gaap:CommonStockMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 srt:MinimumMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 srt:MaximumMember us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 us-gaap:ExchangeTradedMember 2017-12-19 2017-12-20 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001493566 srt:MaximumMember otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001493566 srt:MinimumMember otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2021-01-01 2021-01-01 0001493566 otic:TwoThousandAndFourteenEmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2021-01-01 0001493566 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001493566 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001493566 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001493566 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001493566 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001493566 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001493566 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001493566 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001493566 otic:AGTCCollaborationMember 2020-01-01 2020-12-31 0001493566 otic:GlenmarkCoPromotionAgreementMember 2019-09-30 0001493566 srt:MinimumMember otic:MissionCoPromotionAgreementMember 2020-01-01 2020-12-31 0001493566 otic:MissionCoPromotionAgreementMember 2020-01-01 2020-12-31 0001493566 otic:MissionCoPromotionAgreementMember 2019-01-01 2019-12-31 0001493566 us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0001493566 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001493566 2018-01-01 0001493566 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001493566 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001493566 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-12-31 0001493566 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-01-01 2020-12-31 shares iso4217:USD iso4217:USD shares otic:Segment pure otic:Security otic:Milestone false 2020 FY 0001493566 --12-31 P2Y 2016-12 P94M The Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees true true P94M P1Y 2020 0 0 0 0 0 us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:OtherNoncurrentLiabilitiesMember P7Y1M6D P7Y1M6D P5Y8M12D P6Y1M6D P6Y1M6D P5Y4M24D P1Y3M18D P1Y3M18D P1Y3M18D 10-K true 2020-12-31 false 001-36591 Otonomy, Inc. DE 26-2590070 4796 Executive Drive San Diego CA 92121 619 323-2200 Common stock, par value $0.001 per share OTIC NASDAQ No No Yes Yes Non-accelerated Filer true false false false 103300000 48318970 <p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p> <p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted herein, the information called for by Part III is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2021 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2020.</p> 30767000 25194000 55576000 35476000 2372000 2480000 88715000 63150000 702000 701000 2766000 3702000 14082000 15465000 106265000 83018000 849000 1161000 2953000 5442000 3927000 2593000 3265000 3302000 10994000 12498000 15158000 14967000 13847000 15320000 39999000 42785000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 48318970 48318970 30814211 30814211 48000 31000 570841000 500084000 1000 11000 -504624000 -459893000 66266000 40233000 106265000 83018000 273000 600000 745000 1188000 912000 946000 27997000 32805000 31844000 14575000 11690000 20008000 43760000 45407000 52798000 -43487000 -44807000 -52053000 326000 1723000 1689000 1570000 1591000 4000 -1244000 132000 1685000 -44731000 -44675000 -50368000 -1.10 -1.45 -1.65 40845844 30726786 30610244 -44731000 -44675000 -50368000 -10000 34000 77000 -44741000 -44641000 -50291000 30558726 31000 482198000 -100000 -364850000 117279000 18800 32000 32000 107886 303000 303000 12414000 12414000 -50368000 -50368000 77000 77000 30685412 31000 494947000 -23000 -415218000 79737000 2912 5000 5000 125887 242000 242000 4890000 4890000 -44675000 -44675000 34000 34000 30814211 31000 500084000 11000 -459893000 40233000 17275000 17000 64170000 64187000 92035 206000 206000 137724 270000 270000 6111000 6111000 -44731000 -44731000 -10000 -10000 48318970 48000 570841000 1000 -504624000 66266000 -44731000 -44675000 -50368000 1062000 1149000 1186000 6111000 4890000 12414000 29000 787000 506000 191000 189000 0 0 0 -103000 -108000 -536000 493000 -374000 127000 68000 -2419000 1656000 -166000 1334000 -42000 -672000 -127000 32000 0 -38874000 -36925000 -38434000 68581000 85004000 104270000 48500000 114000000 142750000 134000 700000 496000 -20215000 28296000 37984000 64187000 0 0 0 0 14830000 1126000 0 0 1126000 0 0 270000 242000 303000 206000 5000 32000 0 52000 0 64663000 195000 15165000 5574000 -8434000 14715000 25895000 34329000 19614000 31469000 25895000 34329000 30767000 25194000 33633000 702000 701000 696000 31469000 25895000 34329000 1373000 1394000 4000 67000 76000 7000 0 0 66000 0 0 771000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of Business and Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Otonomy, Inc. (Otonomy or the Company) was incorporated in the state of Delaware on May 6, 2008. Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The Company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss and tinnitus.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone that has completed two Phase 3 trials for the treatment of Ménière’s disease, with a third Phase 3 trial that has completed enrollment of patients with top-line results expected by the end of February 2021. OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine that has completed a Phase 1/2 clinical trial in tinnitus patients with positive top-line results, and the Company expects to initiate a Phase 2 clinical trial in the first quarter of 2021. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) for hearing loss, with positive top-line results announced for a Phase 1/2 clinical trial that the Company intends to continue with an expansion of the trial expected to start in the second quarter of 2021. Otonomy also has multiple preclinical stage programs addressing additional hearing loss pathologies including a gene therapy for treatment of congenital hearing loss (OTO-825), an otoprotectant for prevention of cisplatin-induced hearing loss (OTO-510), and a hair cell repair and regeneration program for severe hearing loss (OTO-6XX). In October 2019, the Company entered into a strategic collaboration with Applied Genetic Technologies Corporation (AGTC), to co-develop and co-commercialize a gene therapy to restore hearing in patients with hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. In July 2020, the Company entered into an exclusive license agreement with Kyorin Pharmaceutical Co., Ltd. (Kyorin) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for the OTO-6XX program.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company developed, received United States Food and Drug Administration (FDA) approval and commercially launched OTIPRIO for use during tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis externa (AOE). In June 2020, the Company entered into a co-promotion agreement with ALK-Abelló, Inc. (ALK) to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows Accounting Standards Codification (ASC) Topic 205-40, <span style="font-style:italic;">Presentation of Financial Statements—Going Concern</span>, which requires that management evaluate whether there are relevant conditions and events that in aggregate raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating activities since inception. In July 2020, the Company sold in a public offering 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase 4,000,000 shares of its common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, the Company had cash, cash equivalents and short-term investments of $86.3 million, outstanding debt of $15.2 million and an accumulated deficit of $504.6 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory approvals for OTIVIDEX, OTO-313, OTO-413 and its other product candidates; and (ii) works to develop additional product candidates through research and development programs. </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or other sources, such as potential collaboration agreements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all.  If the Company is not able to secure adequate additional funding, if or when necessary, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.  The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for a period of at least twelve months from the date of this report</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows Accounting Standards Codification (ASC) Topic 205-40, <span style="font-style:italic;">Presentation of Financial Statements—Going Concern</span>, which requires that management evaluate whether there are relevant conditions and events that in aggregate raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating activities since inception. In July 2020, the Company sold in a public offering 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase 4,000,000 shares of its common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, the Company had cash, cash equivalents and short-term investments of $86.3 million, outstanding debt of $15.2 million and an accumulated deficit of $504.6 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory approvals for OTIVIDEX, OTO-313, OTO-413 and its other product candidates; and (ii) works to develop additional product candidates through research and development programs. </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or other sources, such as potential collaboration agreements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all.  If the Company is not able to secure adequate additional funding, if or when necessary, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.  The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for a period of at least twelve months from the date of this report</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> 17275000 4000000 64200000 86300000 15200000 -504600000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available checking, savings and money market accounts.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s corporate headquarters.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 8 – <span style="font-style:italic;">Fair Value</span>).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis, and whenever events or changes </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records unrealized gains and losses </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on available-for-sale debt securities </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders’ equity on the balance sheet</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">The Company does not hold equity securities in its investment portfolio.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost to sell. During the year ended December 31, 2020, the Company recorded an inventory write down of $0.3 million to cost of product sales. During the years ended December 31, 2019 and 2018, no such write downs were recorded.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2020, 2019 and 2018.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Right-of-Use Assets and Lease Liabilities</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. The Company determines if an arrangement is or contains a lease at each commencement date.<span style="font-size:12pt;"> </span>Accounting Standards Codification (ASC) 842, <span style="font-style:italic;">Leases</span> (ASC 842) <span style="color:#000000;">establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-style:italic;color:#000000;">Leases</span><span style="color:#000000;"> (ASU 2016-02) provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are included in ROU assets, Leases, current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on the balance sheets. The Company has elected a policy not to recognize short-term leases (one year or less) on the balance sheets. ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments over the lease term at the commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial Expense Accruals</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates expenses resulting from its obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records clinical trial expenses in the period in which services are performed and efforts are expended. The Company accrues for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company estimates accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, the Company may adjust its clinical accruals if actual results differ from its estimates.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue by performing the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under <span style="color:#000000;">ASC</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">Topic 606, </span><span style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</span><span style="color:#000000;"> (ASC 606)</span> and <span style="Background-color:#FFFFFF;">when it is probable the Company will collect the consideration exchanged for the goods or services transferred to the customer. </span>At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of OTIPRIO, typically upon delivery by the Company to these distributors. <span style="color:#000000;">The Company has determined the delivery of OTIPRIO to its customers constitutes a single performance obligation and no other performance obligations are present.</span> The Company’s customer contracts have standard payment terms. The Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are not permitted. To date, product returns have been immaterial.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year or the amount is immaterial<span style="color:#000000;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Major Customers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest customers for each of the periods presented:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second largest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (ASC 808).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the statements of operations.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include the costs associated with the Company’s research and development activities, including salaries, benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s partners under its co-promotion agreements.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-based vesting conditions, stock-based compensation expense is recognized using the straight-line method. <span style="Background-color:#FFFFFF;color:#000000;"> For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, 2019 and 2018, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of outstanding options to purchase 9,842,744, 7,495,129 and 5,019,964 shares of the Company’s common stock, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties Related to COVID-19</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 pandemic could pose significant risks to the Company’s business; however, the ultimate impact of the pandemic is highly uncertain.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, the Company had suspended and subsequently updated its guidance regarding timing of trial results. The Company may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic.  In addition, the Company has made and it (and its contract research organizations (CROs)) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020, among other activity.  Third-party manufacturers which the Company uses for the supply of materials for its product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although the Company expects no material impact on the clinical supply of its product candidates for its current clinical trials, should its third-party manufacturers experience extended disruptions, the Company could experience delays in future trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which may delay the development of the Company’s product candidates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to evaluate the impact COVID-19 may have on its ability to effectively conduct its business operations as planned, and work with healthcare providers supporting its clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies and may take further actions as may be required by federal, state or local authorities or that the Company determines are in the best interests of public health and safety and that of patients, employees, partners, and stockholders.  Nonetheless, </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company does not yet know and cannot predict the full extent of potential delays or impacts on its business, its preclinical programs and clinical trials, healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the COVID-19 pandemic will have on the Company’s business, strategy, collaborations, financial condition, liquidity and future results of operations.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Not Yet Adopted</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="color:#000000;">n June 2016, ASU No. 2016-13, </span><span style="font-style:italic;color:#000000;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;"> (ASU 2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable. ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect on its financial position, results of operations or cash flows.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, the Company early adopted ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes</span> (ASU 2019-12). ASU 2019-12 removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, other comprehensive income).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 is effective for the Company beginning January 1, 2020. There was no cumulative effect to be recognized in connection with the early adoption of ASU 2019-12 and the adoption did not have a material impact on the Company’s financial statements or disclosure<span style="Background-color:#FFFFFF;">s.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</p> 1 <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available checking, savings and money market accounts.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s corporate headquarters.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 8 – <span style="font-style:italic;">Fair Value</span>).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis, and whenever events or changes </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records unrealized gains and losses </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on available-for-sale debt securities </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders’ equity on the balance sheet</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">The Company does not hold equity securities in its investment portfolio.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost to sell. During the year ended December 31, 2020, the Company recorded an inventory write down of $0.3 million to cost of product sales. During the years ended December 31, 2019 and 2018, no such write downs were recorded.</p> 300000 0 0 <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred.</p> P10Y <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2020, 2019 and 2018.</p> 0 0 0 <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Right-of-Use Assets and Lease Liabilities</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. The Company determines if an arrangement is or contains a lease at each commencement date.<span style="font-size:12pt;"> </span>Accounting Standards Codification (ASC) 842, <span style="font-style:italic;">Leases</span> (ASC 842) <span style="color:#000000;">establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-style:italic;color:#000000;">Leases</span><span style="color:#000000;"> (ASU 2016-02) provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are included in ROU assets, Leases, current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on the balance sheets. The Company has elected a policy not to recognize short-term leases (one year or less) on the balance sheets. ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments over the lease term at the commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial Expense Accruals</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates expenses resulting from its obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records clinical trial expenses in the period in which services are performed and efforts are expended. The Company accrues for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company estimates accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, the Company may adjust its clinical accruals if actual results differ from its estimates.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue by performing the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under <span style="color:#000000;">ASC</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">Topic 606, </span><span style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</span><span style="color:#000000;"> (ASC 606)</span> and <span style="Background-color:#FFFFFF;">when it is probable the Company will collect the consideration exchanged for the goods or services transferred to the customer. </span>At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of OTIPRIO, typically upon delivery by the Company to these distributors. <span style="color:#000000;">The Company has determined the delivery of OTIPRIO to its customers constitutes a single performance obligation and no other performance obligations are present.</span> The Company’s customer contracts have standard payment terms. The Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are not permitted. To date, product returns have been immaterial.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year or the amount is immaterial<span style="color:#000000;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Major Customers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest customers for each of the periods presented:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second largest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> The following table summarizes the Company’s sales to its largest customers for each of the periods presented: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second largest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third largest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> 0.41 0.38 0.44 0.29 0.33 0.33 0.24 0.24 0.21 <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (ASC 808).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the statements of operations.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include the costs associated with the Company’s research and development activities, including salaries, benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s partners under its co-promotion agreements.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-based vesting conditions, stock-based compensation expense is recognized using the straight-line method. <span style="Background-color:#FFFFFF;color:#000000;"> For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, 2019 and 2018, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of outstanding options to purchase 9,842,744, 7,495,129 and 5,019,964 shares of the Company’s common stock, respectively.</p> 9842744 7495129 5019964 <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties Related to COVID-19</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 pandemic could pose significant risks to the Company’s business; however, the ultimate impact of the pandemic is highly uncertain.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, the Company had suspended and subsequently updated its guidance regarding timing of trial results. The Company may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic.  In addition, the Company has made and it (and its contract research organizations (CROs)) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020, among other activity.  Third-party manufacturers which the Company uses for the supply of materials for its product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although the Company expects no material impact on the clinical supply of its product candidates for its current clinical trials, should its third-party manufacturers experience extended disruptions, the Company could experience delays in future trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which may delay the development of the Company’s product candidates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to evaluate the impact COVID-19 may have on its ability to effectively conduct its business operations as planned, and work with healthcare providers supporting its clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies and may take further actions as may be required by federal, state or local authorities or that the Company determines are in the best interests of public health and safety and that of patients, employees, partners, and stockholders.  Nonetheless, </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company does not yet know and cannot predict the full extent of potential delays or impacts on its business, its preclinical programs and clinical trials, healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the COVID-19 pandemic will have on the Company’s business, strategy, collaborations, financial condition, liquidity and future results of operations.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Not Yet Adopted</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="color:#000000;">n June 2016, ASU No. 2016-13, </span><span style="font-style:italic;color:#000000;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;"> (ASU 2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable. ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect on its financial position, results of operations or cash flows.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, the Company early adopted ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes</span> (ASU 2019-12). ASU 2019-12 removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, other comprehensive income).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 is effective for the Company beginning January 1, 2020. There was no cumulative effect to be recognized in connection with the early adoption of ASU 2019-12 and the adoption did not have a material impact on the Company’s financial statements or disclosure<span style="Background-color:#FFFFFF;">s.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Available-for-Sale Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in available-for-sale debt securities consisting of money market funds, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities. Available-for-sale debt securities are classified as part of either cash and cash equivalents or short-term investments in the balance sheets. Available-for-sale debt securities with maturities of three months or less from the date of purchase have been classified as cash equivalents, and were $23.3 million and $22.1 million as of December 31, 2020 and 2019, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,575</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,576</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,465</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,465</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had four securities in a gross unrealized loss position, <span style="color:#000000;">all of which have been in such position for less than twelve months</span>. <span style="color:#000000;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized </span></p> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">loss positions until their amortized cost basis has been recovered. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined there were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other-than-temporary declines in the value of any available-for-sale securities as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. All the Company’s available-for-sale </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">debt</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> securities mature within </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company obtains the fair value of its available-for-sale debt securities from a professional pricing service. The fair values of available-for-sale debt securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank.</p> 23300000 22100000 Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and were as follows (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,575</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,576</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,465</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,465</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 55085000 2000 1000 55086000 490000 0 0 490000 55575000 2000 1000 55576000 35465000 16000 5000 35476000 35465000 16000 5000 35476000 4 0 P1Y <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Balance Sheet Details</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid and Other Current Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets are comprised of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,179</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">989</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,645</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,879</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,702</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $1.1 million, $1.1 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets are comprised of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 227000 478000 2145000 2002000 2372000 2480000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,179</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">989</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,645</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,879</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,702</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4265000 4179000 1075000 1111000 989000 943000 768000 768000 1548000 1548000 8645000 8549000 5879000 4847000 2766000 3702000 1100000 1100000 1200000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1477000 3443000 1476000 1999000 2953000 5442000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Commitments and Contingencies</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company moved into its current headquarters location in San Diego, California. The lease commenced in December 2016 and has an initial term of 130 months, with an option by the Company to </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extend the lease term for an additional </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company has the right to terminate the lease at the end of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th month of the lease term if it is acquired by a third party and pays an early termination fee. The Company is responsible for payment of taxes and operating expenses for the building, in addition to monthly base rent in the initial amount of approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% annual increases, which monthly base rent </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wa</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s abated for the first </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the lease term. The total estimated base rent payments over the life of the lease are estimated to be approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. Upon execution of the lease in May 2015, the Company provided a security deposit in the form of a letter of credit in the amount of approximately $</span>0.7<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Cash collateralizing the letter of credit is classified as noncurrent restricted cash on the balance sheets. The Company has determined that the lease is an operating lease for accounting purposes.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property Licenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has acquired exclusive rights to develop patented rights, information rights and related know-how for OTIPRIO, OTIVIDEX, OTO-311, OTO-313 and OTO-413 and potential future product candidates under licensing agreements with third parties. The licensing rights obligate the Company to make payments to the licensors for license fees, milestones and royalties. The Company is also responsible for patent prosecution costs, in the event such costs are incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements covering OTIPRIO, OTIVIDEX, OTO-313 and OTO-413 as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,275</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under one of these agreements, the Company has achieved eight development milestones and one regulatory milestone, totaling $3.2 million, related to its clinical trials for OTIPRIO, OTIVIDEX, OTO-311 and OTO-413.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company receives positive results from the OTIVIDEX Phase 3 trial and submits an NDA to the FDA in 2021, the Company may be obligated to make a regulatory milestone payment of $1.0 million under one of the Company’s license agreements. This potential payment is included in the table above.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company is obligated to pay royalties of less than five percent on net sales of OTIPRIO and on sales of any other commercial products developed using these licensed technologies. Such royalty expense for OTIPRIO is recorded to cost of product sales. The Company may also be obligated to pay to the licensors a percentage of fees received if and when the Company sublicenses the technology. As of December 31, 2020, the Company has not entered into any sublicense agreements for the licensed technologies.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into an exclusive license agreement to develop, manufacture and commercialize a novel compound as a potential treatment, OTO-6XX, for severe hearing loss. Under the terms of the agreement, the Company acquired worldwide rights to the compound for an upfront payment of $0.5 million with an additional $0.5 million due upon demonstration of preclinical efficacy. If the Company advances a product containing the compound into full development, the Company may be obligated to make payments for development and commercial milestones and pay a royalty on worldwide net sales. The license agreement was accounted for as an asset acquisition and the upfront cash payment of $0.5 million was expensed to research and development during the year ended December 31, 2020 as there is no future alternative use for the assets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable royalty and milestone obligations (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and other fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and related fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Royalty Arrangements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into an agreement related to OTIPRIO under which the Company is obligated to pay royalties of less than one percent on net product sales of OTIPRIO. The royalties are recorded as selling, general and administrative expense. The royalties are payable until the later of: (i) the expiration of the last to expire patent owned by the Company in such country covering OTIPRIO; or (ii) 10 years after the first commercial sale of OTIPRIO after receipt of regulatory approval for OTIPRIO in such country.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2014, the Company entered into an exclusive license agreement with Ipsen that enables the Company to use clinical and nonclinical gacyclidine data generated by Ipsen to support worldwide development and regulatory filings for OTO-313. Under this license agreement, the Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees, up to a maximum cumulative royalty totaling $10.0 million.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company as of December 31, 2020 which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.</p> P130M P5Y 232000 0.03 P10M 32700000 700000 The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements covering OTIPRIO, OTIVIDEX, OTO-313 and OTO-413 as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,275</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1250000 10275000 1000000 12525000 8 1 3200000 1000000.0 0.05 500000 500000 500000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable royalty and milestone obligations (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and other fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and related fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 500000 0 0 250000 100000 0 750000 100000 0 0.01 P10Y 10000000.0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Debt</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.62%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Term Loan</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2018 (the Closing Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), among the Company, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for working capital and general corporate purposes. The Company has the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment fee of 1.00%. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan was fully funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). The Company paid a facility fee of 0.75% and customary closing fees on the Closing Date.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate). Interest on the Term Loan is payable monthly in arrears. During the year ended December 31, 2020, the terms of the Term Loan were amended to extend the interest-only period from 24 months to 36 months following the Closing Date, followed by consecutive equal monthly payments of principal and interest in arrears through the Maturity Date. The extension was accounted for as a modification, with no material effect on the Company’s financial statements or financial position. The outstanding principal amount of the Term Loan, together with accrued and unpaid interest, is due on December 1, 2023.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the effective interest method.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s obligations under the Loan Agreement are secured by substantially all its assets, excluding intellectual property and subject to certain other exceptions and limitations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained compliance with all such covenants to date. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable, increase the applicable rate of interest by 5.00%, and exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include payment defaults, breaches of covenants or representations and warranties, material adverse changes, certain bankruptcy events, cross defaults with certain other indebtedness, and judgment defaults.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.6 million for the year ended December 31, 2020. Accrued interest, included in accounts payable, was $0.1 million as of December 31, 2020. The outstanding Term Loan balance was $15.2 million as of December 31, 2020, inclusive of accretion of the final payment and net unamortized debt discount.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2020 for the next three fiscal years were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,774</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized discount</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term debt, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.62%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PPP Loan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 10, 2020 the Company obtained an unsecured $1.1 million loan through JPMorgan Chase Bank, N.A. under the Paycheck Protection Program (the PPP Loan) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Loan bore an interest rate of 0.98% and notionally matured two years from the date of issuance. Following the issuance of new, retroactive guidance on the program from the Small Business Administration on April 23, 2020, the Company repaid the PPP Loan principal and accrued interest in full. Interest expense related to the PPP Loan was de minimis for the year ended December 31, 2020.</p> 15000000.0 0.0100 2023-12-01 0.0075 The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate). 0.0525 0.0375 0.090 0.090 24 months 36 months monthly 2023-12-01 0.0400 600000 The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained compliance with all such covenants to date. 0.0500 1600000 100000 15200000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2020 for the next three fiscal years were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,774</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized discount</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term debt, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0 7826000 7774000 15600000 442000 15158000 1100000 0.0098 P2Y 2020-04-23 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facility lease has an option for the Company to extend the lease term for an additional </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and thus, the incremental term was excluded from the calculation of the lease liability.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at the end of the lease term based upon the then fair market value of the equipment. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The Company evaluated the lease in accordance with ASC 842 and recorded this lease as an operating lease in the balance sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ROU assets associated with all the Company’s operating leases are recognized in the balance sheets. Rent expense was $3.1 million during the years ended December 31, 2020, 2019 and 2018.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finance Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to purchase the equipment at the end of the lease term that is expected to be exercised. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The associated ROU asset is recognized within property and equipment, net in the balance sheets and is being amortized over three years in accordance with the Company’s standard depreciation and amortization policies.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease expenses:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,930</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,079</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease Maturities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,247</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: leases, current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,247</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases, net of current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from 48 months to 130 months. P48M P130M The facility lease has an option for the Company to extend the lease term for an additional five years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the lease liability. P5Y 2027 The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee. On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at the end of the lease term based upon the then fair market value of the equipment. P24M 3100000 3100000 3100000 On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to purchase the equipment at the end of the lease term that is expected to be exercised. P24M P3Y <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease expenses:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,930</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,079</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> 3137000 3137000 793000 942000 3930000 4079000 <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease Maturities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,247</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: leases, current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,247</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases, net of current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 3247000 18000 3265000 3333000 0 3333000 3433000 0 3433000 3536000 0 3536000 3642000 0 3642000 6642000 0 6642000 23833000 18000 23851000 6739000 0 6739000 17094000 18000 17112000 3247000 18000 3265000 13847000 0 13847000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Fair Value</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1:<span style="font-style:normal;"> Observable inputs such as quoted prices in active markets for identical assets or liabilities.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2:<span style="font-style:normal;"> Inputs other than quoted prices in active markets that are observable either directly or indirectly.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3:<span style="font-style:normal;"> Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company held no assets or liabilities measured at fair value on a nonrecurring basis and no liabilities measured at fair value on a recurring basis. The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,854</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 0 0 0 0 0 0 The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,854</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 23278000 23278000 0 0 55086000 55086000 0 0 490000 0 490000 0 78854000 78364000 490000 0 22121000 22121000 0 0 35476000 35476000 0 0 57597000 57597000 0 0 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Stockholders’ Equity</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of common stock reserved for future issuance are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,842,744</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,495,129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-funded warrants to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options available for future grant</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,553,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,548,214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for issuance under ESPP</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,301,704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,698,302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,020,558</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sale of Common Stock and Pre-funded Warrants</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company sold 17,275,000 shares of its common stock at a public offering price of $3.25 per share and sold pre-funded warrants to purchase 4,000,000 shares of its common stock at a public offering price of $3.249 per pre-funded warrant. After deducting underwriting discounts and commissions and offering expenses, the Company received net proceeds from the offering of $64.2 million. The public offering price for the pre-funded warrants was equal to the public offering price of the common stock, less the $0.001 per share exercise price of each pre-funded warrant. Per their terms, the outstanding pre-funded warrants to purchase shares of common stock may not be exercised if certain holders’ ownership of the Company’s common stock would exceed 4.99% following such exercise. The pre-funded warrants are exercisable immediately and do not contain an expiration date. The pre-funded warrants include a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. The pre-funded warrants are recorded as a component of stockholders’ equity within additional paid-in capital. The pre-funded warrants are included in the computation of basic net loss per share as the exercise price is negligible and may be exercised at any time until the pre-funded warrants are exercised in full. During the year ended December 31, 2020, none of the pre-funded warrants were exercised; accordingly, as of December 31, 2020, all of the pre-funded warrants remained issued and outstanding.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of common stock reserved for future issuance are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,842,744</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,495,129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-funded warrants to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options available for future grant</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,553,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,548,214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for issuance under ESPP</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,301,704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,698,302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,020,558</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9842744 7495129 4000000 0 2553854 3548214 2301704 1977215 18698302 13020558 17275000 3.25 4000000 3.249 64200000 0.001 0.0499 0 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Stock-Based Compensation and Equity Plans</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted awards under its 2010 Equity Incentive Plan (the 2010 Plan) until June 2014. In July 2014, the Company’s board of directors adopted and the Company’s stockholders approved its 2014 Equity </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive Plan (the 2014 Plan), </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> became effective </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 2014. In connection with the adoption of the 2014 Plan, the Company terminated the 2010 Plan for future use and provided that no further equity awards </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re to be granted under the 2010 Plan. All outstanding awards under the 2010 Plan continue to be governed by their existing terms.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 Plan permits the grant of incentive stock options to the Company’s employees and the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants. Options granted under the 2014 Plan are generally scheduled to vest over four years, subject to continued service, and subject to certain acceleration of vesting provisions, expire no later than 10 years from the date of grant. Options granted under the 2014 Plan must have a per share exercise price equal to at least 100% of the fair market value of a share of the common stock as of the date of grant.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 2,415,948 shares so that the total available for future issuance as of January 1, 2021 was 4,969,802 shares.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, 2,553,854 options were available for grant under the 2014 Plan. The following table summarizes stock option activity for the year ended December 31, 2020 (in thousands except per share amounts and years):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In Years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(659</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.93</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000650">7.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,706</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest as of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000651">7.1</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,706</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000652">5.7</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,890</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information regarding stock options (in thousands, except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   options granted during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash received from options exercised during the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Performance-based Awards</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company granted its chief executive officer a stock option for the purchase of 250,000 shares of the Company’s common stock which is subject to time-based vesting and certain performance-based conditions. Specifically, subject to continued service the option was scheduled to vest upon achievement of a clinical development milestone. On the grant date, the Company determined the fair value of the award and </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined achievement of the milestone was probable of occurrence</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and recognized</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stock-based compensation expense, based upon the grant date fair value, over the implicit service period. The milestone was achieved</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the option grant vested and was fully expensed as of December 31, 2018.</span></p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Option Exchange</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 20, 2017, the Company commenced an option exchange program (Option Exchange) which allowed eligible employees to exchange certain outstanding stock options (Eligible Options), whether vested or unvested, with an exercise price greater than $12.00 per share, for new stock options.  Non-employee members of the Company’s board of directors were not eligible to participate in the Option Exchange. The Option Exchange expired on January 19, 2018.  The closing price of the Company’s common stock on that date was $5.675 per share.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms and conditions of the Option Exchange, the Company accepted for exchange Eligible Options to purchase a total of 1,992,000 shares of the Company’s common stock, representing approximately 81.51% of the total shares of common stock underlying the Eligible Options. All surrendered options were canceled effective as of the expiration of the Option Exchange and in exchange on January 19, 2018, the Company granted new options to purchase an aggregate of 1,570,328 shares of the Company’s common stock with an exercise price of $5.675 per share pursuant to the terms of the Option Exchange and the 2014 Plan.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These new options vest over one to three years, </span>subject to the terms of the Option Exchange <span style="Background-color:#FFFFFF;">and expire eight years from the date of grant. The Company determined this option exchange was an option modification. The exchange of these stock options was treated as a modification for accounting purposes. The difference in the fair value of the canceled options immediately prior to the cancelation and the fair value of the modified options resulted in incremental value, of approximately $0.6 million, which was calculated using the Black-Scholes-Merton option pricing model. T</span>otal stock-based compensation expense to be recognized over the requisite service period is equal to the <span style="Background-color:#FFFFFF;">remaining unrecognized expense for the exchanged option, as of the exchange date,</span> plus the incremental value of the modification to the award.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2014, the Company’s board of directors adopted and the stockholders approved the Company’s 2014 Employee Stock Purchase Plan (the ESPP), which became effective upon adoption by the Company’s board of directors. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The offering periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and December 1 approximately twenty-four months later, and include six-month purchase periods.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares available for issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of (i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 724,784 shares so that the total available for future issuance as of January 1, 2021 was 3,026,488 shares.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had issued <span style="Background-color:#FFFFFF;">595,555</span> shares of common stock under the ESPP and had 2,301,704 shares available for future issuance.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.62%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-Scholes-Merton option pricing model:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Options:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000696">6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000697">6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">5.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000708">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000709">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000710">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate.<span style="font-style:normal;"> The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the option grants.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield.<span style="font-style:normal;"> The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility.<span style="font-style:normal;"> The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term.<span style="font-style:normal;"> The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,456</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,447</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,955</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,890</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,414</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, unrecognized compensation cost related to stock options was $9.8 million which is expected to be recognized over a remaining weighted-average vesting period of 2.5 years. As of December 31, 2020, unrecognized compensation cost related to ESPP rights was $0.4 million which is expected to be recognized over a remaining weighted-average vesting period of 1.2 years.</p> P4Y P10Y 1 Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. 2500000 0.05 2415948 4969802 2553854 The following table summarizes stock option activity for the year ended December 31, 2020 (in thousands except per share amounts and years): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In Years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(659</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.93</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000650">7.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,706</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest as of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000651">7.1</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,706</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000652">5.7</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,890</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7495000 4.43 3099000 3.46 92000 2.23 659000 4.93 9843000 4.11 25706000 9843000 4.11 25706000 5160000 4.84 10890000 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information regarding stock options (in thousands, except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   options granted during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash received from options exercised during the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised during the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2.68 1.64 4.36 206000 5000 32000 59000 2000 76000 250000 12.00 2018-01-19 5.675 1992000 0.8151 1570328 5.675 P3Y P8Y 600000 0.15 The offering periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and December 1 approximately twenty-four months later, and include six-month purchase periods. P24M issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of (i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. 800000 0.015 724784 3026488 595555 2301704 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-Scholes-Merton option pricing model:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Options:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000696">6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000697">6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">5.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000708">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000709">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000710">1.3</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.015 0.025 0.026 0.000 0.000 0.000 0.967 0.981 1.006 0.001 0.020 0.026 0.000 0.000 0.000 0.698 0.695 1.160 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,456</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,447</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,642</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,955</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,890</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,414</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 13000 12000 12000 2456000 2085000 4447000 3642000 2793000 7955000 6111000 4890000 12414000 9800000 P2Y6M 400000 P1Y2M12D <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Collaboration Agreements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.62%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AGTC collaboration</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company announced a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. Under the collaboration agreement, the Company and AGTC equally share the program costs and any revenue or other proceeds related to the program. As of December 31, 2020, the Company recognized a net receivable of $0.1 million from AGTC.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:2.62%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Co-Promotion Agreements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a co-promotion agreement with ALK in June 2020, with Mission Pharmacal Company (Mission) in August 2018 and with Glenmark Therapeutics Inc., USA (Glenmark) in April 2019 (each, a Co-Promotion Agreement) to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed the Company of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on its business operations. In September 2019, the Company reached a settlement with Glenmark regarding the financial and contractual terms impacted by this decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed the Company of its non-renewal of the co-promotion agreement.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALK, Mission and Glenmark (each, a Partner) each agreed to reimburse the Company for certain expenses, including a proportion of product support expenses. All such payments are accounted for as reductions to selling, general and administrative expense. Each Partner has been entitled to a share of gross profits totaling more than 50% from the sale of OTIPRIO to each Partner’s accounts. The Company’s payments to each Partner for its portion of the gross profit is recognized as selling, general and administrative expense. The Company is the principal in the product sale of OTIPRIO and recognizes all revenue and related cost of product sales. For the years ended December 31, 2020 and 2019, the Company recognized reductions in selling, general and administrative expenses related to the Co-Promotion Agreements of $0.3 million and $2.6 million, respectively.</p> 100000 1000000.0 0.50 300000 2600000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed a preliminary IRC Section 382/383 analysis, regarding the limitation of net operating loss and research and development credit carryforwards as of December 31, 2020 and does not believe there to have been an ownership change during the year then ended. The Company will continue to consider changes in ownership that may cause losses of tax attributes in the future.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,013</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,985</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,608</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,395</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,602</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,140</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,612</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the Company’s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company’s net deferred tax assets, as it is more likely than not that such net assets will not be realized. A valuation allowance of approximately $113.8 million and $106.0 million has been established as of December 31, 2020 and 2019, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had federal and state net operating loss carryforwards of approximately $382.8 million net of IRC Section 382 limitations and $124.8 million, respectively. Of the federal net operating loss carryforwards, approximately $142.2 million were generated after January 1, 2018, and therefore do not expire. Federal net operating losses that occur after January 1, 2018 are subject to a taxable income limitation of 80% in accordance with the Tax Cuts and Jobs Act of 2017 (the TCJA). The remaining federal and state net operating loss carryforwards will begin to expire in 2030, unless previously utilized. As of December 31, 2020, the Company also had federal and California research and development credit carryforwards of approximately $12.0 million net of IRC Section 383 limitations and $5.8 million, respectively. The federal research and development credit carryforwards will begin expiring in 2030, unless previously utilized. The California research credit will carry forward indefinitely.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those currently reported for the years ended December 31 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,393</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax (net of federal benefit)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,383</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items, other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,470</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other adjustments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,774</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,308</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">710</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,832</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,858</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,884</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,739</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,098</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior year tax positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has no accruals for interest or penalties in the balance sheets as of December 31, 2020 and 2019 and has not recognized interest or penalties in the statements of operations for the years ended December 31, 2020, 2019 and 2018.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the valuation allowance recorded against the Company’s net deferred tax assets, future changes in unrecognized tax benefits will not impact the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States for federal and state purposes. Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination by the IRS and state tax authorities for all years since inception. The Company is not currently under examination by the federal or any state tax authority.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,013</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,768</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,985</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,608</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,395</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,602</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,140</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,612</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 88013000 78768000 9985000 8920000 10212000 12608000 850000 381000 3816000 4349000 3856000 4395000 234000 181000 116966000 109602000 113826000 105990000 3140000 3612000 3140000 3612000 3140000 3612000 0 0 113800000 106000000.0 382800000 124800000 142200000 0.80 will begin to expire in 2030 will begin to expire in 2030 12000000.0 5800000 will begin expiring in 2030 indefinitely <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those currently reported for the years ended December 31 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,393</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax (net of federal benefit)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,383</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items, other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,470</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other adjustments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,774</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,308</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">710</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,832</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,858</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,884</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> -9393000 -9382000 -10578000 334000 299000 -4383000 9000 189000 -2092000 1595000 2470000 2570000 687000 523000 0 1774000 1595000 2308000 710000 638000 907000 7832000 6858000 15884000 0 0 0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,739</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,098</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior year tax positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,739</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 10739000 10052000 9098000 -21000 -80000 242000 796000 767000 712000 11514000 10739000 10052000 0 0 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Feb. 05, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Trading Symbol OTIC    
Entity Registrant Name Otonomy, Inc.    
Entity Central Index Key 0001493566    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   48,318,970  
Entity Public Float     $ 103.3
Entity Interactive Data Current Yes    
Title of 12(b) Security Common stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-36591    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-2590070    
Entity Address, Address Line One 4796 Executive Drive    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92121    
City Area Code 619    
Local Phone Number 323-2200    
ICFR Auditor Attestation Flag false    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

As noted herein, the information called for by Part III is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2021 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2020.

    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 30,767 $ 25,194
Short-term investments 55,576 35,476
Prepaid and other current assets 2,372 2,480
Total current assets 88,715 63,150
Restricted cash 702 701
Property and equipment, net 2,766 3,702
Right-of-use assets 14,082 15,465
Total assets 106,265 83,018
Current liabilities:    
Accounts payable 849 1,161
Accrued expenses 2,953 5,442
Accrued compensation 3,927 2,593
Leases, current 3,265 3,302
Total current liabilities 10,994 12,498
Long-term debt, net 15,158 14,967
Leases, net of current 13,847 15,320
Total liabilities 39,999 42,785
Commitments and Contingencies 0 0
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued or outstanding at December 31, 2020 and 2019 0 0
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and 2019; 48,318,970 and 30,814,211 shares issued and outstanding at December 31, 2020 and 2019, respectively 48 31
Additional paid-in capital 570,841 500,084
Accumulated other comprehensive income 1 11
Accumulated deficit (504,624) (459,893)
Total stockholders’ equity 66,266 40,233
Total liabilities and stockholders’ equity $ 106,265 $ 83,018
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares Issued 48,318,970 30,814,211
Common stock, Shares outstanding 48,318,970 30,814,211
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Product sales, net $ 273 $ 600 $ 745
Type of Revenue [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Costs and operating expenses:      
Cost of product sales $ 1,188 $ 912 $ 946
Type of Cost, Good or Service [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Research and development $ 27,997 $ 32,805 $ 31,844
Selling, general and administrative 14,575 11,690 20,008
Total costs and operating expenses 43,760 45,407 52,798
Loss from operations (43,487) (44,807) (52,053)
Other income (expense):      
Interest income 326 1,723 1,689
Interest expense (1,570) (1,591) (4)
Total other (expense) income, net (1,244) 132 1,685
Net loss $ (44,731) $ (44,675) $ (50,368)
Net loss per share, basic and diluted $ (1.10) $ (1.45) $ (1.65)
Weighted-average shares used to compute net loss per share, basic and diluted 40,845,844 30,726,786 30,610,244
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]      
Net loss $ (44,731) $ (44,675) $ (50,368)
Other comprehensive loss:      
Unrealized (loss) gain on available-for-sale securities (10) 34 77
Comprehensive loss $ (44,741) $ (44,641) $ (50,291)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2017 $ 117,279 $ 31 $ 482,198 $ (100) $ (364,850)
Beginning balance, shares at Dec. 31, 2017   30,558,726      
Issuance of common stock upon exercise of stock options 32   32    
Issuance of common stock upon exercise of stock options, shares   18,800      
Issuance of common stock under employee stock purchase plan 303   303    
Issuance of common stock under employee stock purchase plan, shares   107,886      
Stock-based compensation expense 12,414   12,414    
Net loss (50,368)       (50,368)
Unrealized (loss) gain on available-for-sale securities 77     77  
Ending balance at Dec. 31, 2018 79,737 $ 31 494,947 (23) (415,218)
Ending balance, shares at Dec. 31, 2018   30,685,412      
Issuance of common stock upon exercise of stock options 5   5    
Issuance of common stock upon exercise of stock options, shares   2,912      
Issuance of common stock under employee stock purchase plan 242   242    
Issuance of common stock under employee stock purchase plan, shares   125,887      
Stock-based compensation expense 4,890   4,890    
Net loss (44,675)       (44,675)
Unrealized (loss) gain on available-for-sale securities 34     34  
Ending balance at Dec. 31, 2019 40,233 $ 31 500,084 11 (459,893)
Ending balance, shares at Dec. 31, 2019   30,814,211      
Issuance of common stock and pre-funded warrants, net of issuancecosts 64,187 $ 17 64,170    
Issuance of common stock and prefunded warrants, net of issuance costs (unaudited), shares   17,275,000      
Issuance of common stock upon exercise of stock options $ 206   206    
Issuance of common stock upon exercise of stock options, shares 92,000 92,035      
Issuance of common stock under employee stock purchase plan $ 270   270    
Issuance of common stock under employee stock purchase plan, shares   137,724      
Stock-based compensation expense 6,111   6,111    
Net loss (44,731)       (44,731)
Unrealized (loss) gain on available-for-sale securities (10)     (10)  
Ending balance at Dec. 31, 2020 $ 66,266 $ 48 $ 570,841 $ 1 $ (504,624)
Ending balance, shares at Dec. 31, 2020   48,318,970      
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net loss $ (44,731) $ (44,675) $ (50,368)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 1,062 1,149 1,186
Stock-based compensation 6,111 4,890 12,414
Accretion of discounts on short-term investments (29) (787) (506)
Amortization of debt discount 191 189 0
Deferred rent 0 0 103
Changes in operating assets and liabilities:      
Prepaid and other assets 108 536 (493)
Accounts payable (374) 127 68
Accrued expenses (2,419) 1,656 (166)
Accrued compensation 1,334 (42) (672)
Right-of-use assets and lease liabilities, net (127) 32 0
Net cash used in operating activities (38,874) (36,925) (38,434)
Cash flows from investing activities:      
Purchases of short-term investments (68,581) (85,004) (104,270)
Maturities of short-term investments 48,500 114,000 142,750
Purchases of property and equipment (134) (700) (496)
Net cash (used in) provided by investing activities (20,215) 28,296 37,984
Cash flows from financing activities:      
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs 64,187 0 0
Proceeds from issuance of long-term debt, net of cash issuance costs 0 0 14,830
Proceeds from short-term debt 1,126 0 0
Principal payments on short-term debt (1,126) 0 0
Proceeds from issuance of common stock under employee stock purchase plan 270 242 303
Proceeds from exercise of stock options 206 5 32
Payments of debt issuance costs 0 (52) 0
Net cash provided by financing activities 64,663 195 15,165
Net change in cash, cash equivalents and restricted cash 5,574 (8,434) 14,715
Cash, cash equivalents and restricted cash at beginning of period 25,895 34,329 19,614
Cash, cash equivalents and restricted cash at end of period 31,469 25,895 34,329
Cash and cash equivalents at end of period 30,767 25,194 33,633
Restricted cash at end of period 702 701 696
Supplemental cash flow information:      
Cash paid for interest 1,373 1,394 4
Supplemental disclosure of non-cash investing and financing activities:      
Purchase of property and equipment in accounts payable and accrued expenses 67 76 7
Debt issuance costs in accounts payable and accrued expenses 0 0 66
Debt issuance costs $ 0 $ 0 $ 771
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Description of Business and Basis of Presentation
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Otonomy, Inc. (Otonomy or the Company) was incorporated in the state of Delaware on May 6, 2008. Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The Company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss and tinnitus.

OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone that has completed two Phase 3 trials for the treatment of Ménière’s disease, with a third Phase 3 trial that has completed enrollment of patients with top-line results expected by the end of February 2021. OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine that has completed a Phase 1/2 clinical trial in tinnitus patients with positive top-line results, and the Company expects to initiate a Phase 2 clinical trial in the first quarter of 2021. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) for hearing loss, with positive top-line results announced for a Phase 1/2 clinical trial that the Company intends to continue with an expansion of the trial expected to start in the second quarter of 2021. Otonomy also has multiple preclinical stage programs addressing additional hearing loss pathologies including a gene therapy for treatment of congenital hearing loss (OTO-825), an otoprotectant for prevention of cisplatin-induced hearing loss (OTO-510), and a hair cell repair and regeneration program for severe hearing loss (OTO-6XX). In October 2019, the Company entered into a strategic collaboration with Applied Genetic Technologies Corporation (AGTC), to co-develop and co-commercialize a gene therapy to restore hearing in patients with hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. In July 2020, the Company entered into an exclusive license agreement with Kyorin Pharmaceutical Co., Ltd. (Kyorin) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound from Kyorin for the OTO-6XX program.

In addition, the Company developed, received United States Food and Drug Administration (FDA) approval and commercially launched OTIPRIO for use during tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis externa (AOE). In June 2020, the Company entered into a co-promotion agreement with ALK-Abelló, Inc. (ALK) to support the promotion of OTIPRIO for the treatment of AOE in physician offices in the United States, which was amended in October 2020 to include promotion of OTIPRIO for use during TTP surgery in pediatric patients.

Basis of Presentation

The Company follows Accounting Standards Codification (ASC) Topic 205-40, Presentation of Financial Statements—Going Concern, which requires that management evaluate whether there are relevant conditions and events that in aggregate raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating activities since inception. In July 2020, the Company sold in a public offering 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase 4,000,000 shares of its common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, the Company had cash, cash equivalents and short-term investments of $86.3 million, outstanding debt of $15.2 million and an accumulated deficit of $504.6 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory approvals for OTIVIDEX, OTO-313, OTO-413 and its other product candidates; and (ii) works to develop additional product candidates through research and development programs.

When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or other sources, such as potential collaboration agreements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all.  If the Company is not able to secure adequate additional funding, if or when necessary, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.  The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for a period of at least twelve months from the date of this report.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available checking, savings and money market accounts.

The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s corporate headquarters.

Short-term Investments

The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 8 – Fair Value).

Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis, and whenever events or changes

in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records unrealized gains and losses on available-for-sale debt securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders’ equity on the balance sheets. The Company does not hold equity securities in its investment portfolio.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value.

Inventory

Inventory is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost to sell. During the year ended December 31, 2020, the Company recorded an inventory write down of $0.3 million to cost of product sales. During the years ended December 31, 2019 and 2018, no such write downs were recorded.

Property and Equipment, Net

Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred.

Impairment of Long-Lived Assets

The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2020, 2019 and 2018.

Right-of-Use Assets and Lease Liabilities

The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. The Company determines if an arrangement is or contains a lease at each commencement date. Accounting Standards Codification (ASC) 842, Leases (ASC 842) establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02) provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases.

Operating leases are included in ROU assets, Leases, current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on the balance sheets. The Company has elected a policy not to recognize short-term leases (one year or less) on the balance sheets. ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease

payments over the lease term at the commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Clinical Trial Expense Accruals

The Company estimates expenses resulting from its obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.

The Company records clinical trial expenses in the period in which services are performed and efforts are expended. The Company accrues for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company estimates accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, the Company may adjust its clinical accruals if actual results differ from its estimates.

Revenue Recognition

The Company recognizes revenue by performing the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under ASC Topic 606, Revenue from Contracts with Customers (ASC 606) and when it is probable the Company will collect the consideration exchanged for the goods or services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of OTIPRIO, typically upon delivery by the Company to these distributors. The Company has determined the delivery of OTIPRIO to its customers constitutes a single performance obligation and no other performance obligations are present. The Company’s customer contracts have standard payment terms. The Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.

Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are not permitted. To date, product returns have been immaterial.

Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year or the amount is immaterial.

Concentration of Major Customers

The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest customers for each of the periods presented:

 

 

 

 

2020

 

 

2019

 

 

2018

 

First largest

 

 

41

%

 

 

38

%

 

 

44

%

Second largest

 

 

29

%

 

 

33

%

 

 

33

%

Third largest

 

 

24

%

 

 

24

%

 

 

21

%

 

Collaborative Arrangements

The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, Collaborative Arrangements (ASC 808).

Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.

Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the statements of operations.

Research and Development

Research and development expenses include the costs associated with the Company’s research and development activities, including salaries, benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.

Selling, General and Administrative

Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s partners under its co-promotion agreements.

Stock-Based Compensation

The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-based vesting conditions, stock-based compensation expense is recognized using the straight-line method.  For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

Income Taxes

The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources.

Net Loss Per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

As of December 31, 2020, 2019 and 2018, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of outstanding options to purchase 9,842,744, 7,495,129 and 5,019,964 shares of the Company’s common stock, respectively.

Risks and Uncertainties Related to COVID-19

In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 pandemic could pose significant risks to the Company’s business; however, the ultimate impact of the pandemic is highly uncertain.

The Company has clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, the Company had suspended and subsequently updated its guidance regarding timing of trial results. The Company may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic.  In addition, the Company has made and it (and its contract research organizations (CROs)) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020, among other activity.  Third-party manufacturers which the Company uses for the supply of materials for its product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although the Company expects no material impact on the clinical supply of its product candidates for its current clinical trials, should its third-party manufacturers experience extended disruptions, the Company could experience delays in future trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which may delay the development of the Company’s product candidates.

The Company continues to evaluate the impact COVID-19 may have on its ability to effectively conduct its business operations as planned, and work with healthcare providers supporting its clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies and may take further actions as may be required by federal, state or local authorities or that the Company determines are in the best interests of public health and safety and that of patients, employees, partners, and stockholders.  Nonetheless,

the Company does not yet know and cannot predict the full extent of potential delays or impacts on its business, its preclinical programs and clinical trials, healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the COVID-19 pandemic will have on the Company’s business, strategy, collaborations, financial condition, liquidity and future results of operations.

 

Recent Accounting Pronouncements

Not Yet Adopted

In June 2016, ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable. ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect on its financial position, results of operations or cash flows.

Recently Adopted

Effective January 1, 2020, the Company early adopted ASU No. 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, other comprehensive income).

ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 is effective for the Company beginning January 1, 2020. There was no cumulative effect to be recognized in connection with the early adoption of ASU 2019-12 and the adoption did not have a material impact on the Company’s financial statements or disclosures.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Available-for-Sale Securities
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Available-for-Sale Securities

3. Available-for-Sale Securities

The Company invests in available-for-sale debt securities consisting of money market funds, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities. Available-for-sale debt securities are classified as part of either cash and cash equivalents or short-term investments in the balance sheets. Available-for-sale debt securities with maturities of three months or less from the date of purchase have been classified as cash equivalents, and were $23.3 million and $22.1 million as of December 31, 2020 and 2019, respectively.

Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and were as follows (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Market Value

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

55,085

 

 

$

2

 

 

$

(1

)

 

$

55,086

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

—

 

 

 

490

 

 

 

$

55,575

 

 

$

2

 

 

$

(1

)

 

$

55,576

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 

 

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 

 

As of December 31, 2020, the Company had four securities in a gross unrealized loss position, all of which have been in such position for less than twelve months. At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized

loss positions until their amortized cost basis has been recovered. The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2020. All the Company’s available-for-sale debt securities mature within one year.

The Company obtains the fair value of its available-for-sale debt securities from a professional pricing service. The fair values of available-for-sale debt securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Details

4. Balance Sheet Details

Prepaid and Other Current Assets

Prepaid and other current assets are comprised of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Inventory

 

$

227

 

 

$

478

 

Other

 

 

2,145

 

 

 

2,002

 

Total

 

$

2,372

 

 

$

2,480

 

Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

4,265

 

 

$

4,179

 

Manufacturing equipment

 

 

1,075

 

 

 

1,111

 

Computer equipment and software

 

 

989

 

 

 

943

 

Leasehold improvements

 

 

768

 

 

 

768

 

Office furniture

 

 

1,548

 

 

 

1,548

 

 

 

 

8,645

 

 

 

8,549

 

Less: accumulated depreciation and amortization

 

 

(5,879

)

 

 

(4,847

)

Total

 

$

2,766

 

 

$

3,702

 

 

Depreciation expense was $1.1 million, $1.1 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued clinical trial costs

 

$

1,477

 

 

$

3,443

 

Accrued other

 

 

1,476

 

 

 

1,999

 

Total

 

$

2,953

 

 

$

5,442

 

 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

5. Commitments and Contingencies

Operating Leases

In December 2016, the Company moved into its current headquarters location in San Diego, California. The lease commenced in December 2016 and has an initial term of 130 months, with an option by the Company to

extend the lease term for an additional five years. The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee. The Company is responsible for payment of taxes and operating expenses for the building, in addition to monthly base rent in the initial amount of approximately $232,000, with 3% annual increases, which monthly base rent was abated for the first ten months of the lease term. The total estimated base rent payments over the life of the lease are estimated to be approximately $32.7 million. Upon execution of the lease in May 2015, the Company provided a security deposit in the form of a letter of credit in the amount of approximately $0.7 million. Cash collateralizing the letter of credit is classified as noncurrent restricted cash on the balance sheets. The Company has determined that the lease is an operating lease for accounting purposes.

Intellectual Property Licenses

The Company has acquired exclusive rights to develop patented rights, information rights and related know-how for OTIPRIO, OTIVIDEX, OTO-311, OTO-313 and OTO-413 and potential future product candidates under licensing agreements with third parties. The licensing rights obligate the Company to make payments to the licensors for license fees, milestones and royalties. The Company is also responsible for patent prosecution costs, in the event such costs are incurred.

The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements covering OTIPRIO, OTIVIDEX, OTO-313 and OTO-413 as follows (in thousands):

 

Development

 

$

1,250

 

Regulatory

 

 

10,275

 

Commercialization

 

 

1,000

 

Total

 

$

12,525

 

 

Under one of these agreements, the Company has achieved eight development milestones and one regulatory milestone, totaling $3.2 million, related to its clinical trials for OTIPRIO, OTIVIDEX, OTO-311 and OTO-413.

If the Company receives positive results from the OTIVIDEX Phase 3 trial and submits an NDA to the FDA in 2021, the Company may be obligated to make a regulatory milestone payment of $1.0 million under one of the Company’s license agreements. This potential payment is included in the table above.

 

In addition, the Company is obligated to pay royalties of less than five percent on net sales of OTIPRIO and on sales of any other commercial products developed using these licensed technologies. Such royalty expense for OTIPRIO is recorded to cost of product sales. The Company may also be obligated to pay to the licensors a percentage of fees received if and when the Company sublicenses the technology. As of December 31, 2020, the Company has not entered into any sublicense agreements for the licensed technologies.

In July 2020, the Company entered into an exclusive license agreement to develop, manufacture and commercialize a novel compound as a potential treatment, OTO-6XX, for severe hearing loss. Under the terms of the agreement, the Company acquired worldwide rights to the compound for an upfront payment of $0.5 million with an additional $0.5 million due upon demonstration of preclinical efficacy. If the Company advances a product containing the compound into full development, the Company may be obligated to make payments for development and commercial milestones and pay a royalty on worldwide net sales. The license agreement was accounted for as an asset acquisition and the upfront cash payment of $0.5 million was expensed to research and development during the year ended December 31, 2020 as there is no future alternative use for the assets.

The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable royalty and milestone obligations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

License and other fees

 

$

500

 

 

$

—

 

 

$

—

 

Milestone fees

 

 

250

 

 

 

100

 

 

 

—

 

Total license and related fees

 

$

750

 

 

$

100

 

 

$

—

 

 

Other Royalty Arrangements

The Company entered into an agreement related to OTIPRIO under which the Company is obligated to pay royalties of less than one percent on net product sales of OTIPRIO. The royalties are recorded as selling, general and administrative expense. The royalties are payable until the later of: (i) the expiration of the last to expire patent owned by the Company in such country covering OTIPRIO; or (ii) 10 years after the first commercial sale of OTIPRIO after receipt of regulatory approval for OTIPRIO in such country.

In October 2014, the Company entered into an exclusive license agreement with Ipsen that enables the Company to use clinical and nonclinical gacyclidine data generated by Ipsen to support worldwide development and regulatory filings for OTO-313. Under this license agreement, the Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees, up to a maximum cumulative royalty totaling $10.0 million.

Litigation

From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company as of December 31, 2020 which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Debt
 12 Months Ended
Dec. 31, 2020
Long Term Debt [Abstract]  
Debt

6. Debt

Term Loan

 

On December 31, 2018 (the Closing Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), among the Company, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time.

 

The Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for working capital and general corporate purposes. The Company has the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment fee of 1.00%. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan was fully funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). The Company paid a facility fee of 0.75% and customary closing fees on the Closing Date.

 

The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate). Interest on the Term Loan is payable monthly in arrears. During the year ended December 31, 2020, the terms of the Term Loan were amended to extend the interest-only period from 24 months to 36 months following the Closing Date, followed by consecutive equal monthly payments of principal and interest in arrears through the Maturity Date. The extension was accounted for as a modification, with no material effect on the Company’s financial statements or financial position. The outstanding principal amount of the Term Loan, together with accrued and unpaid interest, is due on December 1, 2023.

 

 

Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the effective interest method.

 

The Company’s obligations under the Loan Agreement are secured by substantially all its assets, excluding intellectual property and subject to certain other exceptions and limitations.

 

The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained compliance with all such covenants to date. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable, increase the applicable rate of interest by 5.00%, and exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include payment defaults, breaches of covenants or representations and warranties, material adverse changes, certain bankruptcy events, cross defaults with certain other indebtedness, and judgment defaults.

 

Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.6 million for the year ended December 31, 2020. Accrued interest, included in accounts payable, was $0.1 million as of December 31, 2020. The outstanding Term Loan balance was $15.2 million as of December 31, 2020, inclusive of accretion of the final payment and net unamortized debt discount.

 

The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2020 for the next three fiscal years were as follows:

 

2021

 

$

—

 

2022

 

 

7,826

 

2023

 

 

7,774

 

Subtotal

 

 

15,600

 

Unamortized discount

 

 

(442

)

Total long-term debt, net

 

$

15,158

 

PPP Loan

On April 10, 2020 the Company obtained an unsecured $1.1 million loan through JPMorgan Chase Bank, N.A. under the Paycheck Protection Program (the PPP Loan) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Loan bore an interest rate of 0.98% and notionally matured two years from the date of issuance. Following the issuance of new, retroactive guidance on the program from the Small Business Administration on April 23, 2020, the Company repaid the PPP Loan principal and accrued interest in full. Interest expense related to the PPP Loan was de minimis for the year ended December 31, 2020.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Leases
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Leases

7. Leases

Operating Leases

The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from 48 months to 130 months. The facility lease has an option for the Company to extend the lease term for an additional five years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the lease liability. The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee.

On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at the end of the lease term based upon the then fair market value of the equipment. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The Company evaluated the lease in accordance with ASC 842 and recorded this lease as an operating lease in the balance sheets.

The ROU assets associated with all the Company’s operating leases are recognized in the balance sheets. Rent expense was $3.1 million during the years ended December 31, 2020, 2019 and 2018.

 

Finance Leases

On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to purchase the equipment at the end of the lease term that is expected to be exercised. The lease payment includes customary principal and interest as well as costs related to the installation and setup of the equipment. The associated ROU asset is recognized within property and equipment, net in the balance sheets and is being amortized over three years in accordance with the Company’s standard depreciation and amortization policies.

 

 

 

Years Ended December 31,

 

Lease expenses:

 

2020

 

 

2019

 

Operating lease expenses

 

$

3,137

 

 

$

3,137

 

Variable lease expenses

 

 

793

 

 

 

942

 

Total lease expenses

 

$

3,930

 

 

$

4,079

 

 

 

Lease Maturities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Leases

 

 

Finance Leases

 

 

Total

 

2021

 

$

3,247

 

 

$

18

 

 

$

3,265

 

2022

 

 

3,333

 

 

—

 

 

 

3,333

 

2023

 

 

3,433

 

 

—

 

 

 

3,433

 

2024

 

 

3,536

 

 

—

 

 

 

3,536

 

2025

 

 

3,642

 

 

—

 

 

 

3,642

 

Thereafter

 

 

6,642

 

 

—

 

 

 

6,642

 

Total minimum lease payments

 

 

23,833

 

 

 

18

 

 

 

23,851

 

Imputed interest

 

 

(6,739

)

 

 

—

 

 

 

(6,739

)

Total

 

 

17,094

 

 

 

18

 

 

 

17,112

 

Less: leases, current

 

 

(3,247

)

 

 

(18

)

 

 

(3,265

)

Leases, net of current

 

$

13,847

 

 

$

—

 

 

$

13,847

 

 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value

8. Fair Value

The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:

Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

As of December 31, 2020 and 2019, the Company held no assets or liabilities measured at fair value on a nonrecurring basis and no liabilities measured at fair value on a recurring basis. The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurement at Reporting Date Using

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

23,278

 

 

$

23,278

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

55,086

 

 

 

55,086

 

 

 

—

 

 

 

—

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

490

 

 

 

—

 

 

 

$

78,854

 

 

$

78,364

 

 

$

490

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

22,121

 

 

$

22,121

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

35,476

 

 

 

35,476

 

 

 

—

 

 

 

—

 

 

 

$

57,597

 

 

$

57,597

 

 

$

—

 

 

$

—

 

 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Stockholders' Equity

9. Stockholders’ Equity

Common Stock Reserved for Future Issuance

Shares of common stock reserved for future issuance are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Common stock options issued and outstanding

 

 

9,842,744

 

 

 

7,495,129

 

Pre-funded warrants to purchase common stock

 

 

4,000,000

 

 

 

—

 

Common stock options available for future grant

 

 

2,553,854

 

 

 

3,548,214

 

Common stock reserved for issuance under ESPP

 

 

2,301,704

 

 

 

1,977,215

 

Total common stock reserved for future issuance

 

 

18,698,302

 

 

 

13,020,558

 

Sale of Common Stock and Pre-funded Warrants

In July 2020, the Company sold 17,275,000 shares of its common stock at a public offering price of $3.25 per share and sold pre-funded warrants to purchase 4,000,000 shares of its common stock at a public offering price of $3.249 per pre-funded warrant. After deducting underwriting discounts and commissions and offering expenses, the Company received net proceeds from the offering of $64.2 million. The public offering price for the pre-funded warrants was equal to the public offering price of the common stock, less the $0.001 per share exercise price of each pre-funded warrant. Per their terms, the outstanding pre-funded warrants to purchase shares of common stock may not be exercised if certain holders’ ownership of the Company’s common stock would exceed 4.99% following such exercise. The pre-funded warrants are exercisable immediately and do not contain an expiration date. The pre-funded warrants include a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. The pre-funded warrants are recorded as a component of stockholders’ equity within additional paid-in capital. The pre-funded warrants are included in the computation of basic net loss per share as the exercise price is negligible and may be exercised at any time until the pre-funded warrants are exercised in full. During the year ended December 31, 2020, none of the pre-funded warrants were exercised; accordingly, as of December 31, 2020, all of the pre-funded warrants remained issued and outstanding.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation and Equity Plans

10. Stock-Based Compensation and Equity Plans

2014 Equity Incentive Plan

The Company granted awards under its 2010 Equity Incentive Plan (the 2010 Plan) until June 2014. In July 2014, the Company’s board of directors adopted and the Company’s stockholders approved its 2014 Equity

Incentive Plan (the 2014 Plan), which became effective in August 2014. In connection with the adoption of the 2014 Plan, the Company terminated the 2010 Plan for future use and provided that no further equity awards were to be granted under the 2010 Plan. All outstanding awards under the 2010 Plan continue to be governed by their existing terms.

The 2014 Plan permits the grant of incentive stock options to the Company’s employees and the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants. Options granted under the 2014 Plan are generally scheduled to vest over four years, subject to continued service, and subject to certain acceleration of vesting provisions, expire no later than 10 years from the date of grant. Options granted under the 2014 Plan must have a per share exercise price equal to at least 100% of the fair market value of a share of the common stock as of the date of grant.

Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 2,415,948 shares so that the total available for future issuance as of January 1, 2021 was 4,969,802 shares.

As of December 31, 2020, 2,553,854 options were available for grant under the 2014 Plan. The following table summarizes stock option activity for the year ended December 31, 2020 (in thousands except per share amounts and years):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-

Average

Remaining

Contractual

Term

(In Years)

 

 

Aggregate

Intrinsic Value

 

Outstanding as of December 31, 2019

 

 

7,495

 

 

$

4.43

 

 

 

 

 

 

 

 

 

Granted

 

 

3,099

 

 

$

3.46

 

 

 

 

 

 

 

 

 

Exercised

 

 

(92

)

 

$

2.23

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(659

)

 

$

4.93

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options vested and expected to vest as of

   December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options exercisable as of December 31, 2020

 

 

5,160

 

 

$

4.84

 

 

 

5.7

 

 

$

10,890

 

 

The following table summarizes certain information regarding stock options (in thousands, except per share data):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Weighted-average grant date fair value per share of

   options granted during the period

 

$

2.68

 

 

$

1.64

 

 

$

4.36

 

Cash received from options exercised during the

   period

 

 

206

 

 

 

5

 

 

 

32

 

Intrinsic value of options exercised during the period

 

 

59

 

 

 

2

 

 

 

76

 

 

Performance-based Awards

In February 2018, the Company granted its chief executive officer a stock option for the purchase of 250,000 shares of the Company’s common stock which is subject to time-based vesting and certain performance-based conditions. Specifically, subject to continued service the option was scheduled to vest upon achievement of a clinical development milestone. On the grant date, the Company determined the fair value of the award and

determined achievement of the milestone was probable of occurrence and recognized stock-based compensation expense, based upon the grant date fair value, over the implicit service period. The milestone was achieved, and the option grant vested and was fully expensed as of December 31, 2018.

Option Exchange

On December 20, 2017, the Company commenced an option exchange program (Option Exchange) which allowed eligible employees to exchange certain outstanding stock options (Eligible Options), whether vested or unvested, with an exercise price greater than $12.00 per share, for new stock options.  Non-employee members of the Company’s board of directors were not eligible to participate in the Option Exchange. The Option Exchange expired on January 19, 2018.  The closing price of the Company’s common stock on that date was $5.675 per share.

Pursuant to the terms and conditions of the Option Exchange, the Company accepted for exchange Eligible Options to purchase a total of 1,992,000 shares of the Company’s common stock, representing approximately 81.51% of the total shares of common stock underlying the Eligible Options. All surrendered options were canceled effective as of the expiration of the Option Exchange and in exchange on January 19, 2018, the Company granted new options to purchase an aggregate of 1,570,328 shares of the Company’s common stock with an exercise price of $5.675 per share pursuant to the terms of the Option Exchange and the 2014 Plan.

These new options vest over one to three years, subject to the terms of the Option Exchange and expire eight years from the date of grant. The Company determined this option exchange was an option modification. The exchange of these stock options was treated as a modification for accounting purposes. The difference in the fair value of the canceled options immediately prior to the cancelation and the fair value of the modified options resulted in incremental value, of approximately $0.6 million, which was calculated using the Black-Scholes-Merton option pricing model. Total stock-based compensation expense to be recognized over the requisite service period is equal to the remaining unrecognized expense for the exchanged option, as of the exchange date, plus the incremental value of the modification to the award.

2014 Employee Stock Purchase Plan

In July 2014, the Company’s board of directors adopted and the stockholders approved the Company’s 2014 Employee Stock Purchase Plan (the ESPP), which became effective upon adoption by the Company’s board of directors. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The offering periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and December 1 approximately twenty-four months later, and include six-month purchase periods.

The number of shares available for issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of (i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2021, the number of shares available for future issuance was increased by 724,784 shares so that the total available for future issuance as of January 1, 2021 was 3,026,488 shares.

As of December 31, 2020, the Company had issued 595,555 shares of common stock under the ESPP and had 2,301,704 shares available for future issuance.

Stock-Based Compensation Expense

The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-Scholes-Merton option pricing model:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Stock Options:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

1.5

%

 

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

96.7

%

 

 

98.1

%

 

 

100.6

%

Expected term (in years)

 

 

6.1

 

 

 

6.1

 

 

 

5.4

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

0.1

%

 

 

2.0

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

69.8

%

 

 

69.5

%

 

 

116.0

%

Expected term (in years)

 

 

1.3

 

 

 

1.3

 

 

 

1.3

 

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the option grants.

Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.

Expected Volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.

Expected Term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.

Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Cost of product sales

 

$

13

 

 

$

12

 

 

$

12

 

Research and development

 

 

2,456

 

 

 

2,085

 

 

 

4,447

 

Selling, general and administrative

 

 

3,642

 

 

 

2,793

 

 

 

7,955

 

Total stock-based compensation

 

$

6,111

 

 

$

4,890

 

 

$

12,414

 

 

As of December 31, 2020, unrecognized compensation cost related to stock options was $9.8 million which is expected to be recognized over a remaining weighted-average vesting period of 2.5 years. As of December 31, 2020, unrecognized compensation cost related to ESPP rights was $0.4 million which is expected to be recognized over a remaining weighted-average vesting period of 1.2 years.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements
 12 Months Ended
Dec. 31, 2020
Collaborative Arrangement Disclosure [Abstract]  
Collaboration Agreements

11. Collaboration Agreements

AGTC collaboration

In October 2019, the Company announced a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene. Under the collaboration agreement, the Company and AGTC equally share the program costs and any revenue or other proceeds related to the program. As of December 31, 2020, the Company recognized a net receivable of $0.1 million from AGTC.

Co-Promotion Agreements

The Company entered into a co-promotion agreement with ALK in June 2020, with Mission Pharmacal Company (Mission) in August 2018 and with Glenmark Therapeutics Inc., USA (Glenmark) in April 2019 (each, a Co-Promotion Agreement) to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed the Company of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on its business operations. In September 2019, the Company reached a settlement with Glenmark regarding the financial and contractual terms impacted by this decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed the Company of its non-renewal of the co-promotion agreement.

ALK, Mission and Glenmark (each, a Partner) each agreed to reimburse the Company for certain expenses, including a proportion of product support expenses. All such payments are accounted for as reductions to selling, general and administrative expense. Each Partner has been entitled to a share of gross profits totaling more than 50% from the sale of OTIPRIO to each Partner’s accounts. The Company’s payments to each Partner for its portion of the gross profit is recognized as selling, general and administrative expense. The Company is the principal in the product sale of OTIPRIO and recognizes all revenue and related cost of product sales. For the years ended December 31, 2020 and 2019, the Company recognized reductions in selling, general and administrative expenses related to the Co-Promotion Agreements of $0.3 million and $2.6 million, respectively.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

12. Income Taxes

Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed a preliminary IRC Section 382/383 analysis, regarding the limitation of net operating loss and research and development credit carryforwards as of December 31, 2020 and does not believe there to have been an ownership change during the year then ended. The Company will continue to consider changes in ownership that may cause losses of tax attributes in the future.

Significant components of the Company’s deferred tax assets are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

88,013

 

 

$

78,768

 

Research and development credits

 

 

9,985

 

 

 

8,920

 

Depreciation and amortization

 

 

10,212

 

 

 

12,608

 

Accrued expenses

 

 

850

 

 

 

381

 

Lease liabilities

 

 

3,816

 

 

 

4,349

 

Stock compensation

 

 

3,856

 

 

 

4,395

 

Other, net

 

 

234

 

 

 

181

 

Total deferred tax assets

 

 

116,966

 

 

 

109,602

 

Less: valuation allowance

 

 

(113,826

)

 

 

(105,990

)

Total deferred tax assets, net of valuation allowance

 

 

3,140

 

 

 

3,612

 

Deferred tax liability:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(3,140

)

 

 

(3,612

)

Total deferred tax liability

 

 

(3,140

)

 

 

(3,612

)

Total

 

$

—

 

 

$

—

 

Due to the Company’s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company’s net deferred tax assets, as it is more likely than not that such net assets will not be realized. A valuation allowance of approximately $113.8 million and $106.0 million has been established as of December 31, 2020 and 2019, respectively.

At December 31, 2020, the Company had federal and state net operating loss carryforwards of approximately $382.8 million net of IRC Section 382 limitations and $124.8 million, respectively. Of the federal net operating loss carryforwards, approximately $142.2 million were generated after January 1, 2018, and therefore do not expire. Federal net operating losses that occur after January 1, 2018 are subject to a taxable income limitation of 80% in accordance with the Tax Cuts and Jobs Act of 2017 (the TCJA). The remaining federal and state net operating loss carryforwards will begin to expire in 2030, unless previously utilized. As of December 31, 2020, the Company also had federal and California research and development credit carryforwards of approximately $12.0 million net of IRC Section 383 limitations and $5.8 million, respectively. The federal research and development credit carryforwards will begin expiring in 2030, unless previously utilized. The California research credit will carry forward indefinitely.

The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those currently reported for the years ended December 31 (in thousands):

 

 

 

2020

 

 

2019

 

 

2018

 

Federal statutory rate

 

$

(9,393

)

 

$

(9,382

)

 

$

(10,578

)

State tax (net of federal benefit)

 

 

334

 

 

 

299

 

 

 

(4,383

)

Permanent items, other

 

 

9

 

 

 

189

 

 

 

(2,092

)

Stock compensation

 

 

1,595

 

 

 

2,470

 

 

 

2,570

 

Other adjustments

 

 

687

 

 

 

523

 

 

 

—

 

Research and development credits

 

 

(1,774

)

 

 

(1,595

)

 

 

(2,308

)

Uncertain tax positions

 

 

710

 

 

 

638

 

 

 

907

 

Change in valuation allowance

 

 

7,832

 

 

 

6,858

 

 

 

15,884

 

Provision for income taxes

 

$

0

 

 

$

0

 

 

$

0

 

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Balance at the beginning of the year

 

$

10,739

 

 

$

10,052

 

 

$

9,098

 

Adjustments related to prior year tax positions

 

 

(21

)

 

 

(80

)

 

 

242

 

Increases related to current year tax positions

 

 

796

 

 

 

767

 

 

 

712

 

 

 

$

11,514

 

 

$

10,739

 

 

$

10,052

 

The Company’s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has no accruals for interest or penalties in the balance sheets as of December 31, 2020 and 2019 and has not recognized interest or penalties in the statements of operations for the years ended December 31, 2020, 2019 and 2018.

Due to the valuation allowance recorded against the Company’s net deferred tax assets, future changes in unrecognized tax benefits will not impact the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.

The Company is subject to taxation in the United States for federal and state purposes. Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination by the IRS and state tax authorities for all years since inception. The Company is not currently under examination by the federal or any state tax authority.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Description of Business and Basis of Presentation (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The Company follows Accounting Standards Codification (ASC) Topic 205-40, Presentation of Financial Statements—Going Concern, which requires that management evaluate whether there are relevant conditions and events that in aggregate raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating activities since inception. In July 2020, the Company sold in a public offering 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase 4,000,000 shares of its common stock for $64.2 million in net proceeds after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2020, the Company had cash, cash equivalents and short-term investments of $86.3 million, outstanding debt of $15.2 million and an accumulated deficit of $504.6 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory approvals for OTIVIDEX, OTO-313, OTO-413 and its other product candidates; and (ii) works to develop additional product candidates through research and development programs.

When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or other sources, such as potential collaboration agreements. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all.  If the Company is not able to secure adequate additional funding, if or when necessary, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.  The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for a period of at least twelve months from the date of this report.
Use of Estimates

Use of Estimates

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Segment Reporting

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
Concentrations of Credit Risk

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.
Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available checking, savings and money market accounts.

The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s corporate headquarters.
Short-Term Investments

Short-term Investments

The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 8 – Fair Value).

Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis, and whenever events or changes

in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records unrealized gains and losses on available-for-sale debt securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders’ equity on the balance sheets. The Company does not hold equity securities in its investment portfolio.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value.
Inventory

Inventory

Inventory is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost to sell. During the year ended December 31, 2020, the Company recorded an inventory write down of $0.3 million to cost of product sales. During the years ended December 31, 2019 and 2018, no such write downs were recorded.
Property and Equipment, Net

Property and Equipment, Net

Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2020, 2019 and 2018.
Right-of-Use Assets and Lease Liabilities

Right-of-Use Assets and Lease Liabilities

The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. The Company determines if an arrangement is or contains a lease at each commencement date. Accounting Standards Codification (ASC) 842, Leases (ASC 842) establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02) provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases.

Operating leases are included in ROU assets, Leases, current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on the balance sheets. The Company has elected a policy not to recognize short-term leases (one year or less) on the balance sheets. ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease

payments over the lease term at the commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
Clinical Trial Expense Accruals

Clinical Trial Expense Accruals

The Company estimates expenses resulting from its obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided.

The Company records clinical trial expenses in the period in which services are performed and efforts are expended. The Company accrues for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company estimates accruals through financial models taking into account discussion with applicable personnel and outside service providers as to the progress of trials. During the course of a clinical trial, the Company may adjust its clinical accruals if actual results differ from its estimates.
Revenue Recognition

Revenue Recognition

The Company recognizes revenue by performing the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under ASC Topic 606, Revenue from Contracts with Customers (ASC 606) and when it is probable the Company will collect the consideration exchanged for the goods or services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of OTIPRIO, typically upon delivery by the Company to these distributors. The Company has determined the delivery of OTIPRIO to its customers constitutes a single performance obligation and no other performance obligations are present. The Company’s customer contracts have standard payment terms. The Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.

Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are not permitted. To date, product returns have been immaterial.

Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year or the amount is immaterial.
Concentration of Major Customers

Concentration of Major Customers

The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest customers for each of the periods presented:

 

 

 

 

2020

 

 

2019

 

 

2018

 

First largest

 

 

41

%

 

 

38

%

 

 

44

%

Second largest

 

 

29

%

 

 

33

%

 

 

33

%

Third largest

 

 

24

%

 

 

24

%

 

 

21

%

 
Collaborative Arrangements

Collaborative Arrangements

The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, Collaborative Arrangements (ASC 808).

Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.

Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the statements of operations.
Research and Development

Research and Development

Research and development expenses include the costs associated with the Company’s research and development activities, including salaries, benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.
Selling, General and Administrative

Selling, General and Administrative

Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s partners under its co-promotion agreements.
Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-based vesting conditions, stock-based compensation expense is recognized using the straight-line method.  For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.
Income Taxes

Income Taxes

The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
Comprehensive Loss

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources.
Net Loss Per Share

Net Loss Per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

As of December 31, 2020, 2019 and 2018, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of outstanding options to purchase 9,842,744, 7,495,129 and 5,019,964 shares of the Company’s common stock, respectively.
Risks and Uncertainties Related to COVID-19

Risks and Uncertainties Related to COVID-19

In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 pandemic could pose significant risks to the Company’s business; however, the ultimate impact of the pandemic is highly uncertain.

The Company has clinical trial sites in the United States and Europe, which may be affected by travel or quarantine restrictions imposed by federal, state or local governments due to the COVID-19 pandemic. In light of the significant uncertainty regarding the impact of the COVID-19 pandemic, the Company had suspended and subsequently updated its guidance regarding timing of trial results. The Company may in the future need to further update or suspend such guidance as a result of the impact of the COVID-19 pandemic.  In addition, the Company has made and it (and its contract research organizations (CROs)) may need to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial data integrity during the pandemic in accordance with the guidance issued by the FDA in 2020, among other activity.  Third-party manufacturers which the Company uses for the supply of materials for its product candidates or other materials necessary to conduct preclinical studies and clinical trials are located in countries affected by COVID-19.  Although the Company expects no material impact on the clinical supply of its product candidates for its current clinical trials, should its third-party manufacturers experience extended disruptions, the Company could experience delays in future trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA and similar organizations outside the United States, as well as local regulatory agencies and health officials, which may delay the development of the Company’s product candidates.

The Company continues to evaluate the impact COVID-19 may have on its ability to effectively conduct its business operations as planned, and work with healthcare providers supporting its clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies and may take further actions as may be required by federal, state or local authorities or that the Company determines are in the best interests of public health and safety and that of patients, employees, partners, and stockholders.  Nonetheless,

the Company does not yet know and cannot predict the full extent of potential delays or impacts on its business, its preclinical programs and clinical trials, healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the COVID-19 pandemic will have on the Company’s business, strategy, collaborations, financial condition, liquidity and future results of operations.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

Not Yet Adopted

In June 2016, ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable. ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect on its financial position, results of operations or cash flows.

Recently Adopted

Effective January 1, 2020, the Company early adopted ASU No. 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 removes the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, other comprehensive income).

ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 is effective for the Company beginning January 1, 2020. There was no cumulative effect to be recognized in connection with the early adoption of ASU 2019-12 and the adoption did not have a material impact on the Company’s financial statements or disclosures.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Sales to Largest Customers The following table summarizes the Company’s sales to its largest customers for each of the periods presented:

 

 

2020

 

 

2019

 

 

2018

 

First largest

 

 

41

%

 

 

38

%

 

 

44

%

Second largest

 

 

29

%

 

 

33

%

 

 

33

%

Third largest

 

 

24

%

 

 

24

%

 

 

21

%

 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Available-for-Sale Securities (Tables)
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Schedule of Available-for-Sale Debt Securities Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and were as follows (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Market Value

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

55,085

 

 

$

2

 

 

$

(1

)

 

$

55,086

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

—

 

 

 

490

 

 

 

$

55,575

 

 

$

2

 

 

$

(1

)

 

$

55,576

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 

 

 

$

35,465

 

 

$

16

 

 

$

(5

)

 

$

35,476

 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Prepaid and Other Current Assets

Prepaid and other current assets are comprised of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Inventory

 

$

227

 

 

$

478

 

Other

 

 

2,145

 

 

 

2,002

 

Total

 

$

2,372

 

 

$

2,480

 
Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

4,265

 

 

$

4,179

 

Manufacturing equipment

 

 

1,075

 

 

 

1,111

 

Computer equipment and software

 

 

989

 

 

 

943

 

Leasehold improvements

 

 

768

 

 

 

768

 

Office furniture

 

 

1,548

 

 

 

1,548

 

 

 

 

8,645

 

 

 

8,549

 

Less: accumulated depreciation and amortization

 

 

(5,879

)

 

 

(4,847

)

Total

 

$

2,766

 

 

$

3,702

 
Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued clinical trial costs

 

$

1,477

 

 

$

3,443

 

Accrued other

 

 

1,476

 

 

 

1,999

 

Total

 

$

2,953

 

 

$

5,442

 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Schedule of Additional Milestone Payments under Intellectual Property License Agreements The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements covering OTIPRIO, OTIVIDEX, OTO-313 and OTO-413 as follows (in thousands):

Development

 

$

1,250

 

Regulatory

 

 

10,275

 

Commercialization

 

 

1,000

 

Total

 

$

12,525

 
Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations

The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable royalty and milestone obligations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

License and other fees

 

$

500

 

 

$

—

 

 

$

—

 

Milestone fees

 

 

250

 

 

 

100

 

 

 

—

 

Total license and related fees

 

$

750

 

 

$

100

 

 

$

—

 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Debt (Tables)
 12 Months Ended
Dec. 31, 2020
Long Term Debt [Abstract]  
Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations

 

The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2020 for the next three fiscal years were as follows:

 

2021

 

$

—

 

2022

 

 

7,826

 

2023

 

 

7,774

 

Subtotal

 

 

15,600

 

Unamortized discount

 

 

(442

)

Total long-term debt, net

 

$

15,158

 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Summary of Lease Expenses

 

 

Years Ended December 31,

 

Lease expenses:

 

2020

 

 

2019

 

Operating lease expenses

 

$

3,137

 

 

$

3,137

 

Variable lease expenses

 

 

793

 

 

 

942

 

Total lease expenses

 

$

3,930

 

 

$

4,079

 

 
Future Minimum Annual Obligations under Finance and Operating Lease Commitments

Lease Maturities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Leases

 

 

Finance Leases

 

 

Total

 

2021

 

$

3,247

 

 

$

18

 

 

$

3,265

 

2022

 

 

3,333

 

 

—

 

 

 

3,333

 

2023

 

 

3,433

 

 

—

 

 

 

3,433

 

2024

 

 

3,536

 

 

—

 

 

 

3,536

 

2025

 

 

3,642

 

 

—

 

 

 

3,642

 

Thereafter

 

 

6,642

 

 

—

 

 

 

6,642

 

Total minimum lease payments

 

 

23,833

 

 

 

18

 

 

 

23,851

 

Imputed interest

 

 

(6,739

)

 

 

—

 

 

 

(6,739

)

Total

 

 

17,094

 

 

 

18

 

 

 

17,112

 

Less: leases, current

 

 

(3,247

)

 

 

(18

)

 

 

(3,265

)

Leases, net of current

 

$

13,847

 

 

$

—

 

 

$

13,847

 

 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Assets Measured on a Recurring Basis The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis (in thousands):

 

 

Fair Value Measurement at Reporting Date Using

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

23,278

 

 

$

23,278

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

55,086

 

 

 

55,086

 

 

 

—

 

 

 

—

 

Certificates of deposit

 

 

490

 

 

 

—

 

 

 

490

 

 

 

—

 

 

 

$

78,854

 

 

$

78,364

 

 

$

490

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

22,121

 

 

$

22,121

 

 

$

—

 

 

$

—

 

U.S. Treasury securities

 

 

35,476

 

 

 

35,476

 

 

 

—

 

 

 

—

 

 

 

$

57,597

 

 

$

57,597

 

 

$

—

 

 

$

—

 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Shares of Common Stock Reserved for Future Issuance

Shares of common stock reserved for future issuance are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Common stock options issued and outstanding

 

 

9,842,744

 

 

 

7,495,129

 

Pre-funded warrants to purchase common stock

 

 

4,000,000

 

 

 

—

 

Common stock options available for future grant

 

 

2,553,854

 

 

 

3,548,214

 

Common stock reserved for issuance under ESPP

 

 

2,301,704

 

 

 

1,977,215

 

Total common stock reserved for future issuance

 

 

18,698,302

 

 

 

13,020,558

 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans (Tables)
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock Option Activity The following table summarizes stock option activity for the year ended December 31, 2020 (in thousands except per share amounts and years):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-

Average

Remaining

Contractual

Term

(In Years)

 

 

Aggregate

Intrinsic Value

 

Outstanding as of December 31, 2019

 

 

7,495

 

 

$

4.43

 

 

 

 

 

 

 

 

 

Granted

 

 

3,099

 

 

$

3.46

 

 

 

 

 

 

 

 

 

Exercised

 

 

(92

)

 

$

2.23

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(659

)

 

$

4.93

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options vested and expected to vest as of

   December 31, 2020

 

 

9,843

 

 

$

4.11

 

 

 

7.1

 

 

$

25,706

 

Options exercisable as of December 31, 2020

 

 

5,160

 

 

$

4.84

 

 

 

5.7

 

 

$

10,890

 
Summary of Certain Information Regarding Stock Options

The following table summarizes certain information regarding stock options (in thousands, except per share data):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Weighted-average grant date fair value per share of

   options granted during the period

 

$

2.68

 

 

$

1.64

 

 

$

4.36

 

Cash received from options exercised during the

   period

 

 

206

 

 

 

5

 

 

 

32

 

Intrinsic value of options exercised during the period

 

 

59

 

 

 

2

 

 

 

76

 
Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights

The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-Scholes-Merton option pricing model:

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Stock Options:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

1.5

%

 

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

96.7

%

 

 

98.1

%

 

 

100.6

%

Expected term (in years)

 

 

6.1

 

 

 

6.1

 

 

 

5.4

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

 

 

 

Risk-free interest rate

 

 

0.1

%

 

 

2.0

%

 

 

2.6

%

Expected dividend yield

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Expected volatility

 

 

69.8

%

 

 

69.5

%

 

 

116.0

%

Expected term (in years)

 

 

1.3

 

 

 

1.3

 

 

 

1.3

 
Summary of Non-cash Stock Based Compensation Expense

Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Cost of product sales

 

$

13

 

 

$

12

 

 

$

12

 

Research and development

 

 

2,456

 

 

 

2,085

 

 

 

4,447

 

Selling, general and administrative

 

 

3,642

 

 

 

2,793

 

 

 

7,955

 

Total stock-based compensation

 

$

6,111

 

 

$

4,890

 

 

$

12,414

 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Components of Deferred Tax Assets

Significant components of the Company’s deferred tax assets are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

88,013

 

 

$

78,768

 

Research and development credits

 

 

9,985

 

 

 

8,920

 

Depreciation and amortization

 

 

10,212

 

 

 

12,608

 

Accrued expenses

 

 

850

 

 

 

381

 

Lease liabilities

 

 

3,816

 

 

 

4,349

 

Stock compensation

 

 

3,856

 

 

 

4,395

 

Other, net

 

 

234

 

 

 

181

 

Total deferred tax assets

 

 

116,966

 

 

 

109,602

 

Less: valuation allowance

 

 

(113,826

)

 

 

(105,990

)

Total deferred tax assets, net of valuation allowance

 

 

3,140

 

 

 

3,612

 

Deferred tax liability:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(3,140

)

 

 

(3,612

)

Total deferred tax liability

 

 

(3,140

)

 

 

(3,612

)

Total

 

$

—

 

 

$

—

 
Reconciliation of Expected Recovery of Income Taxes

The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those currently reported for the years ended December 31 (in thousands):

 

 

 

2020

 

 

2019

 

 

2018

 

Federal statutory rate

 

$

(9,393

)

 

$

(9,382

)

 

$

(10,578

)

State tax (net of federal benefit)

 

 

334

 

 

 

299

 

 

 

(4,383

)

Permanent items, other

 

 

9

 

 

 

189

 

 

 

(2,092

)

Stock compensation

 

 

1,595

 

 

 

2,470

 

 

 

2,570

 

Other adjustments

 

 

687

 

 

 

523

 

 

 

—

 

Research and development credits

 

 

(1,774

)

 

 

(1,595

)

 

 

(2,308

)

Uncertain tax positions

 

 

710

 

 

 

638

 

 

 

907

 

Change in valuation allowance

 

 

7,832

 

 

 

6,858

 

 

 

15,884

 

Provision for income taxes

 

$

0

 

 

$

0

 

 

$

0

 
Unrecognized Tax Benefit

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Balance at the beginning of the year

 

$

10,739

 

 

$

10,052

 

 

$

9,098

 

Adjustments related to prior year tax positions

 

 

(21

)

 

 

(80

)

 

 

242

 

Increases related to current year tax positions

 

 

796

 

 

 

767

 

 

 

712

 

 

 

$

11,514

 

 

$

10,739

 

 

$

10,052

 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended
Jul. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Description Of Business And Basis Of Presentation [Line Items]      
Cash, cash equivalents and short-term investments   $ 86,300  
Accumulated deficit   $ (504,624) $ (459,893)
Common stock sold in public offering 17,275,000    
Debt outstanding $ 15,200    
Warrants to purchase common stock 4,000,000    
Net proceeds after deducting underwriters commission $ 64,200    
IPO [Member]      
Description Of Business And Basis Of Presentation [Line Items]      
Common stock sold in public offering 17,275,000    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
USD ($)
Segment
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]      
Number of operating segment | Segment 1    
Inventory write-down $ 300,000 $ 0 $ 0
Impairment of long-lived assets $ 0 $ 0 $ 0
Options to Purchase Common Stock [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Potentially dilutive securities excluded from the calculation of diluted net loss per share | shares 9,842,744 7,495,129 5,019,964
Minimum [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Property and equipment useful lives 2 years    
Maximum [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Property and equipment useful lives 10 years    
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail) - Customer Concentration Risk [Member] - Sales Revenue, Net [Member]
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Customer One [Member]      
Entity Wide Revenue Major Customer [Line Items]      
Concentration risk percentage 41.00% 38.00% 44.00%
Customer Two [Member]      
Entity Wide Revenue Major Customer [Line Items]      
Concentration risk percentage 29.00% 33.00% 33.00%
Customer Three [Member]      
Entity Wide Revenue Major Customer [Line Items]      
Concentration risk percentage 24.00% 24.00% 21.00%
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Available-for-Sale Securities - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
USD ($)
Security
Dec. 31, 2019
USD ($)
Schedule of Available-for-sale Securities [Line Items]    
Number of available-for-sale securities in unrealized loss positions for less than twelve months | Security 4  
Other-than-temporary declines in the value of any available-for-sale securities $ 0  
Maximum maturity of available-for-sale debt securities 1 year  
Available-for-sale Securities [Member] | Money Market Funds and Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Cash equivalents $ 23,300,000 $ 22,100,000
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 55,575 $ 35,465
Unrealized Gains 2 16
Unrealized Losses (1) (5)
Market Value 55,576 35,476
U.S. Treasury Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 55,085 35,465
Unrealized Gains 2 16
Unrealized Losses (1) (5)
Market Value 55,086 $ 35,476
Certificates Of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 490  
Unrealized Gains 0  
Unrealized Losses 0  
Market Value $ 490  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details - Prepaid and Other Current Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]    
Inventory $ 227 $ 478
Other 2,145 2,002
Total $ 2,372 $ 2,480
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details - Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 8,645 $ 8,549
Less: accumulated depreciation and amortization (5,879) (4,847)
Total 2,766 3,702
Laboratory Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 4,265 4,179
Manufacturing Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,075 1,111
Computer Equipment and Software [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 989 943
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 768 768
Office Furniture [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,548 $ 1,548
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Property Plant And Equipment [Abstract]      
Depreciation expense $ 1,062 $ 1,149 $ 1,186
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheet Details - Accrued Expenses (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Payables And Accruals [Abstract]    
Accrued clinical trial costs $ 1,477 $ 3,443
Accrued other 1,476 1,999
Total $ 2,953 $ 5,442
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Jul. 31, 2020
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2020
USD ($)
Milestone
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
May 31, 2015
USD ($)
Other Commitments [Line Items]            
Operating lease term   130 months        
Additional operating lease term   5 years 5 years      
Period after which company has the right to terminate lease if it is acquired by a third party and pays early termination fee   94 months 94 months      
Monthly base rent for first year   $ 232,000        
Lease rate increase, percentage   3.00%        
Abatement period of monthly base rent   10 months        
Estimated base rent payments over the life of lease   $ 32,700,000        
Milestone fees     $ 250,000 $ 100,000 $ 0  
Research and development     27,997,000 $ 32,805,000 $ 31,844,000  
License Agreement [Member]            
Other Commitments [Line Items]            
Additional payments due upon demonstration $ 500,000          
Upfront Payment [Member] | License Agreement [Member]            
Other Commitments [Line Items]            
Payment to acquire worldwide rights 500,000          
Research and development $ 500,000          
Intellectual Property [Member]            
Other Commitments [Line Items]            
Milestone fees     $ 3,200,000      
Maximum percentage of royalties on sales     5.00%      
Intellectual Property [Member] | Regulatory [Member]            
Other Commitments [Line Items]            
Number of milestones achieved | Milestone     1      
Milestones potential cash payment     $ 1,000,000.0      
Intellectual Property [Member] | Development [Member]            
Other Commitments [Line Items]            
Number of milestones achieved | Milestone     8      
Royalty Agreements [Member]            
Other Commitments [Line Items]            
Maximum percentage of royalties on sales     1.00%      
Royalty period     10 years      
Data License Agreement [Member]            
Other Commitments [Line Items]            
Description of royalties payable     The Company is obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees      
Maximum cumulative royalties paid under license agreement     $ 10,000,000.0      
Building [Member]            
Other Commitments [Line Items]            
Construction commencement period   2016-12        
Restricted Cash [Member]            
Other Commitments [Line Items]            
Security deposit in the form of letter of credit           $ 700,000
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Other Commitments [Line Items]  
Cash Payments $ 12,525
Development [Member]  
Other Commitments [Line Items]  
Cash Payments 1,250
Regulatory [Member]  
Other Commitments [Line Items]  
Cash Payments 10,275
Commercialization [Member]  
Other Commitments [Line Items]  
Cash Payments $ 1,000
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]      
License and other fees $ 500 $ 0 $ 0
Milestone fees 250 100 0
Total license and related fees $ 750 $ 100 $ 0
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Debt - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Apr. 10, 2020
Dec. 31, 2019
Debt Instrument [Line Items]      
Debt discount, amount $ 442    
Term Loan outstanding 15,158   $ 14,967
Accounts Payable [Member]      
Debt Instrument [Line Items]      
Accrued interest 100    
Secured Term Loan Credit Facility [Member]      
Debt Instrument [Line Items]      
Debt instrument, face amount $ 15,000    
Facility fee percentage 0.75%    
Debt instrument, maturity date Dec. 01, 2023    
Interest rate description The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to time, plus 3.75% (9.0% as of December 31, 2020, the minimum interest rate).    
Debt instrument, interest rate at period end 9.00%    
Debt instrument, minimum interest rate 9.00%    
Interest frequency payments monthly    
Interest only payment term 24 months    
Interest only payment extension term 36 months    
Repayment fee percentage 4.00%    
Debt discount, amount $ 600    
Debt instrument, covenant description The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations, reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained compliance with all such covenants to date.    
Interest expense, including amortization of the debt discount $ 1,600    
Term Loan outstanding $ 15,200    
Secured Term Loan Credit Facility [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Debt instrument, reference rate 5.25%    
Debt instrument, basis spread on variable rate 3.75%    
Secured Term Loan Credit Facility [Member] | Thereafter Second Anniversary of Closing Date [Member]      
Debt Instrument [Line Items]      
Percentage of debt prepayment fee 1.00%    
Secured Term Loan Credit Facility [Member] | Occurrence and During Continuance of Event of Default [Member]      
Debt Instrument [Line Items]      
Increase in applicable rate of interest 5.00%    
Unsecured Loan [Member] | PPP Loan [Member] | JPMorgan Chase Bank, N.A. [Member] | CARES Act Of 2020 [Member]      
Debt Instrument [Line Items]      
Loans amount   $ 1,100  
Interest rate   0.98%  
Loan term   2 years  
Date of early repayment of loan in full Apr. 23, 2020    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Long Term Debt [Abstract]  
2021 $ 0
2022 7,826
2023 7,774
Subtotal 15,600
Unamortized discount (442)
Total long-term debt, net $ 15,158
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Additional Information (Detail) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2016
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Lessee Lease Description [Line Items]        
Operating lease, description   The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from 48 months to 130 months.    
Operating lease term 130 months      
Operating lease, option to extend   true    
Operating lease, option to extend description   The facility lease has an option for the Company to extend the lease term for an additional five years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the lease liability.    
Additional operating lease term 5 years 5 years    
Operating lease term ending year   2027    
Operating lease, option to terminate   true    
Operating lease, option to terminate description   The Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee.    
Period after which company has the right to terminate lease if it is acquired by a third party and pays early termination fee 94 months 94 months    
Rent expense   $ 3.1 $ 3.1 $ 3.1
Computer Equipment [Member]        
Lessee Lease Description [Line Items]        
Operating lease, description   On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at the end of the lease term based upon the then fair market value of the equipment.    
Operating lease term   24 months    
Finance lease, description   On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to purchase the equipment at the end of the lease term that is expected to be exercised.    
Finance lease initial term   24 months    
Finance lease right-of-use asset amortization term   3 years    
Minimum [Member]        
Lessee Lease Description [Line Items]        
Operating lease term   48 months    
Maximum [Member]        
Lessee Lease Description [Line Items]        
Operating lease term   130 months    
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Summary of Lease Expenses (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Lease expenses:    
Operating lease expenses $ 3,137 $ 3,137
Variable lease expenses 793 942
Total lease expenses $ 3,930 $ 4,079
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating Leases, 2021 $ 3,247  
Operating Leases, 2022 3,333  
Operating Leases, 2023 3,433  
Operating Leases, 2024 3,536  
Operating Leases, 2025 3,642  
Operating Leases, Thereafter 6,642  
Operating Leases, Total minimum lease payments 23,833  
Operating Leases, Imputed interest (6,739)  
Operating Leases, Total 17,094  
Operating Leases, Less: leases, current $ (3,247)  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:OtherCurrentLiabilitiesMember  
Operating Leases, Leases, net of current $ 13,847  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherNoncurrentLiabilitiesMember  
Finance Leases, 2021 $ 18  
Finance Leases, 2022 0  
Finance Leases, 2023 0  
Finance Leases, 2024 0  
Finance Leases, 2025 0  
Finance Leases, Thereafter 0  
Finance Leases, Total minimum lease payments 18  
Finance Leases, Imputed interest 0  
Finance Leases, Total 18  
Finance Leases, Less: leases, current (18)  
Finance Leases, Leases, net of current 0  
2021 3,265  
2022 3,333  
2023 3,433  
2024 3,536  
2025 3,642  
Thereafter 6,642  
Total minimum lease payments 23,851  
Imputed interest (6,739)  
Total 17,112  
Less: leases, current (3,265) $ (3,302)
Leases, net of current $ 13,847 $ 15,320
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value - Additional information (Detail) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Fair Value Measurements Nonrecurring [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Assets measured at fair value $ 0 $ 0
Liabilities measured at fair value 0 0
Fair Value Measurements, Recurring [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Assets measured at fair value 78,854,000 57,597,000
Liabilities measured at fair value $ 0 $ 0
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Assets    
Short-term investments $ 55,576 $ 35,476
U.S. Treasury Securities [Member]    
Assets    
Short-term investments 55,086 35,476
Certificates Of Deposit [Member]    
Assets    
Short-term investments 490  
Fair Value Measurements, Recurring [Member]    
Assets    
Assets measured at fair value 78,854 57,597
Fair Value Measurements, Recurring [Member] | Money Market Funds [Member]    
Assets    
Money market funds 23,278 22,121
Fair Value Measurements, Recurring [Member] | U.S. Treasury Securities [Member]    
Assets    
Short-term investments 55,086 35,476
Fair Value Measurements, Recurring [Member] | Certificates Of Deposit [Member]    
Assets    
Certificates of deposit 490  
Level 1 [Member] | Fair Value Measurements, Recurring [Member]    
Assets    
Assets measured at fair value 78,364 57,597
Level 1 [Member] | Fair Value Measurements, Recurring [Member] | Money Market Funds [Member]    
Assets    
Money market funds 23,278 22,121
Level 1 [Member] | Fair Value Measurements, Recurring [Member] | U.S. Treasury Securities [Member]    
Assets    
Short-term investments 55,086 35,476
Level 1 [Member] | Fair Value Measurements, Recurring [Member] | Certificates Of Deposit [Member]    
Assets    
Certificates of deposit 0  
Level 2 [Member] | Fair Value Measurements, Recurring [Member]    
Assets    
Assets measured at fair value 490 0
Level 2 [Member] | Fair Value Measurements, Recurring [Member] | Money Market Funds [Member]    
Assets    
Money market funds 0 0
Level 2 [Member] | Fair Value Measurements, Recurring [Member] | U.S. Treasury Securities [Member]    
Assets    
Short-term investments 0 0
Level 2 [Member] | Fair Value Measurements, Recurring [Member] | Certificates Of Deposit [Member]    
Assets    
Certificates of deposit 490  
Level 3 [Member] | Fair Value Measurements, Recurring [Member]    
Assets    
Assets measured at fair value 0 0
Level 3 [Member] | Fair Value Measurements, Recurring [Member] | Money Market Funds [Member]    
Assets    
Money market funds 0 0
Level 3 [Member] | Fair Value Measurements, Recurring [Member] | U.S. Treasury Securities [Member]    
Assets    
Short-term investments 0 $ 0
Level 3 [Member] | Fair Value Measurements, Recurring [Member] | Certificates Of Deposit [Member]    
Assets    
Certificates of deposit $ 0  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) - shares
Dec. 31, 2020
Dec. 31, 2019
Class of Stock [Line Items]    
Total common stock reserved for future issuance 18,698,302 13,020,558
Options to Purchase Common Stock [Member]    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 9,842,744 7,495,129
Pre-funded Warrants [Member]    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 4,000,000 0
Available Future Grant Year [Member] | Options to Purchase Common Stock [Member]    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 2,553,854 3,548,214
2014 Employee Stock Purchase Plan [Member]    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 2,301,704 1,977,215
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Jul. 31, 2020
Dec. 31, 2020
Class of Stock [Line Items]    
Common stock sold in public offering 17,275,000  
Shares issued, price per Share $ 3.25  
Net proceeds after deducting underwriters commission $ 64.2  
Ownership percentage of common stock 4.99%  
Prefunded warrants exercised   0
Pre-funded Warrants [Member]    
Class of Stock [Line Items]    
Shares issued, price per Share $ 3.249  
Warrants to purchase common stock 4,000,000  
Difference in offering price of warrants to offering price of common stock $ 0.001  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Jan. 01, 2021
Dec. 20, 2017
Feb. 28, 2018
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common shares reserved for issuance       18,698,302 13,020,558
Stock option granted       3,099,000  
Exchange of outstanding stock options, exercise price       $ 4.11 $ 4.43
Common stock exercise price       $ 3.46  
Number of common stock issued pursuant to ESPP purchases       595,555  
Unrecognized compensation costs related to stock options       $ 9.8  
Remaining weighted-average vesting period       2 years 6 months  
Unrecognized compensation cost related to stock options       $ 0.4  
Remaining weighted-average vesting period       1 year 2 months 12 days  
Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Contractual term of options   8 years      
Incremental fair value options   $ 0.6      
Performance-based Awards [Member] | Common Stock [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option granted     250,000    
Options to Purchase Common Stock [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common shares reserved for issuance       9,842,744 7,495,129
Options to Purchase Common Stock [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Option exchange program, expiration date   Jan. 19, 2018      
Exchange of outstanding stock options under option exchange program, closing price per share   $ 5.675      
Options to Purchase Common Stock [Member] | Common Stock [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares purchased   1,992,000      
Percentage of number of common stock purchased   81.51%      
Minimum [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share based compensation vesting period   1 year      
Minimum [Member] | Options to Purchase Common Stock [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Exchange of outstanding stock options, exercise price   $ 12.00      
Maximum [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share based compensation vesting period   3 years      
Equity Incentive Plan 2014 [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share based compensation vesting period       4 years  
Contractual term of options       10 years  
Annual increase in common shares reserved for issuance, percentage of total shares of common stock       5.00%  
Changes in share issuance, description       Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.  
Options available for grant       2,553,854  
Equity Incentive Plan 2014 [Member] | Options to Purchase Common Stock [Member] | Common Stock [Member] | Option Exchange [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option granted   1,570,328      
Common stock exercise price   $ 5.675      
Equity Incentive Plan 2014 [Member] | Subsequent Event [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual increase in common shares reserved for issuance 2,415,948        
Common shares reserved for issuance 4,969,802        
Equity Incentive Plan 2014 [Member] | Minimum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Exercise price, percentage of fair market value       100.00%  
Equity Incentive Plan 2014 [Member] | Maximum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual increase in common shares reserved for issuance       2,500,000  
2014 Employee Stock Purchase Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual increase in common shares reserved for issuance, percentage of total shares of common stock       1.50%  
Changes in share issuance, description       issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of (i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.  
Common shares reserved for issuance       2,301,704 1,977,215
Eligible compensation contribution       15.00%  
Offering periods under plan       24 months  
Offering period description       The offering periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and December 1 approximately twenty-four months later, and include six-month purchase periods.  
2014 Employee Stock Purchase Plan [Member] | Subsequent Event [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common shares reserved for issuance 3,026,488        
2014 Employee Stock Purchase Plan [Member] | Minimum [Member] | Subsequent Event [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual increase in common shares reserved for issuance 724,784        
2014 Employee Stock Purchase Plan [Member] | Maximum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual increase in common shares reserved for issuance       800,000  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
$ / shares
shares
Options  
Outstanding as of beginning of period | shares 7,495
Granted | shares 3,099
Exercised | shares (92)
Forfeited | shares (659)
Outstanding as of end of period | shares 9,843
Options vested and expected to vest | shares 9,843
Options exercisable | shares 5,160
Weighted- Average Exercise Price  
Outstanding as of beginning of period | $ / shares $ 4.43
Granted | $ / shares 3.46
Exercised | $ / shares 2.23
Forfeited | $ / shares 4.93
Outstanding as of end of period | $ / shares 4.11
Options vested and expected to vest | $ / shares 4.11
Options exercisable | $ / shares $ 4.84
Weighted-Average Remaining Contractual Term (In Years)  
Outstanding 7 years 1 month 6 days
Options vested and expected to vest 7 years 1 month 6 days
Options exercisable 5 years 8 months 12 days
Aggregate Intrinsic Value  
Outstanding | $ $ 25,706
Options vested and expected to vest | $ 25,706
Options exercisable | $ $ 10,890
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Weighted-average grant date fair value per share of options granted during the period $ 2.68 $ 1.64 $ 4.36
Cash received from options exercised during the period $ 206 $ 5 $ 32
Intrinsic value of options exercised during the period $ 59 $ 2 $ 76
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 1.50% 2.50% 2.60%
Expected dividend yield 0.00% 0.00% 0.00%
Expected volatility 96.70% 98.10% 100.60%
Expected term (in years) 6 years 1 month 6 days 6 years 1 month 6 days 5 years 4 months 24 days
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 0.10% 2.00% 2.60%
Expected dividend yield 0.00% 0.00% 0.00%
Expected volatility 69.80% 69.50% 116.00%
Expected term (in years) 1 year 3 months 18 days 1 year 3 months 18 days 1 year 3 months 18 days
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation $ 6,111 $ 4,890 $ 12,414
Cost of Product Sales [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation 13 12 12
Research and Development [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation 2,456 2,085 4,447
Selling, General and Administrative [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation $ 3,642 $ 2,793 $ 7,955
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements - Additional information (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
AGTC Collaboration [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Net receivable $ 0.1    
Glenmark Co-Promotion Agreement [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Payment of committed amount in settlement     $ 1.0
Mission Co-Promotion Agreement [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Decrease in selling general and administrative expenses $ 0.3 $ 2.6  
Mission Co-Promotion Agreement [Member] | Minimum [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Share of gross profits, percentage 50.00%    
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Net operating loss carryforwards $ 88,013 $ 78,768
Research and development credits 9,985 8,920
Depreciation and amortization 10,212 12,608
Accrued expenses 850 381
Lease liabilities 3,816 4,349
Stock compensation 3,856 4,395
Other, net 234 181
Total deferred tax assets 116,966 109,602
Less: valuation allowance (113,826) (105,990)
Total deferred tax assets, net of valuation allowance 3,140 3,612
Deferred tax liability:    
Right-of-use assets (3,140) (3,612)
Total deferred tax liability (3,140) (3,612)
Total $ 0 $ 0
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2018
Dec. 31, 2017
Income Taxes [Line Items]          
Valuation allowance $ 113,826,000 $ 105,990,000      
Net operating loss carryforwards       $ 142,200,000  
Percentage of taxable income limitation       80.00%  
Unrecognized tax benefit, income tax penalties and interest accrued 0       $ 0
Unrecognized tax benefits, income tax penalties and interest expense 0 $ 0 $ 0    
State and Local Jurisdiction [Member]          
Income Taxes [Line Items]          
Net operating loss carryforwards $ 124,800,000        
Net operating loss carryforwards, expiration will begin to expire in 2030        
Internal Revenue Service (IRS) [Member]          
Income Taxes [Line Items]          
Net operating loss carryforwards $ 382,800,000        
Net operating loss carryforwards, expiration will begin to expire in 2030        
Tax credit carryforwards $ 12,000,000.0        
Tax credit carryforwards, expiration will begin expiring in 2030        
California Franchise Tax Board [Member]          
Income Taxes [Line Items]          
Tax credit carryforwards $ 5,800,000        
Tax credit carryforwards, expiration indefinitely        
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Federal statutory rate $ (9,393) $ (9,382) $ (10,578)
State tax (net of federal benefit) 334 299 (4,383)
Permanent items, other 9 189 (2,092)
Stock compensation 1,595 2,470 2,570
Other adjustments 687 523 0
Research and development credits (1,774) (1,595) (2,308)
Uncertain tax positions 710 638 907
Change in valuation allowance 7,832 6,858 15,884
Provision for income taxes $ 0 $ 0 $ 0
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Balance at the beginning of the year $ 10,739 $ 10,052 $ 9,098
Adjustments related to prior year tax positions (21) (80) 242
Increases related to current year tax positions 796 767 712
Unrecognized Tax Benefits $ 11,514 $ 10,739 $ 10,052
EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 182 444 1 false 65 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Balance Sheets (Parenthetical) Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Statements of Operations Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Statements of Comprehensive Loss Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Statements of Stockholders' Equity Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity Statements of Stockholders' Equity Statements 6 false false R7.htm 100060 - Statement - Statements of Cash Flows Sheet http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Available-for-Sale Securities Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecurities Available-for-Sale Securities Notes 10 false false R11.htm 100100 - Disclosure - Balance Sheet Details Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingencies Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 100120 - Disclosure - Debt Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebt Debt Notes 13 false false R14.htm 100130 - Disclosure - Leases Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeases Leases Notes 14 false false R15.htm 100140 - Disclosure - Fair Value Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValue Fair Value Notes 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 100160 - Disclosure - Stock-Based Compensation and Equity Plans Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlans Stock-Based Compensation and Equity Plans Notes 17 false false R18.htm 100170 - Disclosure - Collaboration Agreements Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreements Collaboration Agreements Notes 18 false false R19.htm 100180 - Disclosure - Income Taxes Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Description of Business and Basis of Presentation (Policies) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies Description of Business and Basis of Presentation (Policies) Policies http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Available-for-Sale Securities (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesTables Available-for-Sale Securities (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecurities 22 false false R23.htm 100220 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails 23 false false R24.htm 100230 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies 24 false false R25.htm 100240 - Disclosure - Debt (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtTables Debt (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebt 25 false false R26.htm 100250 - Disclosure - Leases (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeases 26 false false R27.htm 100260 - Disclosure - Fair Value (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueTables Fair Value (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValue 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquity 28 false false R29.htm 100280 - Disclosure - Stock-Based Compensation and Equity Plans (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables Stock-Based Compensation and Equity Plans (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlans 29 false false R30.htm 100290 - Disclosure - Income Taxes (Tables) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxes 30 false false R31.htm 100300 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail Description of Business and Basis of Presentation - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail) Details 33 false false R34.htm 100330 - Disclosure - Available-for-Sale Securities - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail Available-for-Sale Securities - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail) Details 35 false false R36.htm 100350 - Disclosure - Balance Sheet Details - Prepaid and Other Current Assets (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail Balance Sheet Details - Prepaid and Other Current Assets (Detail) Details 36 false false R37.htm 100360 - Disclosure - Balance Sheet Details - Property and Equipment, Net (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail Balance Sheet Details - Property and Equipment, Net (Detail) Details 37 false false R38.htm 100370 - Disclosure - Balance Sheet Details - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail Balance Sheet Details - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Balance Sheet Details - Accrued Expenses (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail Balance Sheet Details - Accrued Expenses (Detail) Details 39 false false R40.htm 100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail) Details 41 false false R42.htm 100410 - Disclosure - Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail) Details 42 false false R43.htm 100420 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail) Details 44 false false R45.htm 100440 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Leases - Summary of Lease Expenses (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail Leases - Summary of Lease Expenses (Detail) Details 46 false false R47.htm 100460 - Disclosure - Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail) Details 47 false false R48.htm 100480 - Disclosure - Fair Value - Additional information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail Fair Value - Additional information (Detail) Details 48 false false R49.htm 100490 - Disclosure - Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail) Details 49 false false R50.htm 100500 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) Details 50 false false R51.htm 100510 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 51 false false R52.htm 100520 - Disclosure - Stock-Based Compensation and Equity Plans - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail Stock-Based Compensation and Equity Plans - Additional Information (Detail) Details 52 false false R53.htm 100530 - Disclosure - Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail) Details 53 false false R54.htm 100540 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfCertainInformationRegardingStockOptionsDetail Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail) Details 54 false false R55.htm 100550 - Disclosure - Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail) Details 55 false false R56.htm 100560 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail) Details 56 false false R57.htm 100570 - Disclosure - Collaboration Agreements - Additional information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail Collaboration Agreements - Additional information (Detail) Details 57 false false R58.htm 100580 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail Income Taxes - Components of Deferred Tax Assets (Detail) Details 58 false false R59.htm 100590 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 59 false false R60.htm 100600 - Disclosure - Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail) Details 60 false false R61.htm 100610 - Disclosure - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail) Sheet http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetail Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail) Details 61 false false All Reports Book All Reports otic-10k_20201231.htm otic-20201231.xsd otic-20201231_cal.xml otic-20201231_def.xml otic-20201231_lab.xml otic-20201231_pre.xml otic-ex231_10.htm otic-ex311_11.htm otic-ex312_7.htm otic-ex321_9.htm otic-ex322_8.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "otic-10k_20201231.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 182, "dts": { "calculationLink": { "local": [ "otic-20201231_cal.xml" ] }, "definitionLink": { "local": [ "otic-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "otic-10k_20201231.htm" ] }, "labelLink": { "local": [ "otic-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "otic-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "otic-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 583, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 26, "http://www.otonomy.com/20201231": 4, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 36 }, "keyCustom": 68, "keyStandard": 376, "memberCustom": 25, "memberStandard": 39, "nsprefix": "otic", "nsuri": "http://www.otonomy.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Available-for-Sale Securities", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecurities", "shortName": "Available-for-Sale Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Balance Sheet Details", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Commitments and Contingencies", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Debt", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Leases", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Fair Value", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stockholders' Equity", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-Based Compensation and Equity Plans", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlans", "shortName": "Stock-Based Compensation and Equity Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Collaboration Agreements", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreements", "shortName": "Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Description of Business and Basis of Presentation (Policies)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "shortName": "Description of Business and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Available-for-Sale Securities (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesTables", "shortName": "Available-for-Sale Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Balance Sheet Details (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCommitmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCommitmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Debt (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Leases (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Fair Value (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Stock-Based Compensation and Equity Plans (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables", "shortName": "Stock-Based Compensation and Equity Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Balance Sheets (Parenthetical)", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Income Taxes (Tables)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_oticSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_oticSegment", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_srtMajorCustomersAxis_oticCustomerOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Sales to Largest Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_srtMajorCustomersAxis_oticCustomerOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear", "reportCount": 1, "unique": true, "unitRef": "U_oticSecurity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail", "shortName": "Available-for-Sale Securities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear", "reportCount": 1, "unique": true, "unitRef": "U_oticSecurity", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "shortName": "Available-for-Sale Securities - Schedule of Available-for-Sale Debt Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Balance Sheet Details - Prepaid and Other Current Assets (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail", "shortName": "Balance Sheet Details - Prepaid and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Balance Sheet Details - Property and Equipment, Net (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail", "shortName": "Balance Sheet Details - Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "shortName": "Balance Sheet Details - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:AccruedClinicalTrialCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Details - Accrued Expenses (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail", "shortName": "Balance Sheet Details - Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:AccruedClinicalTrialCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Statements of Operations", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20161231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20161201_20161231", "decimals": "0", "lang": null, "name": "otic:InitialMonthlyBaseRent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:CashMilestonesUnderLicenseAgreements", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail", "shortName": "Commitments and Contingencies - Schedule of Additional Milestone Payments under Intellectual Property License Agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:CashMilestonesUnderLicenseAgreements", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "otic:CostsRecognizedUnderLicenseAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:LicenseAndOtherFees", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail", "shortName": "Commitments and Contingencies - Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "otic:CostsRecognizedUnderLicenseAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "otic:LicenseAndOtherFees", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Debt - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapBalanceSheetLocationAxis_us-gaapAccountsPayableAndAccruedLiabilitiesMember_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail", "shortName": "Debt - Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases - Summary of Lease Expenses (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail", "shortName": "Leases - Summary of Lease Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "otic:ScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail", "shortName": "Leases - Future Minimum Annual Obligations under Finance and Operating Lease Commitments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "otic:ScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsNonrecurringMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Fair Value - Additional information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail", "shortName": "Fair Value - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsNonrecurringMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail", "shortName": "Fair Value - Fair Value Assets Measured on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statements of Comprehensive Loss", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss", "shortName": "Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "shortName": "Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapAwardTypeAxis_oticPrefundedWarrantsMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200701_20200731", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200731", "decimals": "2", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stock-Based Compensation and Equity Plans - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "shortName": "Stock-Based Compensation and Equity Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail", "shortName": "Stock-Based Compensation and Equity Plans - Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfCertainInformationRegardingStockOptionsDetail", "shortName": "Stock-Based Compensation and Equity Plans - Summary of Certain Information Regarding Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail", "shortName": "Stock-Based Compensation and Equity Plans - Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation and Equity Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapTypeOfArrangementAxis_oticAGTCCollaborationMember_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "otic:AmountOfNetPaymentToBeReceivedFromCollaborationAgreementParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Collaboration Agreements - Additional information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "shortName": "Collaboration Agreements - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_us-gaapTypeOfArrangementAxis_oticAGTCCollaborationMember_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "otic:AmountOfNetPaymentToBeReceivedFromCollaborationAgreementParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail", "shortName": "Income Taxes - Components of Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20180101", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Stockholders' Equity", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity", "shortName": "Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail", "shortName": "Income Taxes - Reconciliation of Expected Recovery of Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail)", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20171231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Statements of Cash Flows", "role": "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Description of Business and Basis of Presentation", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation", "shortName": "Description of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "otic-10k_20201231.htm", "contextRef": "C_0001493566_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r463", "r464", "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r463", "r464", "r465" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "otic_AGTCCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGTC Collaboration.", "label": "A G T C Collaboration [Member]", "terseLabel": "AGTC Collaboration [Member]" } } }, "localname": "AGTCCollaborationMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_AccruedClinicalTrialCosts": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued clinical trial costs.", "label": "Accrued Clinical Trial Costs", "terseLabel": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialCosts", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "otic_AdditionalPaymentsDueUponDemonstration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional payments due upon demonstration.", "label": "Additional Payments Due Upon Demonstration", "terseLabel": "Additional payments due upon demonstration" } } }, "localname": "AdditionalPaymentsDueUponDemonstration", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_AmountOfNetPaymentToBeReceivedFromCollaborationAgreementParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net payment to be received from collaboration agreement party.", "label": "Amount Of Net Payment To Be Received From Collaboration Agreement Party", "terseLabel": "Net receivable" } } }, "localname": "AmountOfNetPaymentToBeReceivedFromCollaborationAgreementParty", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_AnnualPercentageIncreaseInMonthlyBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual percentage increase in monthly base rent.", "label": "Annual Percentage Increase In Monthly Base Rent", "terseLabel": "Lease rate increase, percentage" } } }, "localname": "AnnualPercentageIncreaseInMonthlyBaseRent", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_AvailableFutureGrantYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available future grant year.", "label": "Available Future Grant Year [Member]", "terseLabel": "Available Future Grant Year [Member]" } } }, "localname": "AvailableFutureGrantYearMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "otic_CARESActOf2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES Act Of 2020 [Member]", "label": "C A R E S Act Of2020 [Member]", "terseLabel": "CARES Act Of 2020 [Member]" } } }, "localname": "CARESActOf2020Member", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_CashMilestonesPotentialPaymentUnderLicenseAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash milestones potential payment under license agreements.", "label": "Cash Milestones Potential Payment Under License Agreements", "terseLabel": "Milestones potential cash payment" } } }, "localname": "CashMilestonesPotentialPaymentUnderLicenseAgreements", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_CashMilestonesUnderLicenseAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash milestones that may be incurred under license agreements.", "label": "Cash Milestones Under License Agreements", "terseLabel": "Cash Payments" } } }, "localname": "CashMilestonesUnderLicenseAgreements", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "otic_ClinicalTrialExpenseAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for clinical trial expense accruals.", "label": "Clinical Trial Expense Accruals Policy [Text Block]", "terseLabel": "Clinical Trial Expense Accruals" } } }, "localname": "ClinicalTrialExpenseAccrualsPolicyTextBlock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "otic_CollaborativeArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement disclosure.", "label": "Collaborative Arrangement Disclosure [Abstract]" } } }, "localname": "CollaborativeArrangementDisclosureAbstract", "nsuri": "http://www.otonomy.com/20201231", "xbrltype": "stringItemType" }, "otic_CommercializationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercialization.", "label": "Commercialization [Member]", "terseLabel": "Commercialization [Member]" } } }, "localname": "CommercializationMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "domainItemType" }, "otic_ComputersAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computers and software.", "label": "Computers And Software [Member]", "terseLabel": "Computer Equipment and Software [Member]" } } }, "localname": "ComputersAndSoftwareMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "otic_CostsRecognizedUnderLicenseAgreementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs recognized under license agreements.", "label": "Costs Recognized Under License Agreements Table [Text Block]", "terseLabel": "Summary of Costs Recognized under License Agreements and Other Non-Cancellable Royalty and Milestone Obligations" } } }, "localname": "CostsRecognizedUnderLicenseAgreementsTableTextBlock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "otic_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "otic_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "otic_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "otic_DebtInstrumentReferenceRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument reference rate.", "label": "Debt Instrument Reference Rate", "terseLabel": "Debt instrument, reference rate" } } }, "localname": "DebtInstrumentReferenceRate", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_DebtIssuanceCostsIncurredDuringNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt issuance costs incurred during noncash transaction included in accounts payable and accrued expenses.", "label": "Debt Issuance Costs Incurred During Noncash Transaction Included In Accounts Payable And Accrued Expenses", "terseLabel": "Debt issuance costs in accounts payable and accrued expenses" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "otic_DebtRepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt repayment fee percentage.", "label": "Debt Repayment Fee Percentage", "terseLabel": "Repayment fee percentage" } } }, "localname": "DebtRepaymentFeePercentage", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_DecreaseInSellingGeneralAndAdministrativeExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in selling general and administrative expenses.", "label": "Decrease In Selling General And Administrative Expenses", "terseLabel": "Decrease in selling general and administrative expenses" } } }, "localname": "DecreaseInSellingGeneralAndAdministrativeExpenses", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_DeferredTaxAssetsDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets depreciation and amortization.", "label": "Deferred Tax Assets Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxAssetsDepreciationAndAmortization", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "otic_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "otic_DescriptionOfBusinessAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business and basis of presentation.", "label": "Description Of Business And Basis Of Presentation [Line Items]", "terseLabel": "Description Of Business And Basis Of Presentation [Line Items]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_DescriptionOfBusinessAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description Of Business And Basis Of Presentation [Table]", "label": "Description Of Business And Basis Of Presentation [Table]", "terseLabel": "Description Of Business And Basis Of Presentation [Table]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationTable", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_DescriptionOfRoyaltyPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of royalty payment.", "label": "Description Of Royalty Payment", "terseLabel": "Description of royalties payable" } } }, "localname": "DescriptionOfRoyaltyPayment", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_DevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development.", "label": "Development [Member]", "terseLabel": "Development [Member]" } } }, "localname": "DevelopmentMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "domainItemType" }, "otic_DifferenceInOfferingPriceOfWarrantsToOfferingPriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Difference in offering price of warrants to offering price of common stock.", "label": "Difference In Offering Price Of Warrants To Offering Price Of Common Stock", "terseLabel": "Difference in offering price of warrants to offering price of common stock" } } }, "localname": "DifferenceInOfferingPriceOfWarrantsToOfferingPriceOfCommonStock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "otic_EarlyRepaymentOfLongTermDebtDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Early repayment of long term debt, Date.", "label": "Early Repayment Of Long Term Debt Date", "terseLabel": "Date of early repayment of loan in full" } } }, "localname": "EarlyRepaymentOfLongTermDebtDate", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "otic_EmployeeServiceShareBasedCompensationNonvestedAwardsOtherThanOptionsCompensationCostNotYetRecognizedPeriodForRecognition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans other than options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Other Than Options Compensation Cost Not Yet Recognized Period For Recognition", "terseLabel": "Remaining weighted-average vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsOtherThanOptionsCompensationCostNotYetRecognizedPeriodForRecognition", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_EmployeeStockPurchasePlanOfferingPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan offering period description.", "label": "Employee Stock Purchase Plan Offering Period Description", "terseLabel": "Offering period description" } } }, "localname": "EmployeeStockPurchasePlanOfferingPeriodDescription", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_EquityIncentivePlanTwoThousandFourteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity incentive plan two thousand fourteen.", "label": "Equity Incentive Plan Two Thousand Fourteen [Member]", "terseLabel": "Equity Incentive Plan 2014 [Member]" } } }, "localname": "EquityIncentivePlanTwoThousandFourteenMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_FinanceLeaseRightOfUseAssetAmortizationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance lease, right of use asset, amortization term.", "label": "Finance Lease Right Of Use Asset Amortization Term", "terseLabel": "Finance lease right-of-use asset amortization term" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortizationTerm", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_FinanceLeasesImputedInterest": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10030.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance leases imputed interest.", "label": "Finance Leases Imputed Interest", "negatedLabel": "Finance Leases, Imputed interest" } } }, "localname": "FinanceLeasesImputedInterest", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10080.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due after year five.", "label": "Future Minimum Lease Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "FutureMinimumLeasePaymentsDueAfterYearFive", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueInFiveYears": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10070.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due in five years.", "label": "Future Minimum Lease Payments Due In Five Years", "terseLabel": "2025" } } }, "localname": "FutureMinimumLeasePaymentsDueInFiveYears", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueInFourYears": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10060.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due in four years.", "label": "Future Minimum Lease Payments Due In Four Years", "terseLabel": "2024" } } }, "localname": "FutureMinimumLeasePaymentsDueInFourYears", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueInThreeYears": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10050.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due in three years.", "label": "Future Minimum Lease Payments Due In Three Years", "terseLabel": "2023" } } }, "localname": "FutureMinimumLeasePaymentsDueInThreeYears", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueInTwoYears": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10040.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due in two years.", "label": "Future Minimum Lease Payments Due In Two Years", "terseLabel": "2022" } } }, "localname": "FutureMinimumLeasePaymentsDueInTwoYears", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumLeasePaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10030.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments due next twelve months.", "label": "Future Minimum Lease Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "FutureMinimumLeasePaymentsDueNextTwelveMonths", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_FutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum payments due.", "label": "Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "FutureMinimumPaymentsDue", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_GlenmarkCoPromotionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glenmark Co Promotion Agreement.", "label": "Glenmark Co Promotion Agreement [Member]", "terseLabel": "Glenmark Co-Promotion Agreement [Member]" } } }, "localname": "GlenmarkCoPromotionAgreementMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_ImputedInterest": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10010.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Imputed interest.", "label": "Imputed Interest", "negatedLabel": "Imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_IncomeTaxReconciliationOtherPermanentItems": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10030.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation other permanent items.", "label": "Income Tax Reconciliation Other Permanent Items", "terseLabel": "Permanent items, other" } } }, "localname": "IncomeTaxReconciliationOtherPermanentItems", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "otic_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Table]", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (Decrease) in the net amount of right of use assets and lease liabilities, net.", "label": "Increase Decrease In Right Of Use Assets And Lease Liabilities Net", "terseLabel": "Right-of-use assets and lease liabilities, net" } } }, "localname": "IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "otic_InitialMonthlyBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial monthly base rent.", "label": "Initial Monthly Base Rent", "terseLabel": "Monthly base rent for first year" } } }, "localname": "InitialMonthlyBaseRent", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_JPMorganChaseBankNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "JPMorgan Chase Bank, N.A. [Member]", "label": "J P Morgan Chase Bank N A [Member]", "terseLabel": "JPMorgan Chase Bank, N.A. [Member]" } } }, "localname": "JPMorganChaseBankNAMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "otic_LeaseAbatementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease abatement period.", "label": "Lease Abatement Period", "terseLabel": "Abatement period of monthly base rent" } } }, "localname": "LeaseAbatementPeriod", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_LeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement month and year.", "label": "Lease Commencement Month And Year", "terseLabel": "Construction commencement period" } } }, "localname": "LeaseCommencementMonthAndYear", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "otic_LeaseExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration year", "label": "Lease Expiration Year", "terseLabel": "Operating lease term ending year" } } }, "localname": "LeaseExpirationYear", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "otic_LeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10020.0, "parentTag": "otic_FutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities.", "label": "Lease Liabilities", "totalLabel": "Total" } } }, "localname": "LeaseLiabilities", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_LeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10010.0, "parentTag": "otic_LeaseLiabilities", "weight": 1.0 }, "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities current.", "label": "Lease Liabilities Current", "negatedLabel": "Less: leases, current", "terseLabel": "Leases, current" } } }, "localname": "LeaseLiabilitiesCurrent", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "otic_LeaseLiabilitiesNonCurrent": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10020.0, "parentTag": "otic_LeaseLiabilities", "weight": 1.0 }, "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities non-current.", "label": "Lease Liabilities Non Current", "terseLabel": "Leases, net of current" } } }, "localname": "LeaseLiabilitiesNonCurrent", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "otic_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_LicenseAndOtherFees": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail": { "order": 10010.0, "parentTag": "otic_LicenseAndRelatedFees", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-milestone costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.", "label": "License And Other Fees", "terseLabel": "License and other fees" } } }, "localname": "LicenseAndOtherFees", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail" ], "xbrltype": "monetaryItemType" }, "otic_LicenseAndRelatedFees": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.", "label": "License And Related Fees", "totalLabel": "Total license and related fees" } } }, "localname": "LicenseAndRelatedFees", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail" ], "xbrltype": "monetaryItemType" }, "otic_LineOfCreditFacilityInterestOnlyPaymentsExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility interest only payments extension period.", "label": "Line Of Credit Facility Interest Only Payments Extension Period", "terseLabel": "Interest only payment extension term" } } }, "localname": "LineOfCreditFacilityInterestOnlyPaymentsExtensionPeriod", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_LineOfCreditFacilityInterestOnlyPaymentsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility interest only payments period.", "label": "Line Of Credit Facility Interest Only Payments Period", "terseLabel": "Interest only payment term" } } }, "localname": "LineOfCreditFacilityInterestOnlyPaymentsPeriod", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_LineOfCreditFacilityMinimumInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility minimum interest rate.", "label": "Line Of Credit Facility Minimum Interest Rate", "terseLabel": "Debt instrument, minimum interest rate" } } }, "localname": "LineOfCreditFacilityMinimumInterestRate", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_MaximumCumulativeRoyaltiesObligationThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum cumulative royalties obligation threshold.", "label": "Maximum Cumulative Royalties Obligation Threshold", "terseLabel": "Maximum cumulative royalties paid under license agreement" } } }, "localname": "MaximumCumulativeRoyaltiesObligationThreshold", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_MaximumPercentageOfRoyaltyOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of royalty on net sales.", "label": "Maximum Percentage Of Royalty On Net Sales", "terseLabel": "Maximum percentage of royalties on sales" } } }, "localname": "MaximumPercentageOfRoyaltyOnNetSales", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_MilestoneFees": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail": { "order": 10020.0, "parentTag": "otic_LicenseAndRelatedFees", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone costs incurred related to licensing agreements. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.", "label": "Milestone Fees", "terseLabel": "Milestone fees" } } }, "localname": "MilestoneFees", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCostsRecognizedUnderLicenseAgreementsAndOtherNonCancellableRoyaltyAndMilestoneObligationsDetail" ], "xbrltype": "monetaryItemType" }, "otic_MissionCoPromotionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mission co-promotion agreement.", "label": "Mission Co Promotion Agreement [Member]", "terseLabel": "Mission Co-Promotion Agreement [Member]" } } }, "localname": "MissionCoPromotionAgreementMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_MoneyMarketFundsAndCertificateOfDepositMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Money market funds and certificate of deposit.", "label": "Money Market Funds And Certificate Of Deposit [Member]", "terseLabel": "Money Market Funds and Certificates of Deposit [Member]" } } }, "localname": "MoneyMarketFundsAndCertificateOfDepositMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_NetProceedsAfterDeductingUnderwritersCommission": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds after deducting underwriters commission.", "label": "Net Proceeds After Deducting Underwriters Commission", "terseLabel": "Net proceeds after deducting underwriters commission", "verboseLabel": "Net proceeds after deducting underwriters commission" } } }, "localname": "NetProceedsAfterDeductingUnderwritersCommission", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_NumberOfMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestones achieved.", "label": "Number Of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "localname": "NumberOfMilestonesAchieved", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "otic_OccurrenceAndDuringContinuanceOfEventOfDefaultMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Occurrence and during continuance of event of default.", "label": "Occurrence And During Continuance Of Event Of Default [Member]", "terseLabel": "Occurrence and During Continuance of Event of Default [Member]" } } }, "localname": "OccurrenceAndDuringContinuanceOfEventOfDefaultMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_OperatingLeasesImputedInterest": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating leases imputed interest.", "label": "Operating Leases Imputed Interest", "negatedLabel": "Operating Leases, Imputed interest" } } }, "localname": "OperatingLeasesImputedInterest", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "otic_OwnershipPercentageOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage of common stock", "label": "Ownership Percentage Of Common Stock", "terseLabel": "Ownership percentage of common stock" } } }, "localname": "OwnershipPercentageOfCommonStock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan under paycheck protection program.", "label": "Paycheck Protection Program [Member]", "terseLabel": "PPP Loan [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_PaymentOfCommittedAmountInSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of committed amount in settlement.", "label": "Payment Of Committed Amount In Settlement", "terseLabel": "Payment of committed amount in settlement" } } }, "localname": "PaymentOfCommittedAmountInSettlement", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "otic_PercentageOfDebtPrepaymentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt prepayment fee.", "label": "Percentage Of Debt Prepayment Fee", "terseLabel": "Percentage of debt prepayment fee" } } }, "localname": "PercentageOfDebtPrepaymentFee", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_PercentageOfTaxableIncomeLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of taxable income limitation.", "label": "Percentage Of Taxable Income Limitation", "terseLabel": "Percentage of taxable income limitation" } } }, "localname": "PercentageOfTaxableIncomeLimitation", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_PeriodForRightToTerminateAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for right to terminate agreement.", "label": "Period For Right To Terminate Agreement", "terseLabel": "Period after which company has the right to terminate lease if it is acquired by a third party and pays early termination fee" } } }, "localname": "PeriodForRightToTerminateAgreement", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_PrefundedWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded warrants exercised", "label": "Prefunded Warrants Exercised", "terseLabel": "Prefunded warrants exercised" } } }, "localname": "PrefundedWarrantsExercised", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "otic_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded warrants member.", "label": "Prefunded Warrants [Member]", "terseLabel": "Pre-funded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "otic_ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and prefunded warrants, net of issuance costs.", "label": "Proceeds From Issuance Of Common Stock And Prefunded Warrants Net Of Issuance Costs", "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNetOfIssuanceCosts", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "otic_ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.", "label": "Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "otic_ProfitSharingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit sharing percentage.", "label": "Profit Sharing Percentage", "terseLabel": "Share of gross profits, percentage" } } }, "localname": "ProfitSharingPercentage", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_RegulatoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory.", "label": "Regulatory [Member]", "terseLabel": "Regulatory [Member]" } } }, "localname": "RegulatoryMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "domainItemType" }, "otic_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash [Member]" } } }, "localname": "RestrictedCashMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_RisksAndUncertaintiesRelatedToCOVID19PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for risks and uncertainties related to COVID-19.", "label": "Risks And Uncertainties Related To C O V I D19 Policy [Text Block]", "terseLabel": "Risks and Uncertainties Related to COVID-19" } } }, "localname": "RisksAndUncertaintiesRelatedToCOVID19PolicyTextBlock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "otic_RoyaltyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty period.", "label": "Royalty Period", "terseLabel": "Royalty period" } } }, "localname": "RoyaltyPeriod", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_ScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payments under non cancellable leases.", "label": "Schedule Of Future Minimum Lease Payments Under Non Cancellable Leases Table [Text Block]", "terseLabel": "Future Minimum Annual Obligations under Finance and Operating Lease Commitments" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesTableTextBlock", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "otic_SecuredTermLoanCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured term loan credit facility.", "label": "Secured Term Loan Credit Facility [Member]", "terseLabel": "Secured Term Loan Credit Facility [Member]" } } }, "localname": "SecuredTermLoanCreditFacilityMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAnnuallyPercentageOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award additional shares authorized annually percentage of common stock outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Annually Percentage Of Common Stock Outstanding", "terseLabel": "Annual increase in common shares reserved for issuance, percentage of total shares of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAnnuallyPercentageOfCommonStockOutstanding", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardClosingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, closing price per share.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Closing Price Per Share", "terseLabel": "Exchange of outstanding stock options under option exchange program, closing price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardClosingPricePerShare", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration of offering period permitted with respect to the plan for eligible employees to purchase shares of company's common stock.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Of Offering Period", "terseLabel": "Offering periods under plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfOfferingPeriod", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnually": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award number of additional shares authorized annually.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Annually", "terseLabel": "Annual increase in common shares reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnually", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesPurchasedForAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, percentage of shares purchased for award.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Purchased For Award", "terseLabel": "Percentage of number of common stock purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesPurchasedForAward", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "otic_ShareBasedCompensationArrangementByShareBasedPaymentAwardProgramExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, program expiration date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Program Expiration Date", "terseLabel": "Option exchange program, expiration date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardProgramExpirationDate", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "otic_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies line items.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "otic_ThereafterSecondAnniversaryOfClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thereafter second anniversary of closing date.", "label": "Thereafter Second Anniversary Of Closing Date [Member]", "terseLabel": "Thereafter Second Anniversary of Closing Date [Member]" } } }, "localname": "ThereafterSecondAnniversaryOfClosingDateMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "otic_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen Employee Stock Purchase Plan.", "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "otic_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) related to prior year tax positions.", "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions", "terseLabel": "Adjustments related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "otic_UpfrontPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront Payment [Member]", "terseLabel": "Upfront Payment [Member]" } } }, "localname": "UpfrontPaymentMember", "nsuri": "http://www.otonomy.com/20201231", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r104" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r227", "r229", "r430" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r239", "r240", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r428", "r431" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r239", "r240", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r428", "r431" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r227", "r229", "r430" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r227", "r228", "r390", "r427", "r429" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r162", "r227", "r228", "r390", "r427", "r429" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r230", "r239", "r240", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r428", "r431" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r230", "r239", "r240", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r428", "r431" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities [Member]", "terseLabel": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Accretion of discounts on short-term investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r196" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r57", "r58", "r59", "r418", "r436", "r437" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r60", "r108", "r109", "r110", "r330", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r241", "r243", "r279", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r243", "r268", "r278" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r73", "r88", "r360" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potentially dilutive securities excluded from the calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r145", "r154", "r160", "r179", "r326", "r331", "r351", "r395", "r414" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r52", "r102", "r179", "r326", "r331", "r351" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available For Sale Securities", "terseLabel": "Market Value", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available For Sale Securities [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available For Sale Securities Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r167", "r181" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.", "label": "Available For Sale Securities Gross Unrealized Gains", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesGrossUnrealizedGains", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss": { "auth_ref": [ "r169" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.", "label": "Available For Sale Securities Gross Unrealized Loss", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesGrossUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.", "label": "Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year", "terseLabel": "Number of available-for-sale securities in unrealized loss positions for less than twelve months" } } }, "localname": "AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available For Sale Securities [Text Block]", "terseLabel": "Schedule of Available-for-Sale Debt Securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Availableforsale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r107", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Description of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California Franchise Tax Board [Member]" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r93", "r94", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchase of property and equipment in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r33", "r90" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r13", "r91", "r97", "r394" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "terseLabel": "Cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r90", "r96" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r352" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates Of Deposit At Carrying Value", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificates Of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement Accounting Policy", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r320", "r321", "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r204", "r400", "r422" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r201", "r202", "r203", "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total common stock reserved for future issuance", "verboseLabel": "Common shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, Shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and 2019; 48,318,970 and 30,814,211 shares issued and outstanding at December 31, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r68", "r402", "r424" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r135", "r136", "r164", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r135", "r136", "r164", "r349", "r350", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r135", "r136", "r164", "r349", "r350", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r130", "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r135", "r136", "r164", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r135", "r136", "r164", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r70", "r390" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Product Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r69" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Total costs and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs And Expenses [Abstract]", "terseLabel": "Costs and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r134", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r396", "r398", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r208", "r398", "r413" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "totalLabel": "Subtotal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r19", "r409" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument Covenant Description", "terseLabel": "Debt instrument, covenant description" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r361", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument Interest Rate Increase Decrease", "terseLabel": "Increase in applicable rate of interest" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r43", "r342" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r105", "r218", "r221", "r222", "r223", "r360", "r361", "r362", "r410" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r360", "r362" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "negatedLabel": "Unamortized discount", "terseLabel": "Debt discount, amount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r93", "r94", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction", "terseLabel": "Debt issuance costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities Available For Sale Term", "terseLabel": "Maximum maturity of available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r20", "r21", "r298", "r397", "r412" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedLabel": "Total deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r299" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r301" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Total deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other, net" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r304", "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r300" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less: valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r287", "r301" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities", "totalLabel": "Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities Leasing Arrangements", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liability:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Eligible compensation contribution" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r194" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation and Equity Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r97", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Remaining weighted-average vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized compensation cost related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation costs related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options to Purchase Common Stock [Member]", "verboseLabel": "Options to Purchase Common Stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Wide Revenue Major Customer [Line Items]", "terseLabel": "Entity Wide Revenue Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r108", "r109", "r110", "r112", "r117", "r119", "r125", "r180", "r217", "r224", "r273", "r274", "r275", "r309", "r310", "r353", "r354", "r355", "r356", "r357", "r358", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExchangeTradedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction that takes place on an organized exchange.", "label": "Exchange Traded [Member]", "terseLabel": "Option Exchange [Member]" } } }, "localname": "ExchangeTradedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment Of Debt [Axis]", "terseLabel": "Extinguishment of Debt" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment Of Debt Type [Domain]", "terseLabel": "Extinguishment of Debt, Type" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r337", "r338", "r339", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Fair Value Assets Measured on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r338", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r337", "r338", "r341", "r342", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r231", "r232", "r237", "r238", "r338", "r380" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r231", "r232", "r237", "r238", "r338", "r381" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r338", "r382" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r337", "r338", "r341", "r342", "r343", "r346" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value Measurements Nonrecurring [Member]", "terseLabel": "Fair Value Measurements Nonrecurring [Member]" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r97", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r368", "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10040.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease Liability", "totalLabel": "Finance Leases, Total" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r368" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "negatedLabel": "Finance Leases, Less: leases, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r368" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Finance Leases, Leases, net of current" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Finance Leases, Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10160.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due After Year Five", "terseLabel": "Finance Leases, Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10110.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "Finance Leases, 2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10150.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "Finance Leases, 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10140.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "Finance Leases, 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10130.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "Finance Leases, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10120.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "Finance Leases, 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r187", "r188", "r190", "r191", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Office Furniture [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r88", "r193", "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment Of Long Lived Assets Held For Use", "verboseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r97", "r192", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r290", "r296", "r303", "r311", "r313", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r118", "r119", "r144", "r288", "r312", "r314", "r426" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r97", "r285", "r286", "r296", "r297", "r302", "r307", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10080.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10040.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10050.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Other adjustments" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Income Tax Reconciliation State And Local Income Taxes", "terseLabel": "State tax (net of federal benefit)" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10070.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Income Tax Reconciliation Tax Contingencies", "terseLabel": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r289" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail": { "order": 10060.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "negatedLabel": "Research and development credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedRecoveryOfIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Information By Category Of Debt Security [Axis]", "terseLabel": "Debt Security Category" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r73", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense Debt", "terseLabel": "Interest expense, including amortization of the debt discount" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r82", "r85", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r10", "r11", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service I R S [Member]", "terseLabel": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r49" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r50", "r97", "r124", "r182", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory Policy [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write Down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r178", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment Policy [Text Block]", "terseLabel": "Short-Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r177", "r393", "r407", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Available-for-Sale Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r376", "r378" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total lease expenses" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Cost [Abstract]", "terseLabel": "Lease expenses:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Lease Expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases Of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee Finance Lease Description", "terseLabel": "Finance lease, description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Finance Lease Term Of Contract1", "terseLabel": "Finance lease initial term" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Right-of-Use Assets and Lease Liabilities" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee Operating Lease Description", "terseLabel": "Operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.", "label": "Lessee Operating Lease Existence Of Option To Terminate", "terseLabel": "Operating lease, option to terminate" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Operating Leases, Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10240.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Operating Leases, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10190.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "Operating Leases, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10230.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Operating Leases, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10220.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Operating Leases, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10210.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Operating Leases, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r377" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10200.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Operating Leases, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Operating lease, option to extend description" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseOptionToTerminate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Terminate", "terseLabel": "Operating lease, option to terminate description" } } }, "localname": "LesseeOperatingLeaseOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Additional operating lease term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r102", "r155", "r179", "r327", "r331", "r332", "r351" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r102", "r179", "r351", "r399", "r420" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r102", "r179", "r327", "r331", "r332", "r351" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Data License Agreement [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line Of Credit Facility Commitment Fee Percentage", "terseLabel": "Facility fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityFrequencyOfPayments": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).", "label": "Line Of Credit Facility Frequency Of Payments", "terseLabel": "Interest frequency payments" } } }, "localname": "LineOfCreditFacilityFrequencyOfPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line Of Credit Facility Interest Rate At Period End", "terseLabel": "Debt instrument, interest rate at period end" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDescription": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).", "label": "Line Of Credit Facility Interest Rate Description", "terseLabel": "Interest rate description" } } }, "localname": "LineOfCreditFacilityInterestRateDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r209", "r398", "r416" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "totalLabel": "Total long-term debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt [Abstract]" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r106", "r206" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": 10030.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r106", "r206" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": 10050.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r106", "r206" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail": { "order": 10040.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal In Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtSummaryOfEstimatedAggregateAmountsAndTimingOfPaymentsOnLongTermDebtObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt, net", "verboseLabel": "Term Loan outstanding" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTerm": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Long Term Debt Term", "terseLabel": "Loan term" } } }, "localname": "LongTermDebtTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long Term Debt [Text Block]", "terseLabel": "Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansFromBank": { "auth_ref": [ "r19", "r398", "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.", "label": "Long Term Loans From Bank", "terseLabel": "Loans amount" } } }, "localname": "LongTermLoansFromBank", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Long Term Purchase Commitment By Category Of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long Term Purchase Commitment Category Of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r207" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Manufacturing Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r133", "r135", "r136", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers Policy Policy [Text Block]", "terseLabel": "Concentration of Major Customers" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r86", "r89" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r61", "r63", "r67", "r89", "r102", "r111", "r113", "r114", "r115", "r116", "r118", "r119", "r120", "r145", "r153", "r156", "r159", "r161", "r179", "r351", "r401", "r423" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other (expense) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r145", "r153", "r156", "r159", "r161" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r374", "r378" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease expenses" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r368" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail2": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Operating Leases, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r368" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10170.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Operating Leases, Less: leases, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r368" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail": { "order": 10180.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating Leases, Leases, net of current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesFutureMinimumAnnualObligationsUnderFinanceAndOperatingLeaseCommitmentsDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r367" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r363", "r364", "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Operating Leases Rent Expense Minimum Rentals", "terseLabel": "Estimated base rent payments over the life of lease" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases Rent Expense Net", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards Limitations On Use", "terseLabel": "Net operating loss carryforwards, expiration" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r40" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAdditionalMilestonePaymentsUnderIntellectualPropertyLicenseAgreementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments Table [Text Block]", "terseLabel": "Schedule of Additional Milestone Payments under Intellectual Property License Agreements" } } }, "localname": "OtherCommitmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r57" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized (loss) gain on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r186" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense Current", "terseLabel": "Other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.", "label": "Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]", "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments" } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other Than Temporary Impairment Losses Investments Availableforsale Securities", "terseLabel": "Other-than-temporary declines in the value of any available-for-sale securities" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r81" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments Of Debt Issuance Costs", "negatedLabel": "Payments of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r75", "r166" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "Payments To Acquire Available For Sale Securities", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments To Acquire Intangible Assets", "terseLabel": "Payment to acquire worldwide rights" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based Awards [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued or outstanding at December 31, 2020 and 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r31", "r32" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherCurrentAssetsDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Proceeds from issuance of long-term debt, net of cash issuance costs" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r74", "r77" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds From Maturities Prepayments And Calls Of Shortterm Investments", "terseLabel": "Maturities of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds From Short Term Debt", "terseLabel": "Proceeds from short-term debt" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r78", "r272" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "verboseLabel": "Cash received from options exercised during the period" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfCertainInformationRegardingStockOptionsDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r61", "r63", "r83", "r102", "r111", "r118", "r119", "r145", "r153", "r156", "r159", "r161", "r179", "r325", "r328", "r329", "r333", "r334", "r351", "r403" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r197" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r195" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r197", "r421" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r34", "r97", "r197", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r197" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r195" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property and equipment useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r80" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments Of Short Term Debt", "negatedLabel": "Principal payments on short-term debt" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r283", "r459" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r97", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r13", "r90", "r96", "r394", "r417" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents", "periodEndLabel": "Restricted cash at end of period" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r16", "r96", "r455" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r224", "r276", "r419", "r435", "r437" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r108", "r109", "r110", "r112", "r117", "r119", "r180", "r273", "r274", "r275", "r309", "r310", "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r142", "r143", "r152", "r157", "r158", "r162", "r163", "r164", "r226", "r227", "r390" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Product sales, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks And Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyAgreementsMember": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Agreements [Member]", "terseLabel": "Royalty Agreements [Member]" } } }, "localname": "RoyaltyAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r135", "r164" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Sales Revenue, Net [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r170", "r171", "r172", "r173", "r174", "r176", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Reconciliation of Expected Recovery of Income Taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r243", "r267", "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Non-cash Stock Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]", "terseLabel": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSalesToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]", "terseLabel": "Summary of Estimated Aggregate Amounts and Timing of Payments on Long-term Debt Obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule Of Other Current Assets Table [Text Block]", "terseLabel": "Prepaid and Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]", "terseLabel": "Summary of Sales to Largest Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.", "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block]", "terseLabel": "Summary of Certain Information Regarding Stock Options" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r250", "r256", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]", "terseLabel": "Weighted-Average Underlying Assumptions Used to Determine Fair Value of Stock Options and ESPP Rights" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r46", "r100", "r126", "r127", "r213", "r215", "r216", "r218", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r22", "r23", "r24", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule Of Stock By Class [Text Block]", "terseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r295", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Unrecognized Tax Benefit" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit in the form of letter of credit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r97", "r146", "r147", "r148", "r149", "r150", "r151", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r97", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling General And Administrative Expenses Policy [Text Block]", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Share based compensation vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfNonCashStockBasedCompensationExpenseDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Options available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term (In Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Intrinsic value of options exercised during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfCertainInformationRegardingStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted", "verboseLabel": "Stock option granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share of options granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansSummaryOfCertainInformationRegardingStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description", "terseLabel": "Changes in share issuance, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r271" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r252", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding as of end of period", "periodStartLabel": "Outstanding as of beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding as of end of period", "periodStartLabel": "Outstanding as of beginning of period", "terseLabel": "Exchange of outstanding stock options, exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost", "terseLabel": "Incremental fair value options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r242", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award", "terseLabel": "Number of shares purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r242", "r248" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted", "verboseLabel": "Common stock exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r97", "r245", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Contractual term of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r262", "r277" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r271" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Options vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Exercise price, percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Shares issued, price per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShorttermDebtAverageOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.", "label": "Shortterm Debt Average Outstanding Amount", "terseLabel": "Debt outstanding" } } }, "localname": "ShorttermDebtAverageOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r108", "r109", "r110", "r112", "r117", "r119", "r125", "r180", "r217", "r224", "r273", "r274", "r275", "r309", "r310", "r353", "r354", "r355", "r356", "r357", "r358", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r108", "r109", "r110", "r125", "r390" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r217", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Number of common stock issued pursuant to ESPP purchases" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r217", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock and prefunded warrants, net of issuance costs (unaudited), shares", "verboseLabel": "Common stock sold in public offering" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r217", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Shares Share Based Compensation", "terseLabel": "Issuance of common stock under employee stock purchase plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r217", "r224", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansStockOptionActivityDetail", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r217", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuancecosts" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r224", "r244", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Value Share Based Compensation", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r217", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r102", "r165", "r179", "r351" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets", "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r87" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "negatedLabel": "Deferred rent" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r359", "r379" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r359", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r359", "r379" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansWeightedAverageUnderlyingAssumptionsUsedToDetermineFairValueOfStockOptionsAndESPPRightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward Limitations On Use", "terseLabel": "Tax credit carryforwards, expiration" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAndEquityPlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Type Of Cost Good Or Service Extensible List", "terseLabel": "Type of Cost, Good or Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Type Of Revenue Extensible List", "terseLabel": "Type of Revenue [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r231", "r238", "r404" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureAvailableForSaleSecuritiesScheduleOfAvailableForSaleDebtSecuritiesDetail", "http://www.otonomy.com/20201231/taxonomy/role/DisclosureFairValueFairValueAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r284", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued", "terseLabel": "Unrecognized tax benefit, income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense", "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureIncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Loan [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty By Nature [Axis]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyNatureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty Nature [Domain]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r128", "r129", "r131", "r132", "r137", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r375", "r378" ], "calculation": { "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease expenses" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares used to compute net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.otonomy.com/20201231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5558-128473" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121595440&loc=d3e34039-112682" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r463": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r464": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r465": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r466": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r467": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r468": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 81 0001564590-21-005551-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-005551-xbrl.zip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